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2 Abstract
Human C-reactive protein (CRP), the classical acute phase reactant, is a 
member of the pentraxin family of calcium dependent ligand binding 
proteins. When ligand bound, particularly to phosphocholine residues 
found in cell membranes, bacterial cell walls and lipoprotein particles, CRP 
activates the complement cascade through engagement of C lq. Prior 
studies have suggested an important role for CRP both epidemiologicaUy 
and biologically in atherothrombosis and its consequences. In the largest 
study to date of the epidemiological association between CRP and future 
cardiac events in healthy individuals, we demonstrate in contrast to previous 
studies, that the additive value of this inflammatory marker is less than 
previously thought. Further study of the biology of this ancient molecule in 
a number of animal models of disease has faded to confirm a protective role 
for CRP in endotoxaemia, and despite evidence of upregulated production 
in a transgenic mouse strain prone to atherosclerosis, we have demonstrated 
no apparent effect of human CRP on atherogenesis. Finally we have clearly 
and robustly shown that decamerisation of pentameric CRP by a novel low 
molecular weight palindromic inhibitor effectively prevents the ligand 
binding properties of this protein. This has established a platform for 
pharmacological inhibition of CRP in myocardial infarction and stroke 
where the complement activation initiated by CRP binding to necrotic cells 
has been suggested to be pro-inflammatory and deleterious.
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s/c Sub-cutaneous
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8 Introduction
8.2 Introduction
C-reactive protein (CRP), named for its capacity to precipitate the somatic C-polysaccharide (CPS) of Streptococcus pneumoniae, was the first acute phase protein to be described, and is an exquisitely 
sensitive systemic marker of inflammation and tissue damage with broad clinical 
utility for monitoring and differential diagnosis. As a member of the pentraxin 
family of plasma proteins, the other major member being serum amyloid P 
component (SAP), it is part of the lectin fold superfamily of calcium-dependent 
ligand binding and lectin (carbohydrate binding) proteins [1-3].
In 1930 Tillet and Francis reported the mixing of acute phase sera (i.e. sera 
obtained from an individual during an acute inflammatory illness) with varying 
dilutions of Fraction C, a non-protein somatic fraction of Streptococcus 
pneumoniae; this fraction was chemically distinct from both the type-specific 
capsular polysaccharide and the non-type-specific “somatic nucleoprotein”. 
The presence or absence of precipitation was noted and Figure 1 shows the 
original findings in a subject with pneumococcal pneumonia.
21
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Figure 1 Reproduction of the first demonstration of CRP 
- after Til let and Francis [4]
Their report described how serum obtained on admission to the hospital reacted 
with high dilutions of Fraction C. This reactive capacity completely disappeared 
over the next two days, as the disease resolved, mirroring the body temperature. 
Abemethy, Macleod and Avery in two further papers in the Journal of 
Experimental Medicine in 1941, showed that “C precipitin” was a protein which 
was separate from antibodies and required calcium for precipitation [5, 6]. 
Maclyn Mcarty continued the pivotal work of Avery at the Rockefeller Institute 
crystallising the protein and raising specific antibodies that were used for 
detection of CRP in patients [7].
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8.3 The Acute Phase Response
The acute phase response is the immediate set of host inflammatory reactions that 
occur after such challenges as tissue damage, infection, inflammation, and 
malignant neoplasia [8, 9]. A complex cascade of cytokine production occurs in 
all endothermic species and mediates a non-specific physiological and 
biochemical response (Tables 1 and 2).
Table 1 Acute phase phenomena other than effects on plasma proteins
Neuroendocrine Fever
Increased vasopressin secretion 
Increased catecholamine secretion
Haematological Leukocytosis 
Thrombocytosis 
Anaemia of chronic disease
Metabolic Decreased gluconeogenesis 
Increased lipogenesis and lipolysis 
Cachexia
Non-protein Hypozincaemia 
Hypoferraemia 
Increased retinol and glutathione
The synthesis of a number of proteins is in particular rapidly up-regulated,
principally in hepatocytes [10], under the control of cytokines originating at the
site of pathology (notably interleukin-1 [IL-1], tumour necrosis factor-a [TNF-a]
and interleukin-6 [IL-6]). An acute-phase protein has been defined as one whose
plasma or serum concentration increases (positive acute phase proteins) or
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decreases (negative acute phase proteins) by at least 25% during inflammatory 
disorders (Figure 2) [9]. The responses of serum amyloid A protein (SAA) and 
of the pentraxins, CRP, and, in the mouse, SAP are exquisitely sensitive, even to 
subclinical processes. Other acute phase proteins include proteinase inhibitors, 
coagulation, complement, and transport proteins, but the only molecule that 
displays sensitivity, response speed, and dynamic range comparable to CRP is 
SAA [11-14].
30,100
30,000-
700-
C- reactive protein600-
500-
Serum  am yloid A
400-
300
H aptoglobin
Fibrinogen200
100 -
Transferrin
Album in
210 7 14
Time after Inflammatory Stimulus (days)
Figure 2 Changes in Plasma Concentrations of Acute Phase Proteins 
- after Gabay and Kushner [9]
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Table 2 The acute phase response and changes in plasma protein concentration
Proteinase inhibitors a  1-antitrypsin 
a  1 -antichymotrypsin 
a2-macroglobulin 
Antithrombin
Inter a-antitrypsin
Coagulation/fibrinolysis
proteins
Fibrinogen 
Prothrombin 
Factor VIII 
Plasminogen
Complement cascade 
proteins
Cls
C2
B
C3
C4
C5
C1INH
Properdin
Transport proteins Haptoglobin
Haemopexin
Caeruloplasmin
Miscellaneous proteins C-reactive protein 
Serum amyloid A protein 
Fibronectin 
a  1-acid glycoprotein 
Gc globulin
Albumin 
Transthyretin 
High density 
lipoprotein 
Low density 
lipoprotein
The pertinent features of the most widely used direct laboratory markers of the 
acute phase response are summarised in Table 3. The erythrocyte sedimentation 
rate (ESR) is an indirect marker of inflammation and is a measure of red blood 
cell aggregation. Factors influencing the ESR include the haematocrit, plasma 
viscosity, and the concentration of plasma proteins such as fibrinogen and 
albumin. It therefore lacks the precision of CRP or SAA.
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No clearly defined role for this broad innate response is held, but it probably 
arose as a means to isolate and neutralise pathogens and prevent further pathogen 
entry while minimising tissue damage and promoting repair processes, thereby 
permitting host homeostatic mechanisms to rapidly restore normal physiological 
function [14]. Although the acute phase response has most likely evolved as a 
survival mechanism for the short term, its maintenance over the longer term in 
cases of chronic inflammation may have negative consequences. A good 
example of this is AA amyloidosis, which has a lifetime incidence of 1-5% 
among patients with chronic inflammatory disorders such as juvenile and adult 
rheumatoid arthritis; chronic inflammation results in amyloid deposits containing 
fragments of the acute phase reactant SAA, with subsequent end organ damage, 
particularly in the kidney [15].
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Table 3 Summary characteristics for CRP, SAA, Albumin and Leukocyte count
H i n n n H ■ n n n n s n q n
Description Classical pentraxin acute phase 
protein
Apolipoprotein of high density 
lipoprotein particles 
(polymorphic)
Negatively charged protein; 
major protein component of 
serum
White blood cells
Biological properties Calcium dependent ligand 
binding protein 
Binds damaged cells and 
certain micro-organisms 
Activates complement when 
ligand bound
Displaces apo-A-I from HDL 
particles; Involved in 
cholesterol transport and 
metabolism, and in modulating 
immunological responses
Contributes to maintenance of 
osmotic pressure; Transport 
protein and assists in the 
distribution, metabolism, or 
regulation of a number of 
marginally soluble substances
Cellular and humoral defence 
(e.g. antibody and cytokine 
production)
Main site of synthesis Hepatic Hepatic Hepatic Bone marrow
Main regulators of synthesis Interleukins 1 and 6 
Tumour necrosis factor alpha
Interleukins 1 and 6 
Tumour necrosis factor alpha
Negative acute phase reactant 
(values fall as cytokines 
stimulate hepatic synthesis of 
positive acute phase proteins)
Various cytokines/growth 
factors
Important associations Smoking
BMI
Other acute phase reactants e.g. 
fibrinogen
Cholesterol
BMI
Other acute phase reactants e.g. 
fibrinogen
Smoking 
BMI 
Blood pressure
Smoking 
BMI 
Blood pressure
Baseline values Median 1.41mg/l 
90th centile 5.82mg/l
Median 3 mg/1 
90th centile lOmg/1
40+/-3.0 g/1 7.0 +/-1.8 x 1071
Self-correlation (r) -0.6 Not reported -0.5 -0.7
Inflammatory response -10000 fold rise -1000 fold rise 20% fall 3 fold rise
to'O
8.4 C-reactive protein in health and disease
In healthy volunteer blood donors the median concentration of CRP is 0.8 mg/1 
[19], but following an acute phase stimulus, values may increase by the order of 
10000 fold, with denovo hepatic synthesis starting very rapidly, serum 
concentrations beginning to rise by about 6 hours, and peaking around 48 hours 
after a single stimulus [20]. In the general, ostensibly healthy, population the 
median baseline value is slightly higher and tends to increase with age; females 
are often reported as having slightly higher circulating concentrations, perhaps 
secondary to oestrogen effects on CRP synthesis; however the precise 
characteristics of the population studied is important and not all studies show a 
gender difference [21-24]. In most, but not all diseases (Table 4) the circulating 
value of CRP much more accurately reflects on-going inflammation than do 
other biochemical parameters of inflammation, such as plasma viscosity or the 
erythrocyte sedimentation rate. This is because the plasma half-life of CRP is the 
same, at about 19 hours, under all conditions, and the sole determinant of the 
plasma concentration is therefore the synthesis rate, which, in turn, reflects the 
intensity of the pathological process(es) stimulating CRP production [25]. 
In vivo turnover studies of human CRP in man did not demonstrate any 
detectable tissue deposition of CRP, even in inflamed or infected foci [25], and 
in animal studies the only significant cellular site of CRP clearance and 
catabolism was the hepatocyte [26].
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Table 4 Clinical disease and the CRP response
M a j o r  (  /<’/ '  r e s p o n s e
Infections Bacterial 
Fungal 
Mycobacterial 
Viral (severe or systemic)
Hypersensitivity complications of infection Rheumatic fever 
Erythema nodosum
Acquired and inherited inflammatory diseases Rheumatoid arthritis 
Juvenile chronic arthritis 
Ankylosing spondylitis 
Psoriatic arthritis 
Systemic vasculitis 
Polymyalgia rheumatica 
Reiter’s disease 
Crohn’s disease 
Familial Mediterranean fever
Tissue necrosis Myocardial infarction 
Tumour embolisation 
Acute pancreatitis
Trauma Surgery
Bums
Fractures
Neoplasia Lymphoma
Carcinoma
Sarcoma
Systemic lupus erythematosus 
Scleroderma 
Dermatomyositis 
Ulcerative colitis 
Leukaemia 
Graft-versus-host disease
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Liver failure impairs CRP production [27], but no other intercurrent pathologies 
and very few drugs reduce CRP values unless they also affect the underlying 
acute phase stimulus. The CRP value is thus a very useful non-specific 
biochemical marker of inflammation, measurement of which contributes 
importantly to (Table 5):
• Screening for organic disease;
• Monitoring the response to treatment of inflammation and infection, and
• Detecting intercurrent infection in the few specific diseases characterised 
by modest or absent acute phase responses to those diseases themselves.
It is not known why systemic lupus erythematosus (SLE) and the other 
conditions listed in Table 4 fail to elicit major CRP production, despite evident 
inflammation and tissue damage [28], nor why the CRP responses to intercurrent 
infection are apparently intact in such patients [29]. Animal models of lupus 
mirror this observation, with levels of murine SAP (the equivalent acute phase 
protein in mice) not rising in response to progression of autoimmune lupus-like 
disease in (NZB x NZW) FI mice [30]. Furthermore just as in human lupus, 
where the occurrence of intercurrent microbial infection can stimulate an acute- 
phase response, so injection of bacterial lipopolysaccharide or casein also 
stimulated "normal" acute phase SAP production [30].
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Table 5 Routine and speculated uses for CRP measurement
( l i n k  a l  u s e s  o l  ( k l ’
Screening assay for organic disease_________________________________
Assessing disease activity in inflammatory conditions
Juvenile chronic arthritis 
Rheumatoid arthritis 
Ankylosing spondylitis 
Reiter’s syndrome 
Psoriatic arthropathy 
Vasculitides 
Crohn’s disease 
Rheumatic fever 
Familial fevers including familial Mediterranean fever 
__________________________ Acute pancreatitis_________________________
Diagnosis and management of infections
Bacterial endocarditis 
Neonatal septicaemia and meningitis 
Intercurrent infection in systemic lupus erythematosus 
Intercurrent infection in leukaemia and its treatment 
Postoperative complications including infection and thromboembolism
Differential diagnosis /  classification of inflammatory disease
Systemic lupus erythematosus versus rheumatoid arthritis 
_________________ Crohn’s disease versus ulcerative colitis________________
Risk prediction in cardiovascular disease (Speculative)
Long term future predictive value of CRP in healthy populations 
Outcome of patients with acute coronary syndromes and following invasive
coronary procedures 
Instigation of statin therapy for the primary prevention of cardiovascular disease
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8.5 Structure and function
Human CRP is a calcium dependent ligand binding protein, which binds with 
highest affinity to phosphocholine (PC) residues, as well as a variety of other 
autologous and extrinsic ligands, and aggregates or precipitates the cellular, 
particulate or molecular structures bearing these ligands [31-35]. The known 
ligands can be divided into three major groups: 1) compounds that contain 
phosphocholine or related structures [36-41], 2) polycationic compounds such as 
poly-L-lysine and protamine sulphate [42, 43], and 3) carbohydrates that contain 
D-galactose-related structures [44]. Autologous ligands include native and 
modified plasma lipoproteins, damaged cell membranes, a number of different 
phospholipids and related compounds, small nuclear ribonucleoprotein particles, 
and apoptotic cells. Extrinsic ligands include many glycan, phospholipid and 
other components of micro-organisms, such as capsular and somatic components 
of bacteria, fungi and parasites, as well as plant products [1, 45, 46]. When 
human CRP is ligand bound, it is recognized by Clq and it potently activates the 
classical complement pathway, engaging C3, the main adhesion molecule of the 
complement system, and the terminal membrane attack complex, C5-C9 [47-52]. 
Bound CRP may also provide secondary binding sites for factor H, and thereby 
regulate alternative pathway amplification and C5 convertases [53-56] (see 
Figure 88, Chapter 13). The secondary effects of CRP that follow ligand binding 
resemble some of the key properties of antibodies, suggesting that under various 
circumstances CRP may contribute to host defence against infection, function as 
a pro-inflammatory mediator, and participate in physiological and 
pathophysiological handling of autologous constituents [32, 57-60] (Figure 3).
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Figure 3 Representation of suggested functions of CRP
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8.5.1 Phytogeny
The pentraxins are a superfamily of conserved proteins that are characterised by 
a cyclic multimeric structure [12]. This family of proteins, named originally for 
its electron micrographic appearance (Figure 4) [61], from the Greek penta -  
five, ragos -  berries, comprises the classical short pentraxins (CRP/SAP) as well 
as the more recently described long pentraxins, in which only the C-terminal 
domain shows characteristic features of the pentraxin family; long pentraxins, 
such as PTX3, have an unrelated, long amino-terminal domain coupled to the 
carboxy-terminal pentraxin domain, and differ, with respect to short pentraxins, 
in their gene organisation, chromosomal localisation, cellular source, synthetic 
regulation and ligand binding properties [62]. They are not discussed further.
CRP and SAP are highly conserved in evolution with homologous proteins 
throughout the vertebrates and even in the phylogenetically distant arthropod, 
Limulus polyphemus (the horseshoe crab), in which it is the most abundant 
haemolymph protein, with concentrations reaching 6 mg/ml [63-68]. Whereas a 
single CRP gene has been found in humans, three independent CRP genes have 
been isolated from Limulus. Structural data generated from the amino acid 
sequences of the proteins, has suggested that human and Limulus CRPs’ diverged 
about 500 million years ago [69, 70]. Structurally the calcium-mediated ligand 
binding by CRP, human SAP and Limulus polyphemus CRP is similar, but 
sequence differences in the hydrophobic pocket explain the differential ligand 
specificities exhibited by the homologous proteins. Insertions and deletions
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elsewhere most probably account for the different hexameric quaternary structure 
of Limulus polyphemus CRP.
Figure 4 Negatively stained electron micrograph of human CRP 
- this shows the typical pentameric disc like structure face on and side on (arrows) [3].
The cyclic pentameric or hexameric arrangements with several equivalent 
binding sites, one on each subunit, is important for the biological functions of 
pentraxins, which involve binding or linking several cells or molecules together 
to form a stable multicomponent system [71].
In contrast to man, mouse CRP is a trace protein the concentration of which 
increases only modestly in the acute phase response to a maximum of about
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2 mg/1 [72]. No mouse CRP knockout has yet been made, and in vivo work on 
CRP function has largely been confined to mice transgenic for rabbit [73] or 
human CRP [74]. It is important to be aware that artefactual heterologous 
systems may not provide physiologically relevant information. In spite of the 
evolutionary conservation of sequence, subunit organisation and protein fold, 
there are major structural and functional differences between CRP’s of different 
species, including glycosylation, capacity to activate autologous complement, 
and regulation of basal and acute phase synthesis. For example rat CRP closely 
resembles human CRP in its amino acid composition, in having five subunits per 
molecule and in its electron microscopic appearance as a pentameric annular 
disc. It differs, however, from all other mammalian CRP's in being a 
glycoprotein bearing a single complex oligosaccharide on each polypeptide 
subunit. Furthermore one pair of its subunits per molecule is linked by an 
interchain disulphide bridge whereas in other animals the subunits of both CRP 
and SAP are all non-covalently associated [75]. Another species difference is 
seen with rabbit CRP, which in acute phase hyperlipidaemic serum, circulates in 
association with very low density lipoproteins [76, 77], and is therefore unlike 
human CRP which is always uncomplexed [78]. Rabbit CRP however, unlike rat 
CRP, behaves more like human CRP in terms of its dynamic changes during an 
acute phase response [79, 80]. These and other such differences therefore 
command extreme caution in extrapolating from animal models to man, and 
generate difficulties in designing robust experiments to investigate the properties 
of pentraxins.
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8.5.2 Serum amyloid P component
SAP, named for its universal presence in amyloid deposits [81], is a constitutive, 
non-acute phase plasma glycoprotein in man and all other species studied, except 
the mouse in which it is a major acute phase protein [11]. SAP binds to DNA in 
chromatin exposed to or released in the extracellular environment by apoptosis or 
necrosis, stabilises it, and protects it from degradation [82-84]. SAP deficient 
mice, created by gene targeting, degrade chromatin more rapidly than normal, 
have enhanced antibody responses to exogenous chromatin, and spontaneously 
develop marked anti-chromatin autoimmunity [85]. However it has become clear 
latterly that the autoimmunity seems to be independent of SAP deficiency, and 
reflects murine strain effects, namely expression of 129/Sv chromosome 1 genes 
on a C57BL/6 background [86-88]. This point reiterates the extreme caution 
needed in interpretation of models in which manipulation of protein expression 
occurs in artefactual and heterologous systems, including the possibility of 
unexpected effects of interstrain genetic interactions or ectopic protein 
expression.
Other properties of SAP relate to its binding affinity for bacteria such as 
Streptococcus pyogenes, as well as Neisseria meningitidis and rough variants of 
Escherichia coli. This binding has powerful antiopsonic effects, reducing 
phagocytosis and killing of bacteria and thus enhances their virulence [89].
Finally SAP binds to all types of amyloid fibrils, the abnormal protein aggregates 
responsible for the amyloidosis diseases [90, 91]. Binding of SAP stabilises
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amyloid fibrils in vitro [92] and in mice appears to contribute to the pathogenesis 
of amyloidosis (as shown by delayed and reduced amyloid deposition in SAP 
deficient mice) [93]. These observations taken together generated the impetus to 
design a low molecular weight molecule capable of pharmacological depletion of 
SAP, with the aim of developing a novel treatment for human amyloidosis. This 
has now entered clinical studies and will robustly test the hypothesis in patients 
[94].
8.5.3 Innate immunity
The conservation of the structure of CRP and of its calcium-dependent specific 
binding of ligands containing PC and related substances, together with the lack 
of any known deficiency or protein polymorphism, suggest that this protein must 
have had survival value. Microbial infection is a major driving force of change 
during evolution, and CRP has many features compatible with an important role 
in innate immunity.
The innate immune system discriminates self from non-self using a restricted 
number of pattern recognition receptors that recognise pathogen associated 
molecular patterns, and most micro-organisms that penetrate the body’s external 
barriers are recognised and cleared by cells and molecules which exhibit these 
broad specificities [95-97]. If infectious organisms evade these mechanisms, the 
specific antigen receptor-bearing lymphocytes of the adaptive immune system 
come into play, and significant subsets of lymphocytes, even in previously
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unexposed animals, express germ line encoded specificity for immunogenic 
epitopes of pathogens. The T-cell independent natural IgM antibodies produced 
by the progeny of these cells comprise a significant proportion of serum 
immunoglobulins at birth, and can both provide protection against some viral and 
bacterial infections [98], and play a role, via complement activation in enhancing 
specific adaptive T cell dependent antibody production [99]. The antigen-specific 
receptors of the natural antibody producing lymphocytes often contain highly 
conserved sequences, and represent an “evolutionary memory” bridging pattern 
recognition molecules and the phylogenetically more recent and sophisticated 
adaptive responses. Importantly, many of the natural antibodies encoded by 
nonmutated germline Vh or Vl genes react with a variety of self-determinants, 
including carbohydrates and glycolipids, as well as cross-reacting with bacterial 
or oncofoetal antigens. They may thus have a significant role in handling 
autologous ligands as well as extrinsic antigens.
One important class of highly conserved natural antibodies expresses the 
so-called T15 idiotype, binds to PC as does CRP, and like CRP protects against 
Streptococcus pneumoniae infection [100-103]. PC is a component of many 
prokaryotes and is universally present in eukaryotes [104]. In Streptococcus 
pneumoniae, PC is present in the somatic ribitol teichoic acid component [37] 
and is associated with different sugar residues in a variety of other organisms, 
including other Streptococci, Clostridium, and Bacillus species, and 
H. influenzae [105, 106]. PC is also found in the external components of a 
variety of pathogenic protozoa, fungi, nematodes, and other intestinal parasites 
[107]. PC is ubiquitous in the phospholipids of cellular membranes of higher
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animals, and importantly also in the circulating plasma lipoproteins that are 
intimately involved in the pathogenesis of atherosclerosis [108]. The specific 
binding of CRP to low density and very low density lipoproteins (LDL and 
VLDL), [109-111] and to the membranes of damaged cells has long been 
recognised, and more recently it has been observed that CRP also recognises 
apoptotic cells in a Ca dependent manner, enhancing their opsonisation and 
phagocytosis by macrophages [59]. The original finding that native, 
non-aggregated, human CRP does not bind to native LDL has lately been 
confirmed and extended with the observation that native CRP does bind to 
oxidised LDL [112]. This, as well as the binding of CRP to apoptotic cells and to 
oxidised but not to non-oxidised phosphatidyl choline (PtC), is mediated by 
recognition of exposed PC residues. The interaction between CRP and 
cholesterol in lipoprotein particles in particular is reportedly mediated by the PC 
binding site of CRP and the 3-beta-hydroxyl group of cholesterol [113]. The 
spectrum of ligand recognition by CRP closely resembles that of E06, an 
autoantibody to oxidised LDL, which is a T15 clono-specific anti-PC antibody 
with specific binding to PC on oxidised but not on native PtC [114,115].
An important physiological role of CRP may thus be in handling of autologous 
materials including oxidised PC-bearing phospholipids within oxidised LDL and 
on the plasma membranes of apoptotic cells. Similarly, pathophysiological 
effects of CRP may also be mediated via these interactions with autologous 
ligands [116]. Intriguingly, the spectrum of autologous ligand recognition by 
CRP overlaps that of pathogenic anti-phospholipid autoantibodies [117].
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8.5.4 Structure
The human CRP molecule (Mr 115,135) is composed of 5 identical 
non-glycosylated polypeptide subunits (Mr 23,027) each containing 206 amino 
acid residues. The protomers are non-covalently associated in an annular 
configuration with cyclic pentameric symmetry. The CRP protomer has the 
characteristic “lectin fold” composed of a two layered p sheet with flattened 
jellyroll topology. Two calcium ions are bound 4A apart by protein side-chains 
coming from loops at the concave face, termed the B face as this is the site of 
ligand binding. The other, A , face carries a single a  helix (Figure 5) [32, 118].
Figure 5 Ribbon diagram and space filling model of CRP
- The ribbon diagram on the left shows the lectin fold with two calcium atoms (spheres) 
in the ligand binding site of each protomer; the space filling model (right) shows a single 
phosphocholine molecule located in the ligand binding site of each protomer [3].
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The crystallographic structure of the CRP-PC complex, and indirect evidence 
from mutagenesis studies, show that key residues in the ligand binding pocket 
responsible for recognition of PC are Phe66 and Glu88 [119, 120]. Clq, the 
recognition protein of the classical pathway, probably binds to complexed or 
aggregated CRP in a pocket at the open end of a cleft on the A faces of the 
protomers in the intact pentamer. Mutagenesis studies of CRP suggest that 
A spll2  and Tyrl75 are important contact residues for C lq binding, that Glu88 
influences the conformational change in Clq necessary for complement 
activation, and that Asnl58 and His38 probably contribute to the correct 
geometry of the binding site [121,122].
In vitro studies have suggested that some bioactivities of CRP are expressed on 
loss of the pentameric symmetry, resulting in formation of modified or 
monomeric CRP (that has distinct antigenic and physicochemical characteristics) 
[123-127]. The lack of any in vivo evidence for the presence of modified CRP, 
along with the knowledge of the robustness of the non-covalent association of the 
monomers (6-8M urea chelation or acid treatment being required to generate 
monomers), suggests that great caution should be exercised before accepting a 
biological function for modified CRP.
8.5.5 Genes and gene expression
The genes for both CRP and SAP are on chromosome 1, and the CRP gene 
consists of a coding sequence for a signal peptide of 18 residues and the first 2
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amino acids of the native protein, followed by an intron of 278 base pairs and 
then the coding sequence for the remaining 204 residues [128-130]. A single non 
functional pseudogene [131] with 50-80% region-specific homology is found 
close to the authentic CRP gene and typical promoter sequences are located 
upstream of the cap region (104 nucleotides from the start of the signal peptide). 
Plasma CRP is produced by hepatocytes [10], although other sites for CRP 
synthesis and possibly secretion have been suggested [132-136]. CRP may thus 
have local roles in particular micro-environments as well as its functions effected 
via the systemic circulation.
Increased CRP production is induced predominantly by the cytokine IL-6, but 
either IL-1 or TNF-a may also contribute [137,138]. Control of CRP expression 
is principally at the level of transcription and in vitro studies in hepatocyte cell 
lines have identified some of the intra-cellular signalling pathways [139-141] and 
also shown that secretion is more efficient during an acute phase response [142]. 
Thus cell culture studies investigating the transcription of CRP in Hep 3B cells 
suggest expression is induced by IL-6, acting through C/EBP isoforms (CCAAT- 
enhancer-binding proteins) and STAT3. STAT (signal transducers and activators 
of transcription) family members, induce their effects by binding to palindromic 
sequences with TT(N)5AA motifs and an IL-6 responsive element in the 
proximal region of the human CRP 5'-flanking region that bears a TT(N)4AA 
motif, has been demonstrated and termed the CRP acute phase response element. 
IL-ip, which alone has no effect, greatly enhances IL-6-induced transcription 
and IL-lp activates the NF-kB system. This is suggested to involve IL-lp 
induced nuclear translocation of p50-containing dimers; p50 interacts with
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C/EBPp activated by both IL-6 and IL-lp to induce CRP expression. Binding of 
Rel p50 to the nonconsensus kB site enhances and stabilises binding of C/EBPp 
to the CRP promoter and binding of both C/EBPp and p50 to their overlapping 
cognate sites is required for induction of CRP expression by IL-6. More 
recently a protein kinase C dependent transcriptional regulation of CRP gene 
expression has also been demonstrated in cell culture [143]. Such knowledge of 
the cell biology may of course be used to identify inhibitors of CRP synthesis.
Healthy subjects tend to have rather stable, individual, baseline CRP 
concentrations [144], that in family studies are significantly 35-40% heritable 
[145]. Predictably there are significantly higher correlations of CRP (and SAA) 
values among monozygotic than among dizygotic twins [146], where the 
estimated hereditability reaches -50% for CRP [146]. Nevertheless CRP values 
remain strongly related to other factors such as total and central abdominal 
obesity, blood pressure, and lipid levels, independent even of the genetic 
influences seen in monozygotic twins [147].
Although human CRP is notable for the lack of reported deficiency states or 
protein polymorphisms [148], associations between CRP production and genetic 
polymorphisms in IL-1 [149], IL-6 [150], tumour necrosis factor [151] and apoE 
[152-155] have been reported. Increasing information is now also available on 
non-coding genetic polymorphisms within the CRP gene itself. In one large 
prospective cohort of apparently healthy men, plasma CRP concentrations were 
shown to be significantly reduced among carriers of a 1059G/C polymorphism in 
the human CRP gene (GC or CC) as compared with non-carriers (GG).
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However, there was no significant association with risk of arterial thrombosis 
[156]. When the genotypes of two common polymorphisms within the CRP 
gene, an exonic 1059G/C and an intronic T/A base substitution were assessed in 
a moderately sized community-based study, there were effects, albeit small, but 
persistent even after adjustment for age, sex, body mass index, ethnicity, 
hypertension, smoking, diabetes, hyperlipidaemia, and aspirin use, on baseline 
CRP values: GG versus GC or CC genotypes, median CRP levels 0.22 vs 0.15 
mg/1 and TT versus AT versus AA genotypes, median CRP levels 0.19 vs. 0.23 
vs. 0.24 mg/1 [157]. A +1444C/T polymorphism in the CRP gene has also been 
associated with differences in CRP concentration and one study suggests an 
effect of this polymorphism on the CRP response to an inflammatory stimulus. 
Individuals homozygous for the +1444T allele showed higher CRP 
concentrations compared with C-allele carriers after periodontal therapy [158]. A 
polymorphic GT repeat in the intron of the CRP gene is reportedly also 
associated with differences in baseline CRP concentrations in both normal 
individuals and in patients with SLE [159], and with susceptibility to invasive 
pneumococcal disease [160]. Similarly a polymorphism at the CRP gene locus 
(in man the genes for CRP and SAP map to lq23.2 within an interval linked with 
SLE) influenced gene expression and predisposed patients to SLE [161].
Specific genetic polymorphisms that reliably correlate both with baseline CRP 
concentrations and/or CRP production in the acute phase response will 
increasingly be used to test, through genetic association studies, the case for a 
pathogenetic role of CRP in inflammatory disease [162-167].
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8.6 C-reactive protein and coronary heart disease
Inflammation has a pivotal role in atherothrombotic cardiovascular disease and 
individuals with coronary artery disease have elevated markers of inflammation 
such as CRP [168, 169] (Figure 6). Earlier work suggested a prognostic 
association between increased CRP production and outcome after acute 
myocardial infarction [170] and in acute coronary syndromes [171]. In the mid 
1990’s immunoassays for CRP, with greater sensitivity than those previously in 
routine use, revealed a powerful predictive relationship between increased CRP 
production, even within the range previously considered to be normal, and 
atherothrombotic events [172-186]. Circulating CRP values correlate closely 
with other markers of inflammation, some of which show similar, albeit 
generally less significant, predictive associations, and baseline CRP values also 
reflect metabolic states associated with atherothrombotic events [16,17,179].
Hence there is a powerful predictive association between raised serum CRP 
values and the outcome of acute coronary syndromes, and, remarkably, between 
even modestly increased CRP production and future atherothrombotic events in 
otherwise healthy individuals. Meta-analysis of all published studies up to the 
year 2000, comprising a total of 1,953 coronary events, showed a relative risk of 
approximately 2.0 for a future coronary event in subjects with a single initial 
base-line CRP value in the upper third compared with those in the lower third of 
the distribution in the general population, (tertile cut offs, >2.4 vs. <0.9 mg/1) 
[179].
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Figure 6 Higher baseline CRP values in those with established coronary disease
- In two studies where I measured CRP values, when comparing the population 
distribution of CRP in healthy individuals [168], with those known to have coronaiy 
artery disease [169], a raised median CRP concentration is evident.
CRP itself is particularly interesting with respect to cardiovascular biology and
pathology because not only does it bind selectively to LDL [111], especially
oxidised and enzyme modified LDL as found in atheromatous plaques [187], but
it is deposited in the majority of such plaques [188-190] and it has a range of
pro-inflammatory properties that could potentially contribute to the pathogenesis,
progression and complications of atheroma [3, 191]. Tissue necrosis is a potent
acute phase stimulus, and following myocardial infarction, there is a major CRP
response the magnitude of which reflects the extent of myocardial necrosis [20,
170]. Furthermore the peak CRP values at around 48 hours after the onset,
powerfully predict outcome after myocardial infarction [170, 192-195].
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Importantly, CRP is deposited, with complement, within all acute myocardial 
infarcts [196-200], and experimental evidence suggests that the CRP response 
not only reflects tissue damage in this context, but may also contribute 
significantly to the severity of ischaemic myocardial injury [201].
The production of CRP following myocardial necrosis is the typical acute phase 
response to cell death and inflammation, mediated by the action on the liver of 
the cytokine cascade, especially IL-6, triggered by such events [202]. However 
the stimuli that trigger the low grade up-regulation of CRP production that 
predicts coronary events in general populations [168, 179, 203, 204], or the 
more substantial CRP values associated with poor prognosis in severe unstable 
angina [172, 205-208] or after angioplasty [209, 210], are not clear (Figure 7). 
The association with future stroke as well as the outcome following stroke [211- 
214], along with the ability of CRP to powerfully predict outcome in chronic 
renal disease also require explanation [215-217]. Potential acute phase stimuli 
may arise from inflammation within atheromatous lesions themselves, and thus 
reflect their extent and/or severity or instability [218]. However atherosclerotic 
burden per se as determined by coronary artery calcification, for example, does 
not necessarily always correlate with CRP concentrations [219-221], although 
one analysis from the Framingham Heart Study did find an association between 
CRP and coronary calcification [222].
The distinction between so called “disease markers” and “process markers” is 
important particularly with respect to inflammation, not least because our 
concepts of the underlying disease processes continue to evolve. Measures of
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inflammation, such as CRP, and indices of atherosclerosis, such as coronary 
artery calcification may provide quite distinct information regarding 
cardiovascular risk. Hence, for example, the evidence that there is widespread 
activation of neutrophils across the coronary vascular beds of unstable angina 
patients, challenges the concept of a single vulnerable plaque in unstable 
coronary syndromes [223], Similarly in the CAPTURE study (Chimeric c7E3 
AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial) 
[224] troponin T, but not CRP, was predictive of cardiac risk during the initial 
72 hour period, whereas CRP was an independent predictor of both cardiac risk 
and repeated coronary revascularisation (coronary artery bypass graft surgery 
and percutaneous transluminal coronary angioplasty) during the six months of 
follow-up. At four year review [225], both elevated troponin T and CRP were 
associated with impaired outcome, independently of other established risk 
factors, but with a different time course. Elevated troponin was associated with 
increased procedure related risk, and elevated CRP with increased risk for 
subsequent events.
Alternatively increased production of CRP may reflect inflammation elsewhere 
in the body, although there is no strong correlation with serological evidence of 
the various chronic microbial infections, such as C. pneumoniae and H. pylori, 
that have been putatively linked with coronary heart disease [179]. Indeed, 
within what was until recently accepted as the reference range for circulating 
CRP concentration, up to 5 or 10 mg/1 [19], higher values have now been found 
to be strongly associated with increased body mass index [226, 227] and, also 
with many features of the insulin resistance or metabolic syndrome [228-232], up
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to and including frank diabetes mellitus [233-235]. This may reflect in part the 
fact that adipocytes are the source of a substantial portion of baseline IL-6 
production [236], but in general it suggests that some or even most of the 
inflammatory marker profile associated with increased atherothrombotic risk in 
the population at large, may not be triggered by inflammation or tissue damage in 
the classical sense. Rather it may be a sign of a particular metabolic state which 
happens also to be pro-atherogenic, or at least predisposing to atherothrombotic 
events [237]. Indeed, CRP production predicts the development of type 2 
diabetes independently of traditional risk factors [238]. In insulin resistant obese 
individuals, elevated CRP values fall in parallel with improvements in insulin 
resistance associated with weight loss, but the association between CRP and 
insulin resistance is independent of body mass [239]. Oral contraceptive use 
[229] and systemic but not transdermal post-menopausal hormone replacement 
therapy [240-244] are also associated with significantly raised baseline CRP 
concentrations without any sign of tissue-damaging inflammation. Other 
reported associations with elevated baseline CRP values include periodontal 
disease, smoking, consumption of coffee, and stress [16,245-250]. Also, lately, 
other conditions not classically viewed as involving inflammation have been 
associated with elevations in CRP concentration, for example, atrial fibrillation 
[251-253]. Weight loss predictably leads to lower baseline CRP concentrations 
[254-256], as does moderate alcohol intake [257-259] and there is an association 
between exercise and reductions in CRP production [260-262].
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Figure 7 Sources and roles of acute phase reactants in cardiovascular disease
Of note, is the class effect of HMG CoA-reductase inhibitors (statins), which 
reproducibly reduce CRP values, independent of their effects on lipid values 
[263-267]. A similar effect seems to occur with the fibrates [268, 269]. As well 
as possible reductions in atherosclerotic plaque inflammation [218] direct 
hepatocyte effects seem important. PPARa-activators (e.g. fenofibrate) notably 
directly suppress IL-1-induced but not IL-6-induced expression of CRP in cell 
culture [270] and it appears that the anti-inflammatory action of statins and 
fibrates on human CRP expression in hepatocytes is based on up-regulation of 
the cytosolic inhibitor of NFkB, IicBa, resulting in reduced NFkB activity. 
Administration of statins or PPARa activators to human CRP transgenic mice 
results in lowered basal and IL-ip-induced human CRP gene expression [271].
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Effects via inhibition of protein geranylgeranylation (and subsequent inhibition 
of IL-6 induced production of CRP) have also been suggested [272].
Some studies suggest that statins reduce the risk of future cardiovascular events 
to the same extent in patients with raised LDL cholesterol values and in those 
with normal LDL but with base-line CRP concentrations above the median [273]. 
Indeed the risk reduction was essentially the same in the two groups, suggesting 
that, in primary cardiovascular disease prevention programmes, statin therapy 
may be appropriately indicated not only by raised lipid values, but also by 
increased CRP concentrations [274]. Ridker et al. have now published findings 
they suggest demonstrate that patients with acute coronary syndromes in whom 
low CRP levels are achieved after statin therapy have a decreased risk of 
recurrent myocardial infarction or death, regardless of the levels of LDL 
cholesterol attained. The observed benefit was largely attributed to the anti­
inflammatory effects of statins, as assessed by CRP values. Hence the 
controversial suggestion that strategies to lower cardiovascular risk with statins 
should include monitoring CRP as well as cholesterol [275].
Ridker has also extensively propagated the idea that increased CRP values 
identify individuals at risk who are not detected, for example, by the 
Framingham risk score [276, 277]. Such a suggestion, and the proposed change 
in clinical practice, however requires further extensive work. It is critically 
important to recognise that the CRP response is non-specific and is triggered by
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many disorders unrelated to cardiovascular disease. In using CRP for coronary 
heart disease risk assessment it is therefore essential to clearly establish true 
baseline CRP values, not distorted by either trivial or serious intercurrent 
pathologies. At the individual level, as opposed to epidemiological studies, this 
requires at least a proper history and physical examination of the patient, and 
possibly also appropriate relevant investigations, together with 2 or 3 serial CRP 
measurements if the first result is in the higher risk range (>2.5 mg/1) (Table 6). 
If the CRP value persistently remains above 10 mg/1, indicating the presence of a 
significant acute-phase response, a full history and physical examination of the 
patient is indicated, ideally together with relevant investigations, to determine the 
cause and alleviate it if possible [3]. Interestingly though, chronic inflammatory 
conditions, such as rheumatoid arthritis and haemodialysis for end-stage renal 
failure, that are characterised by persistently elevated CRP concentrations in 
some individuals, are associated with premature cardiovascular disease [278, 
279].
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Table 6 Present suggested use of CRP in cardiovascular disease
S u m n i ; i r \  b o x  ( 1 )
• Raised baseline CRP values predict coronary events, stroke, and 
progression of peripheral disease
• Relative risk of coronary event is 2.0 for single baseline CRP 
concentration >2.4 mg/1 versus <1 mg/1
• Increased CRP production may reflect:
- Inflammation in atherosclerotic plaques?
- Total atherosclerotic burden?
- Inflammation elsewhere in the body?
- Metabolic status rather than inflammation?
- Individual higher CRP responsiveness to prevalent endogenous or 
environmental acute phase stimuli?
• CRP is not uniquely associated with cardiovascular disease; other 
systemic markers of inflammation show similar associations, though less 
marked than with CRP
8.6.1 C-reactive protein and pathogenesis of atherosclerosis
The original identification of the possibility that CRP may contribute to 
pathogenesis of atherosclerosis [110, 111], has lately become the focus of much 
work in this field [280]. The binding of CRP to lipids, especially lecithin 
(phosphatidyl choline), and to plasma lipoproteins, especially what was formerly
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called P-lipoprotein, has been known for over 60 years [281, 282], and the first 
suggestion of a possible relationship to atherosclerosis came when it was 
demonstrated that aggregated, but not native, non-aggregated, CRP selectively 
bound just LDL and some VLDL from whole serum [111]. However native CRP 
does bind to partially degraded, so-called modified LDL [187], as it is found in 
atheromatous plaques, and to oxidised LDL [112, 283]. Furthermore CRP is 
present in most such plaques examined ex vivo [188, 189]. This CRP could 
contribute to complement activation in the plaques [56], and there is 
experimental evidence supporting a possible role of complement in atherogenesis 
[284-286]. CRP has also been reported to stimulate tissue factor production by 
peripheral blood monocytes and could thereby have important pro-coagulant 
effects [287, 288]. However this latter action of CRP has not been well defined 
or robustly controlled [289]; for example, all the published work has been done 
with commercially sourced CRP of incompletely defined provenance and purity, 
and there have been few robust specificity controls. Nevertheless if the 
phenomenon is reproducible it provides a possible direct link between increased 
CRP production and atherothrombotic events. Similarly it has been claimed that 
CRP is recognized by a subset of cellular Fc(y) receptors and could thereby 
engage multiple processes of inflammation [189, 290-294]. One study using 
ultrasensitive confocal fluorescence microscopy claims only a weak direct 
interaction with the Fc(y)RIIa receptor, which is significantly enhanced in the 
presence of antibodies to CRP [295] and more robustly controlled studies, using 
recombinant and highly purified CRP and avoiding use of whole IgG anti-CRP 
antibodies, do not confirm such interactions with human cells at all [296-298].
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Endothelial dysfunction, a marker of atherosclerosis related to coronary events, is 
associated in epidemiological studies with markers of systemic inflammation 
including CRP production [299, 300], and CRP has been reported to have direct 
effects on both inducible and constitutive endothelial nitric oxide synthesis [301- 
303]. We for example demonstrated (with careful specificity controls) that pure 
human CRP has specific, direct effects on vascular function in vitro via increased 
NO production [304]. However the in vivo relevance of this is unclear. 
Expression of adhesion molecules in endothelial cell cultures is also reportedly 
increased by in vitro exposure to CRP [305-307], as are angiotensin type 1 
receptors in vascular smooth muscle [308]. The expression and activity of 
plasminogen activator inhibitor-1 by human aortic endothelial cells has also been 
claimed to be upregulated by CRP [309]. CRP values are clearly related to the 
development, severity and progress of coronary artery disease in transplanted 
hearts, and immunohistochemical detection of arterial endothelial ICAM-1 was 
associated with elevated serum CRP concentrations [310]. In other studies 
addition of CRP to LDL in cell culture systems apparently stimulates the 
formation of foam cells, typical of atherosclerotic plaques. It is not known 
whether this reflects opsonisation of the LDL particles by CRP or an effect of 
CRP on the phagocytic cells themselves [311,312].
All these experimental in vitro observations, and many others [313-325], must be 
treated with great caution [326] until the purity and integrity of the CRP used 
have been rigorously established and the specificity of the observed effects 
formally established, for example by the use of specific CRP absorbents, ligands, 
antibodies and inhibitors of binding. Thus for example the finding that sodium
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azide and endotoxin in CRP preparations affects the apparent biology of CRP in 
vitro (see Chapter 14). Furthermore in extrapolating results from in vitro models, 
it is critical to bear in mind key facts about human CRP, in particular its systemic 
distribution as a plasma protein and its 10000 fold dynamic concentration range 
in the acute phase response. These properties would seem to make inherently 
unlikely some of the claims for CRP as a fine modulator of sophisticated cellular 
functions.
8.6.2 Myocardial infarction and stroke
Once arterial occlusion has occurred and there is ischaemic tissue damage with 
cellular necrosis and ensuing local inflammation, the possible pathogenetic 
contribution of CRP is much clearer. Apart from the epidemiological association 
between higher peak CRP values and poor prognosis, there is robust 
immunohistochemical evidence of CRP deposition within all acute myocardial 
infarcts, co-localised with activated complement components [197-199]. 
Although this suggests that CRP might have deleterious effects, investigation of 
such mechanisms in man will require a drug that selectively inhibits CRP effects 
in vivo. However, rat CRP does not activate rat complement, in contrast to 
human CRP which potently activates rat as well, of course, as human 
complement [75]. The rat model of myocardial infarction, produced by coronary 
artery ligation, could therefore be used to investigate specifically the complement 
dependent pro-inflammatory role of human CRP in myocardial infarction. When 
rats undergoing coronary artery ligation received daily injections of pure human
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CRP some of the coronary artery ligated rats treated with human CRP died, and 
those surviving to day 5, when all animals were killed, had infarcts 40% larger 
than buffer or SAP-treated controls. This enhancement of infarct size by human 
CRP was completely abrogated by in vivo complement depletion of the rats using 
cobra venom factor, and hence was complement dependent [201]. It has long 
been known that in vivo complement depletion markedly reduces inflammation 
and infarct size in this and similar animal models [327-330]. A substantial 
proportion of final myocardial infarction size following acute coronary occlusion 
is determined by complement mediated inflammation, and human CRP, both in 
the rat model and perhaps also in the clinical situation, is responsible for at least 
some of this complement activation [331].
Work has also been performed with respect to ischaemic stroke, in which it is 
known that CRP values increase in concentration after the event [214]. Rats 
subjected to middle cerebral artery occlusion and then treated with human CRP 
develop significantly larger cerebral infarcts compared with control subjects 
receiving human serum albumin [332]. Human CRP may thus contribute to 
ischaemic tissue damage in the brain as well as in the heart.
8.7 Sum m ary: C -reactive protein, a novel therapeutic target?
There is compelling epidemiological and laboratory evidence that CRP is a
sensitive marker of the inflammation and/or metabolic processes associated with
atherothrombotic events. The presence of CRP within most atherosclerotic
plaques and all acute myocardial infarction lesions, coupled with binding of CRP
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to lipoproteins and its capacity for pro-inflammatory complement activation, 
suggest that CRP may contribute to the pathogenesis and complications of 
cardiovascular disease (Table 7). Availability of drugs to block CRP binding 
and its effects in vivo would provide a powerful tool for determining whether 
CRP is just a marker or does indeed participate in the pathogenesis of atheroma 
and/or its complications. Such agents may also have cardioprotective effects in 
acute myocardial infarction as well as acutely in stroke. Existing knowledge of 
the structure and function of CRP, including its three dimensional structure alone 
and complexed with ligands, coupled with experience in developing an inhibitor 
of the related protein, SAP, establish an excellent platform for drug design.
Table 7 Possible specific associations of CRP with cardiovascular disease
S 11 in n k i r \  h o \  ( 2  )
• CRP binds selectively to LDL, especially ‘modified’ LDL
• CRP is deposited in atherosclerotic plaques
• Aggregated and/or ligand complexed CRP activates complement and can 
be pro-inflammatory
• CRP is co-deposited with activated complement in all acute myocardial 
infarction lesions
• Human CRP and complement are reported to increase final myocardial 
infarction and stroke size in experimental models
• CRP may therefore be a therapeutic target
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This thesis addresses further the biology of CRP by tackling this interesting and 
important protein at an epidemiological, in vitro, in vivo, and pharmacological 
level. It includes a robust assessment of whether or not CRP is a useful clinical 
predictor of heart disease and attempts further clarification of whether or not 
CRP is, at times, a biological villain or just an innocent, albeit convenient to 
measure, bystander.
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9 Laboratory Materials and Methods
9.2 G eneral reagents and laboratory chem icals
Where not specified or described, reagents, laboratory chemicals, and antibodies 
were purchased from either Sigma-Aldrich Company Ltd (Gillingham, England) 
or VWR International Ltd (Poole, England).
9 3  Com m on buffers
Common buffers and solutions, and their compositions, are listed below. 0.1% 
w/v sodium azide was added unless the buffer was intended for in vivo studies.
TN 0.01 M Tris, 0.14 M NaCl, pH 8.0
TC 0.01 M Tris, 0.14 M NaCl, 0.002 M CaCl2, pH 8.0
TE 0.01 M Tris, 0.14 M NaCl, 0.01 M EDTA, pH 8.0
PBS 0.01 M phosphate buffer, 0.0027 M KC10.137 M NaCl, pH 7.4
PEBT PBS containing 10 mM EDTA, 1% BSA, 0.2% Tween 20, pH 7.4
BE 0.07 M Barbitone buffer containing 0.01 M EDTA, pH 8.6
BC 0.07 M Barbitone buffer containing Ca Lactate (4H20 ), pH 8.6
TCB TC containing 1% w/v bovine serum albumin
TCB 4% TC containing 4% w/v BSA
TEB TE containing 1% w/v BSA
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9.4 Protein preparation
CRP (human, rabbit and rat) and SAP (human and mouse) previously purified by 
affinity chromatography from either ascites or serum were available in the 
laboratory [75, 77, 333-335]. In particular human CRP was prepared from 
malignant effusion fluids removed for therapeutic purposes collected from 
patients without active infections (source material tested negative for hepatitis B 
and C, anti-HTV-1 and HTV-2). CRP was purified by sequential DEAE anion 
exchange and ligand elution calcium dependent affinity chromatography on 
phosphoethanolamine-carboxyhexyl Sepharose. After calcium chelation and 
concentration, the CRP was buffer exchanged into TC buffer with or without 
azide, depending on its ultimate use. The CRP was >99% pure by overloaded 
silver stained 8-18% reduced sodium dodecyl sulphate polyacrylamide 
electrophoresis, was all in its native pentameric form by analytical size exclusion 
chromatography, and was fully functional by calcium dependent binding to 
immobilised phosphoethanolamine.
Human CRP concentrations in final preparations were established by absorbance 
at 280 nm, corrected for light scattering at 320 nm, and using the specific 
extinction coefficient for pure CRP (1.75 for 1 mg/ml) established by 
interferometric measurement of refractive index [336]; similarly for human SAP 
where the extinction coefficient is 1.71 for 1 mg/ml [336].
The protomers of human CRP are non-glycosylated and have an Mr of 23,027, as 
predicted by the amino acid sequence and confirmed by electrospray ionization
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mass spectrometry measurement [25]. The mass of a pentamer is therefore Mr 
115,135. The protomer mass of human SAP is 25,462 D, as predicted by the 
amino acid and complete, invariant, glycan sequence, and confirmed by 
electrospray ionization mass spectrometry measurement [90]. An SAP pentamer, 
therefore has an Mr of 127,310.
The Gram negative bacterial LPS content was 100 pg/mg of CRP, measured by 
the kinetic chromogenic Limulus amebocyte lysate assay (BioWhittaker Europe 
S.P.R.L., Parc Industriel de Petit Rechain, B-4800, Venders, Belgium).
9.5 PC- and PE-Sepharose
PC-Sepharose and PE-Sepharose formed the basis for affinity chromatography 
and demonstration of calcium dependent binding (as evident by changes in 
concentration of the pentraxin protein after incubation with a suspension of 
beads) of isolated proteins, radiolabelled pentraxins and pentraxins in the 
presence and absence of antagonists in vitro and ex vivo.
9.5.1 Preparation of PC-Sepharose
1 g of aminophenylphosphorylcholine (Sigma) was offered to 60 ml CH 
Sepharose 4B (Pharmacia) and coupled according to the manufacturer’s 
instructions. The PC-Sepharose was then washed into TC.
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9.5.2 Preparation of PE-Sepharose
28.3 g of phosphoethanolamine was offered to 800 ml CH Sepharose 4B 
(Pharmacia) and coupled according to the manufacturer’s instructions.
9.6 SD S-PA G E electrophoresis
Under reduced and denatured conditions, purity of protein preparations was 
demonstrated by SDS-PAGE electrophoresis using two proprietary gels 
according to the manufacturers instruction; NOVEX 4-20% Tris Glycine gels 
(Invitrogen Ltd, Paisley, UK) and ExcelGels (Pharmacia Biotech, St Albans, 
UK). Appropriate molecular weight calibration standards were used.
9.7 N orm al H um an serum
Venous blood from healthy volunteers was allowed to clot at room temperature 
for approximately 1 hour, then centrifuged at 2000g (Sorvall RT7 centrifuge with 
RTH-750 rotor, Kendro Laboratory Products Ltd, Stevenage, England) and the 
sera collected. Pooled normal human serum (NHS) was stored at -70°C to avoid 
activation of the complement pathway. To inactivate the complement pathway, 
NHS was heat-treated in a 56°C water bath for 30 minutes.
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9.8 Antibodies
Certain anti-sera were available within the laboratory [72, 334, 337]. Others 
were commercially sourced as above.
Monospecific rabbit and sheep anti-sera against human CRP, SAP, mouse SAP 
and rabbit CRP: These were raised by immunisation with isolated pure proteins 
emulsified in Freund’s complete adjuvant (CFA; Difco Labs, Surrey) followed 
by booster injections in incomplete Freund’s adjuvant (ICFA; Difco).
Anti-human C3 serum: A monospecific antiserum against human C3 (“A” and 
“D” determinants) was obtained by immunisation of a sheep with specific 
antigen-antibody precipitates formed in agarose gel between purified human C3 
and a non-specific sheep anti-human C3.
Anti-mouse C3 serum: Monospecific antiserum against mouse C3 was raised in a 
sheep following immunisation with yeast-mouse complement complexes 
incorporated in Freund’s incomplete adjuvant.
The specificity of all anti-sera was previously determined by double diffusion in 
agarose.
The monoclonal anti-human CRP 21F12 was a gift of Dr S. Eda (Roche 
Diagnostics, Basle).
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9.9 Immunochemical Techniques
9.9.1 Double immunodiffusion
Double immunodiffusion was performed in 1% w/v agarose (Indubiose A 37, 
BioSepra, France) in BE buffer or TC buffer (if calcium dependent interactions 
were being studied).
9.9.2 Electroimmunoassay
Concentrations of human CRP, human SAP and mouse SAP were measured by 
rocket immunoelectrophoresis in 1% w/v agarose (Indubiose A 37) gels in BE 
buffer, after the methods of Laurell [338]. Whole monospecific antisera 
incorporated into gels cast onto GelBond film (Flowgen Instruments Ltd., 
Sittingboume, Kent), were incorporated at optimal concentrations for each 
protein respectively. Electrophoresis was performed at 15°C, 200 volts constant 
for 6-8 hours. For mouse C3, 1% w/v agarose C gel (Amersham-Pharmacia, 
Little Chalfont, England) was used, containing sheep anti-serum to mouse C3 
and run for 20 hours, with BC buffer across a 100V gradient at 15°C.
2 pi samples and standards, which consisted of dilutions of whole sera containing 
or spiked with known concentrations of each protein, were used. Migration of 
rocket immunoprecipitates was compared against standards and the range of the
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assays was in the order of 2-150 mg/1, and the coefficient of variation of replicate 
assays less than 10% [339].
9.9.3 Antigen-antibody crossed immunoelectrophoresis
A modification of the Laurell technique [340] was used to estimate conversion of 
C3 by assessment of C3 cleavage products, with anti-C3 (murine or human) in 
the second stage gel. Cobra Factor (CoF) from the venom of the Naja naja cobra, 
available in the laboratory, and prepared as previously described, was used to 
generate control C3 cleavage products (5U per experiment) [341, 342]. Murine 
and human sera prepared for complement by prompt centrifugation and 
subsequent storage at -70°C was used as a complement source, and complement 
activation took place at 37°C.
9.9.4 Staining of immunoprecipitates
After washing in 5% w/v NaCl, gels were pressed, dried and stained in 0.2% 
Coomassie blue (Brilliant Blue R250, Sigma) dissolved in acetic acid / ethanol / 
distilled water (1:4.5:4.5), and destained as required in a similar solution not 
containing dye.
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9.10 H aem olytic com plem ent fixation assay
Complement activation was also assessed by a standard haemolytic complement 
fixation assay; sheep red blood cells in Alseviers and anti-sheep red blood cell 
were purchased from TCS Biosciences and complement fixation test medium 
from Oxoid.
9.11 M easurem ent o f  hum an CRP by autom ated assays
Human CRP was measured in serum or buffer as appropriate using a high 
sensitivity automated microparticle enhanced latex turbidimetric immunoassay 
(COBAS MIRA; Roche Diagnostics, Basle). The lower limit of detection was 
0.2 mg/1 with an interassay CV of 4.2% at 4 mg/1 and 6.3% at 1 mg/1 [343, 344]. 
Specific properties of this assay, described in detail later (Chapter 13.6.3.3), 
mean that ligand bound human CRP loses its immunoreactivity in this assay. 
This therefore also allows the use of this particular assay to determine any 
specific fluid phase binding of potential calcium dependent ligands for CRP. 
The efficacy of novel CRP ligands was thus tested in this assay, in both buffer 
and serum, in vitro and ex vivo. Known concentrations of protein were mixed 
with know concentrations of drug; incubation took place at room temperature for 
30 minutes. Results are expressed as the molar ratio of drug to pentraxin 
protomer.
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Alternatively, the concentration of human CRP was analyzed with a sensitive 
latex-enhanced immunoassay performed on a Dade-Behring BNII Nephelometer. 
The run-to-run CVs, at CRP concentrations of 0.47, 10.5, and 54.9 mg/1 are 
reported as 6.4%, 3.7%, and 2.9%, respectively [345].
Standardisation of both CRP assays is based on the WHO International 
Reference Standard (85/407) [346].
9.12 Protein radiolabelling
Purified proteins were iodinated by the N-bromosuccinimide (British Drug 
Houses, Poole) method as previously described [347]. For use in vitro and for in 
vivo clearance studies in mice, pure pentraxins were labeled with 125I (Na125I, 
Amersham International, Bucks). 0.005% w/v KI in distilled water was added to 
pure protein in TE or TC, followed by Na125I. Following addition of 
N-bromosuccinimide 0.025% w/v in distilled water, the contents were mixed for 
15 seconds before transfer to a Sephadex G25 prepacked column (PD10, 
Pharmacia) which was blocked (BSA) and equilibrated in TN or TC. The 
column was promptly eluted with 8 ml of TN or TC, which served to quench the 
reaction and to separate iodinated protein from free radioiodide. After this gel 
filtration step more than 95% of the radioactivity in the protein fraction was 
precipitable with 10% w/v trichloroacetic acid. Binding to PE-Sepharose 
demonstrated retained function and a Cobra™II Auto-Gamma Counter (Packard 
Bioscience) was used throughout for quantification of radioactivity.
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9.13 Animals
9.13.1 Husbandry and routine testing
All mice used were maintained in a conventional animal house (Comparative 
Biology Unit, Royal Free Hospital), and use was in accordance with the Animals 
(Scientific Procedures) Act 1986. Wild type C57/BL6J mice were sourced from 
Charles River Laboratories, UK. Animals were age and sex matched.
Human CRP transgenic mice (CRPTg), on a C57/BL6J background, were a gift 
of Dr B. Kyewski (German Cancer Research Center, Heidelberg, Germany) [74]. 
After injection of LPS into CRPTg mice it has been reported that peak 
concentrations of serum IL-6 (170 ± 35 ng/ml) are attained within 2 hours. This 
is followed by hepatic production of human CRP with peak values occurring 
within 18 hours. CRPTg mice carry a 31-kb Clal fragment of human genomic 
DNA comprising the CRP gene, 17 kb of 5'-flanking sequence, and 11.3 kb of 3'- 
flanking sequence. It has been established that the cis-acting elements within the 
CRP transgene are responsible for liver-specific and for lipopolysaccharide 
(LPS)-induced acute phase expression of human CRP. CRPTg mice exhibit a 
sexually dimorphic pattern of constitutive expression of human CRP with basal, 
testosterone dependent expression of the transgene only in males [348-351]. In 
view of reported infertility of homozygote CRPTg mice (personal observation, 
Dr B. Kyewski), the colony was maintained as heterozygotes with respect to the 
human CRP transgene.
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ApoE'AtmlUnc mice, originally from the Jackson Laboratories were obtained from 
Charles River Laboratories, having been backcrossed for six generations onto a 
C57BL/6J background and undergone three generations of brother/sister
_ / _ i m  1 1 In /*mating. ApoE mice were back crossed three times as appropriate, with 
human CRP transgenic mice until a colony of apoE'/_tmlUnc/CRP Tg mice was 
generated.
Animals were identified at around 6 weeks of age by polymerase chain reaction 
of DNA extracted from tail biopsy, using PCR primers as described below.
9.13.2 DNA Extraction
Mouse tail tips were added to 300 pi of lysis buffer (100 mM Tris, 5 mM EDTA, 
0.2% SDS, 200 mM NaCl, pH 8.5) containing 100 mg/1 proteinase K (Roche) 
and incubated for 48 hours at 37°C. Following digestion, samples diluted 1 in 5 
in water, were heated at 88°C for 15 minutes prior to use.
9.13.3 Polymerase Chain Reaction
CRPTg mice were identified as follows. Using Ready-To-Go™ (RTG) PCR 
beads (Amersham Pharmacia Biotech) and the primers 
CCATGGAGAAGCTGTTGTG (sense) and GTACTGGAGCTACTGTGACT 
(antisense) the DNA was amplified under the following conditions : 95°C
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2min30sec [1 cycle] (denaturation); 95°C 30sec, 60°C 30sec, 72°C 30sec [35 
cycles] (denaturation, anneal, extension); and 72°C 5sec [1 cycle] (final 
extension). PCR amplified products were size fractionated by 1% agarose gel 
electrophoresis (20 minutes 70V; AquaPor LE [National Diagnostics] in 0.089M 
Tris-borate, 0.089M Boric acid). After staining with ethidium bromide, DNA 
bands were visualised with a UV transilluminator. Positive animals demonstrate 
a 600 base pair band. Apo E genetic testing was similarly carried out, using 
three primers: IMR180 (5’-GCCTAGCCGAGGGAGAGCCG-3’ Tm=69.8°C), 
IMR181 (5 * -TGTGACTTGGGAGCTCTGC AGC-3 ’ Tm=67.4°C), IMR182 
(5’-GCCGCCCCGACTGCATCT-3’ Tm=69.3°C). The first two amplify a 155bp 
wildtype band, while the IMR180 and IMR182 amplify a 245bp band. The latter 
band is present in both heterozygote and knockout mice. Using RTG tubes to 2pi 
of previously prepared DNA the following amount of primers were added: lp l of 
IMR180,1.3pl of IMR181 and 0.5 pi of IMR182. The volume was made to 25pl 
by adding water and run as following: 94°C 3 min [1 cycle] (denaturation); 94°C 
30sec 68°C 30 sec 72°C 30 sec [35 cycles] (denaturation, anneal, extension); 
72°C 7 sec [1 cycle] (final extension). The PCR products were run on an agarose 
gel and the results visualised by UV light as above.
9.13.4 Phlebotomy
Blood was collected by tail bleeding or at bleed out (under anaesthesia) into
1.5 ml vials (Eppendorf, Hamburg, Germany) and allowed to clot for 6 hours at 
room temperature. Serum was separated by centrifugation at 14000 rpm in a
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microfuge (Sigma-Aldrich, Poole, UK) for 5 minutes, and stored in aliquots at 
-70°C prior to analysis. For sequential blood sampling mice were bled at 
different time points from the cut tip of tail after pre-warming them for 5 minutes 
under a hot lamp.
9.13.5 Insertion of mini osmotic pumps
Mice (20-25 g) maintained under isoflurane anaesthesia had primed osmotic 
displacement pumps (ALZET, Charles River Laboratories, UK) inserted into a 
sub-cutaneous pocket on the back. Pumps delivering 1 pl/hour for 7 days with a 
reservoir volume of approximately 221 pi, filled with 0.76M RMM in TC or 
buffer were used. Animals were bled prior to pump insertion and as appropriate 
subsequently.
9.14 Experimental protocols
9.14.1 Generation of autologous acute phase response
Autologous sterile acute phase responses were generated by sub-cutaneous 
administration of either 0.5 ml of 10% (w/v) casein (ICN Pharmaceuticals) in 
0.05 M NaHCC>3 buffer or 0.25-0.5ml 2% (w/v) aqueous silver nitrate [352].
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Mouse acute phase serum was obtained by exsanguination from dissected 
subclavian vessels of anaesthetised animals 24-36 hours following stimulation. 
After clotting and centrifugation, serum was stored at -70°C. Alternatively 
animals were challenged with endotoxin as described below.
9.14.2 Local Shwartzman Reaction
A local Shwartzman reaction was elicited by intra-dermal administration of 10 or 
20 jig Salmonella enteritidis endotoxin (1 mg/ml in azide free PBS). The 
affected skin was subsequently harvested 24 hours later and formalin fixed, prior 
to wax embedding and sectioning. Haematoxylin and eosin staining was then 
performed [353].
9.14.3 LPS lethality model
LPS (E. coli 0111:B4, E. coli 055:B5 or Salmonella typhimurium, 1 mg/ml in 
azide free PBS) was administered, at doses between 5-10 mg/kg, by intra- 
peritoneal injection and lethality was documented over the subsequent 72 hours. 
In some experiments acute phase responses in wild type and human CRP 
transgenic mice were initiated 24 hours before LPS challenge as above. In other 
experiments isolated pure human CRP in TC solution was injected 
intra-peritoneally 15 minutes before and 4 hours after LPS challenge. Control 
animals challenged with LPS received injections of solvent alone.
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9.14.4 Binding of LPS in the fluid phase to human CRP
LPS (E. coli 0111:B4; E. coli J5 [Rc mutant]; E. coli 026:B6; in PBS at 
1 mg/ml) were tested for their ability to be recognised by CRP, by incubation of 
human CRP with LPS for 30 minutes at room temperature, followed by 
determination of the apparent CRP concentration on the COBAS MIRA assay. 
Pneumococcal C-polysaccharide (Serum Statens Institute, Denmark) was used as 
a positive control for loss of immunoreactivity. All solutions and dilutions were 
buffered in TC.
9.14.5 Collagen arthritis
Murine type II collagen arthritis was generated in C57/BL6 mice based on the 
method of Campbell et al. [354]. Mice were immunised with chick collagen (in 
complete Freund's adjuvant), intra-dermally at several sites in the base of the tail, 
with a total of 100 pi emulsion, on day 0, with an identical boost on day 21. The 
chick collagen type II (Sigma) was dissolved overnight at 4°C in 10 mM acetic 
acid to make a 2 mg/ml solution. Complete Freund’s adjuvant (CFA) was made 
by grinding 100 mg of heat killed M. tuberculosis (H37Ra; Difco Laboratories) 
in 20 ml incomplete Freund’s adjuvant (Difco). A fresh emulsion of equal 
volumes of chick collagen at 2 mg/ml in 10 mM acetic acid with CFA was made 
prior to immunisation.
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A macroscopic arthritis score was determined two to three times per week for up 
to 100 days, depending on whether any arthritis developed:
0 No swelling or redness;
1 Swelling/redness of paw or one joint;
2 Two joints involved;
3 More than two joints involved;
4 Severe arthritis of the entire paw and joints
The arthritis score for each mouse is the sum of the scores of all four paws.
The mice were sacrificed, and their limbs fixed in 10% buffered formalin and 
decalcified in 5% formic acid. The tissue was then processed and embedded in 
paraffin, prior to sectioning and staining with haematoxylin and eosin.
Serum samples stored at -70°C were assayed for transgenic human CRP, murine 
SAP, and mouse anti-collagen antibodies. The final assay was performed as 
follows. Microtitre plates with N-oxysuccinimide activated surfaces (Coming 
Costar, Bucks, UK) were coated by incubation with 100 pi per well of the 
antigen, chick Collagen Type II diluted to 0.1 mg/ml in PBS, for 1 hour at 21°C. 
After decanting, the wells were each washed with 200 pL PBS-Tween (PBS, 
pH 7.4, containing 0.05% Tween 20) three times and then subsequently blocked 
with 100 pL 0.2M Tris pH 8.0 for 1 hour at 21°C. After further washing with 
PBS-Tween, 100 pi samples diluted in PEBT, were added in triplicate and 
incubated at 37°C for 1 hour. The plates were then decanted and each well was 
washed three further times with 200 pi of PEBT buffer, after which 100 pL I125
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radiolabelled sheep-anti-mouse Ig (Amersham-Biosciences, Little Chalfont, UK), 
diluted in PEBT, was offered for 1 hour at 37°C. Following a final decanting 
and washing step, the wells were blotted dry and counted individually in the 
y-counter. Bound radioactivity was quantified on the gamma counter.
9.14.6 Determination of Atherosclerosis area in mouse aorta
Male mice of the four different genotypes, apoE+/+, apoE'7', apoE+/+-hCRP+, and 
apoE^’-hCRP*, were housed at 4 animals per cage under conventional conditions 
and received normal mouse diet (RM1, Special Diet Services Ltd, Witham, 
Essex, England) ad libitum throughout. Groups were closely age matched and 
apoE'7' and apoE‘7-hCRP+ mice were litter mates. One cohort was studied from 
age 8 weeks with serial tail bleeds at 4 week intervals until being killed for 
measurement of atherosclerotic lesions at 20 weeks. A second cohort was killed 
at 12 weeks and a third at 56 weeks. Group sizes were as shown in the results. 
All blood samples were taken at least 4 hours after the start of the daily light 
phase when food consumption was minimal. Serum was separated after clotting 
overnight and was stored frozen at -70°C until analysed, except for gel filtration 
studies that were performed on unfrozen samples that were briefly kept at 4°C 
until tested.
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9.14.7 Analysis of atherosclerotic lesions
The mice were euthanased by carbon dioxide asphyxiation and bled out from the 
inferior vena cava. The hearts and aortae were immediately perfused in situ with 
oxygenated Krebs-Henseleit buffer at 37°C under a pressure of approximately 
110 cm of water via a cannula inserted in the left ventricle and an outlet created 
by cutting the right atrium. After approximately 30 minutes the buffer was 
replaced with buffered formal saline at 37°C and the perfusion was continued for 
a further 30 minutes. The hearts and aortae were then removed, cleaned of 
extravascular fat and stored in formalin until they were processed. Cross-sections 
of the aortic root were used for analysis. After equilibrating the tissue in OCT 
compound overnight the hearts were immersed in OCT compound in a syringe 
with the aorta facing the cork. The tissue was frozen by immersion in liquid 
nitrogen and the hearts were then sectioned (Bright Instrument Company Ltd, 
UK) perpendicular to the axis of the aorta, starting within the heart and 
proceeding in the direction of the aorta. After the aortic root had been identified 
by the appearance of the three-valve leaflets, alternate 10 pm sections were taken 
and mounted on Polysine slides (VWR). Sections were air dried overnight and 
stained with oil red O (VWR), counterstained with Mayer's haematoxylin and 
covered using an aqueous mountant (Shandon). Alternate 10 pm sections 
through the aortic sinus were examined in a Leica DM XRA2 microscope 
equipped with a 2.5x objective and total magnification of 40x, and the whole 
area within the outer perimeter of the oil red O stained zones was quantified. 
Quantification of the atherosclerotic lesion areas was performed by drawing
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around the lesions by hand using the QWIN software. Some of the sections were 
tom or folded and the images of these were discarded. Colour images were 
captured by analogue video camera under identical lighting, microscope, camera 
and PC conditions and were analyzed using Leica QWIN software [355].
The mean lesion area (pm2) for each animal was calculated from the sum of the 
areas in all sections in which the aortic valve leaflets were present, divided by the 
number of sections analyzed. Colour thresholds were set that quantified the 
areas that were stained red within the lesions. Absolute values for the cross- 
sectional areas of the lesions were obtained by previous calibration of the 
software using an image of a micrometer slide. Plaques were also examined after 
staining with haematoxylin and eosin as well as with Verhoeff Van-Gieson 
staining for elastin.
9.14.8 Immunohistochemistry
Immunoperoxidase immunohistochemical staining was performed using standard
techniques on sections that were not used for oil red O staining. After blocking
by incubation with 20%vol/vol normal rabbit serum and elimination of
endogenous peroxidase activity by incubation with H2O2, optimal dilutions of
primary antisera (mono-specific goat anti-human CRP and sheep anti-mouse C3)
determined by prior titration were applied. Tissue bound primary antibodies
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were detected using rabbit anti-goat IgG antibody (DAKO Ltd, Ely, UK), that 
cross reacts with sheep IgG, followed by peroxidase-goat anti-peroxidase 
complexes (DAKO), visualisation with diaminobenzidine and hematoxylin 
counterstaining. The specificity of all immunostaining was established by its 
complete abolition when the primary antisera were absorbed before use with the 
respective pure antigens; human CRP that had previously been immobilised 
covalently on CNBr-activated Sepharose (Amersham), and mouse C3 was 
captured on plain Sepharose beads by complement fixation in fresh mouse 
serum, as previously described [356].
9.14.9 Gel filtration
Size exclusion chromatography to study CRP-lipoprotein interactions in murine 
serum was performed using the AKTA™ explorer 100 HPLC modular system 
(Amersham Biosciences) with a 24.7ml Superdex 200 HR10/30 column 
(exclusion limit 1.3 x 106 Da and separation range 104 -6 x 105 Da). Undiluted 
100 pL serum samples were eluted at 0.25 ml/min with TC buffer monitored at 
280 nm, and 250 pL fractions were collected for CRP and cholesterol assay.
Similarly using the AKTA™ explorer isolated proteins were gel filtered under 
standardised conditions [357], at room temperature, to study novel pentraxin- 
ligand interactions. Column equilibration and elution was performed with TE or 
TC buffers as appropriate, with added ligand, quoted as an excess of drug to 
pentraxin protomer.
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9.14.10 Determination of serum cholesterol and triglycerides
The MIRA automated analyser was used to measure, enzymatically, serum 
cholesterol and triglycerides in mouse samples (Roche Diagnostics, UK). 
Calibrators and controls were purchased from Roche (C.f.a.s. calibrator for 
automated systems and Precinorm L).
9.14.11 Protein clearance studies in mice
Known concentrations of protein, radiolabelled or cold, were injected (100 pi 
volumes) intra-venously into the lateral tail veins of mice. Potential ligands or 
buffer controls, were either pre-incubated with the protein for 30 minutes at 
37°C, injected intra-peritoneally (maximum volume 200 pi) prior to the injection 
of tracer, or delivered by an osmotic pump. Serial tails bleeds were performed 
into pre-weighed tubes and using the gamma counter, counts per minute per 
gram of blood were calculated [26]. Alternatively the concentration of protein 
was directly measured. Sera was also used to assess for residual binding of 
pentraxins to PE-Sepharose; the concentration of pentraxin being measured 
before and after a 30 minute (37°C) incubation with PE-Sepharose beads.
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9.14.12 Streptococcus pneumoniae lethality model
Streptococcus pneumoniae (strains WU2 and A66.1 were provided by Dr D. E. 
Briles, University of Alabama, USA; strains Wt and D39-6 were a gift of Dr J. 
Brown, Imperial College) was grown from frozen aliquots on pre-poured 
Columbia agar plates in a CO2 enriched environment at 37°C (Oxoid). A single 
colony was selected and Todd Hewitt Broth inoculated. After 8 hours growth, 
0.5 ml of broth was transferred to 5 ml of fresh broth, for incubation for a further 
2-3 hours. Bacteria were harvested thus at mid-log phase. Bacterial numbers 
were estimated prior to inoculation in mice in sterile Ringers lactate solution by 
measurement of absorbance at 420 nm (A420 of 1 is ~ 2 x 108 CFU), and 
subsequently by colony counting. Mice were inoculated intra-peritoneally with 
an inocula ranging from 50-1000 colony forming units, and lethality noted over 
the subsequent 72 hours. As appropriate passive administration of human CRP 
and/or putative selective antagonists of CRP binding, were give intra-peritoneally 
at varying doses and time intervals. In vitro studies looking at binding of CRP 
(native and radiolabelled) were performed using pelleted bacteria, in the presence 
and absence of calcium and other CRP ligands.
9.14.13 Lipoprotein isolation and modification
VLDL was isolated from heparinised plasma and was a gift of Miss N. Marshall 
(University of Liverpool) [358].
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For LDL, blood withdrawn from volunteers was drawn into a syringe containing 
63 mM EDTA and 42 pM diethylenediamino-pentaacetic acid (DTPA) at a ratio 
(by volume) of 1:20 anticoagulant. Plasma was separated by centrifugation at 
lOOOg. A potassium bromide density gradient ultracentrifugation method was 
utilised to isolate LDL from the plasma using a Beckman L-70 centrifuge with a 
fixed angle rotor (Ti-70) working at 150,000g (1.006 mg/mL<density< 1.063 
mg/mL). The isolated lipoproteins were dialysed at 4°C against 12 mM Tris (pH 
7.4) and the protein concentration of each lipoprotein preparation was 
determined using the modified method of Lowry [359], with stock solutions of 
BSA as standard.
9.14.13.1 Modification of LDL (Enzymatic [E] and Oxidative [Ox])
Native human LDL was isolated and enzymatic modification with trypsin, 
cholesterol esterase, and neuraminidase was undertaken. LDL was diluted to 
3 mg/mL cholesterol in HEPES buffer (20 mmol/L Hepes, 150 mmol/L NaCl, 
2 mmol/L CaCL, pH 7.0). Initially 6.6 pg/mL trypsin (Sigma) and 40 pg/mL 
cholesterol esterase (Boehringer Mannheim) were added for 8 hours at 37°C. 
Trypsin inhibitor (Sigma) was then added at 10 pg/mL after the initial incubation 
with trypsin and cholesterol esterase. The pH of the solution was adjusted to 5.5 
by addition of morpholinoethane sulfonic acid buffer, pH 5.0, and neuraminidase 
(Behringwerke) was added at 79 mU/mL for 14 hours, 37°C [360].
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Oxidised LDL was prepared by incubation of LDL with copper sulphate. 
Varying concentrations of CUSO4.5 H2O in normal PBS (40 pM downwards) were 
incubated with equal volumes of LDL overnight at 37°C.
Modified lipoproteins were stored at 4°C and used within a week, after dialysis 
into appropriate buffers. The buffers included PBS, 0.1 M Carbonate 
(Na2C0 3 /NaHC0 3 ) pH9.0, and 0.1 M Boric acid buffer pH8.0 (KC1 and H3BO3)
9.15 Novel CRP and SAP Ligands
Novel synthetic routes were developed by Professor S. Ley and colleagues 
(Department of Chemistry, University of Cambridge) to produce new 
pharmacological ligands for CRP and SAP. Ligands, expressed as the molarity 
with respect to pentraxin protomer, were used as solutions in TN or TC 
(described further in Chapter 13). CPHPC, a selective pharmacological inhibitor 
of SAP binding was manufactured by Roche Pharmaceuticals [94]. Other 
ligands were purchased commercially from Sigma.
9.15.1 Inhibition of CRP binding -  plate based assay
Using microtitre plates (Costar) 100 pi volumes of either modified lipoproteins
or pneumococcal C-polysaccharide (Serum Statens Institut, Denmark) were
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attached to wells. This was either through hydrophobic interactions (EIA/RIA 
High Binding Type 1) or covalently (N-oxysuccinimide surface amine binding 
polystyrene stripwell plates). Incubation with 0.2 M Tris blocked residual 
binding sites and three buffer washes, 200 pi, between each step was always 
performed. Radiolabelled human CRP (I125) was offered to the immobilised 
ligands (incubated at 37°C for 30 minutes) and binding was shown to be calcium 
dependent. Comparison of inhibition by novel ligands was made against 
phosphorylcholine, the best-known natural ligand.
9.15.2 Electron microscopy
Transmission electron microscopy with negative staining by 2% aqueous uranyl 
acetate of pure human CRP on carbon coated grids was performed by the 
Electron Microscopy Department, Royal Free Hospital, to visualise CRP in the 
presence and absence of potential CRP ligands.
9.15.3 Mass spectrometry and X-ray crystallography
NanoESI MS measurements of CRP with and without ligand, were performed on 
an LCT mass spectrometer (Micromass), with Dr A. Aquilina in Professor C. 
Robinson’s laboratory, University of Cambridge. Typically, 2 pi of solution was 
electrosprayed from gold-coated glass capillaries prepared in-house. In order to
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preserve non-covalent interactions, the following instrument parameters were 
used: capillary voltage, 1.5 kV; cone gas, 100 1/hour; sample cone, 140 V; 
extractor cone, 8 V; ion-transfer stage pressure, 8.0x1 O'3 mbar; ToF analyser 
pressure, 2.0xlO"6 mbar. The pressure in the ion-transfer stage was decreased 
from 8.0x1 O'3 to 5.0x10‘3 mbar to dissociate monomers from the pentamers and 
to remove excess solvent from the complex. All spectra were calibrated 
externally using a solution of Csl, and were processed with MassLynx software 
(Micromass). Buffer salts were removed by applying 20 pi of stock solution to a 
Micro-BioSpin chromatography column (Bio-Rad Laboratories) previously 
equilibrated in an electrospray buffer (EB), 200 mM ammonium acetate, pH 8.0 
(with or without 1 mM calcium). The process was repeated to achieve 
satisfactory buffer exchange [361].
X-ray crystallography, and subsequent data analysis, was performed by Professor 
S. Wood and colleagues (Southampton University), with purified human CRP in 
the presence and absence of ligand, using methods applied previously for the 
study of the SAP-CPHPC complex [94]. Crystals of the CRP-RMM complex 
were grown by hanging drop vapour diffusion from 11 mg/ml CRP with a ten­
fold molar excess of RMM in 150 mM NaAc pH 4.6, 50 mM CaC^, and 
52% v/v 2-methyl-2,4-pentanediol.
86
9.16 Statistical analysis
Statistical analyses were carried out using SPSS (Version 10.0). Discrete 
variables were compared using yfl or Fisher’s exact test, as appropriate. 
Continuous variables are expressed as mean ± SD and compared by means of the 
unpaired, 2-sided t test or analysis of variance (ANOVA) for > two groups. 
Variables not normally distributed are reported as medians and inter-quartile 
ranges or geometric means +/- SD, and analysed using nonparametric tests. 
Kaplan-Meier survival analysis was performed and P values sought by the log 
rank test or Breslow test.
Section 10.5 describes in detail, separately, the methods for the Reykjavik Study.
87
10 Assessing the role of C-reactive protein determination
in coronary heart disease prediction
10.2 Introduction
A therosclerosis is the underlying cause of most cardiovascular disease, starting early in life and progressing for decades before being complicated with acute myocardial infarction, stroke or 
angina. The development of atherosclerosis involves a complex and self­
reinforcing interaction between lipid accumulation and modification, the 
endothelium, smooth muscle cells and macrophages, inflammatory cytokines and 
various blood components [362]. Laboratory and epidemiological data show that 
baseline values of CRP, SAA, leukocyte count, and serum albumin, predict 
future risk of coronary heart disease [179]. It remains unclear whether such 
associations are causal or reflect confounding by classic risk factors, chronic 
infective processes, or early disease [363-365]. Refining the association by 
increasing the available data is important, in particular assessing whether or not 
so called new markers of risk add value to established markers. With Professor 
J. Danesh, Dr J. Wheeler, the Iceland Heart Association, Roche Diagnostics and 
the Royal Free Hospital Clinical Chemistry Department, this chapter describes 
the collaborative effort to further study the predictive power of CRP 
measurement in coronary heart disease risk prediction [168].
88
1 0 3  R isk  Factors
There has been much excitement at the potential use of CRP as a new marker of 
cardiovascular disease but widespread changes to clinical practice must be based 
on good evidence [366, 367]. The concept of the risk factor for chronic diseases, 
such as cardiovascular disorders, is derived from the application of 
epidemiological methods initially developed for infectious and nutritional 
deficiency diseases; the aim being to identify factors) linked to the development 
of the disease.
Established risk factors (e.g. gender, smoking, diabetes, hypertension and 
hypercholesterolaemia) have enabled reasonably accurate assessment of risk 
among groups and individuals to provide guidance for management. In addition, 
risk factors have provided important clues to the biology of cardiovascular 
diseases [368]. Although the importance of conventional risk factors is well 
established, it is commonly suggested that more than 50% of patients with CHD 
lack any of the conventional risk factors [369, 370]. This implies that other 
factors play a significant role in the development of disease and, furthermore, 
that there is a substantial void in current understanding of the pathogenesis of 
CHD. This perceived void has led to considerable research on non-traditional risk 
factors and genetic causes of heart disease. However, data to support this "50%" 
belief are limited, and some have suggested that conventional risk factors play a 
much more significant role [371-374].
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For clinical prediction models, a variety of criteria arise for risk factors that 
might be useful and practical (Table 8) [375]. These criteria importantly imply 
that to be useful, the factor must be an independent predictor of risk. That is, it 
must improve the predictive power of other risk factors already identified and 
used for prediction.
Table 8 Characteristics of biomarkers of disease
I d e a l  c l i a r a c  te i i s d e  s o f  h i o m a r U t  r s  j '
• The measure should add important independent information about the risk of 
prognosis, beyond that of current risk markers.
• The measure should account for a significant proportion of the risk 
associated with the given condition; for common conditions such as 
cardiovascular disease, this could be a modest proportion of risk, if the 
impact overall is clinically significant.
• The measure should be reproducible.
• The measure should be sensitive and specific, with a high predictive value.
• The test should be readily available and practical to implement.
10.4 Inflam m ation, C -reactive protein, and coronary heart 
disease risk
Inflammation occurs in the vasculature as a response to injury, lipid
peroxidation, and perhaps infection [364]. Various risk factors, including
hypertension, diabetes, and smoking, are amplified by the harmful effects of
oxidised low-density-lipoprotein cholesterol, initiating a chronic inflammatory
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reaction, the result of which is a vulnerable plaque, prone to rupture and 
thrombosis [363]. As noted already epidemiological and clinical studies have 
shown strong and consistent relationships between markers of inflammation and 
risk of future cardiovascular events. Inflammation can potentially be detected 
directly, locally, within vessels by imaging techniques as well as emerging 
techniques, such as identification of temperature or pH heterogeneity. It can also 
though be detected more easily, systemically, by measurement of inflammatory 
markers [376].
A number of different markers of inflammation are measurable in blood [377]. 
These include cytokines, chemokines, soluble adhesion molecules, and acute- 
phase reactants. Of these, the most reliable and readily accessible for clinical 
use is CRP, and in particular what some have termed high sensitivity CRP 
(hsCRP). The “high sensitivity” refers simply to the lower detection limit of the 
assay procedures being used. The analyte is the same regardless of the assay 
range and very sensitive CRP assays have been reported from research 
laboratories for 30 years [19, 378, 379]. The new development is the 
introduction of commercial and automated routine CRP immunoassay systems 
with greater sensitivity than before. CRP has several advantages over other 
markers. First, the analyte is stable (CRP in serum or plasma samples is stable 
when refrigerated for at least 7 days and for extended periods of time, many 
decades, when frozen). Second, many automated hsCRP methods are 
commercially available and third an international secondary serum reference 
material (CRM 470, produced by the International Federation for Clinical 
Chemistry [380]) is readily available for standardisation of kit calibrators.
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hsCRP assays are those that have a low enough detection limit to permit CRP 
measurement in all, or nearly all, healthy subjects. This translates into a lower 
limit of quantification of <0.3 mg/L and assay imprecision of <10% at a CRP 
concentration <0.5 to 1.0 mg/L, although exact performance requirements have 
not been defined [381,382].
To date, CRP values have been used prognostically in a variety of different 
cardiovascular settings [383-385]. Interpretation of such studies must bear in 
mind the differing pathophysiological processes involved in, for example, 
myocardial infarction, unstable angina and stable angina. Nevertheless CRP is 
invariably produced in large amounts in response to myocardial necrosis and the 
peak values of circulating CRP powerfully predict outcome after myocardial 
infarction. CRP production, as well, predicts poor prognosis in severe unstable 
angina or after angioplasty, and may have the potential to guide primary and 
secondary prevention strategies involving HMG CoA-reductase inhibitors. 
Finally CRP production also predicts coronary events in general populations. 
Figure 8 from John Danesh’s work [179], shows the previous meta-analysis 
addressing the prognostic ability of CRP to predict future coronary heart disease 
events, in healthy individuals. On the basis of the data then available, comparing 
individuals with CRP concentrations in the top third with those in the bottom 
third at baseline, gave a combined risk ratio of 1.9 for coronary heart disease 
(95% Cl 1.5 to 2.3). The estimated mean usual log CRP values in the top third 
and bottom thirds were 0.38 and 0.02 mg/1 in the general population, which 
correspond to mean estimated usual values of 2.4 and 1.0 mg/1 respectively.
92
Type of cohort Mo. of Oogrooof
Piaaent study 
Rfcftar seal 1997 
Koanigstai, 1999 
Kuisrstsi 1998 
Iowa at al, 1999 
Tracy Mat. 1997 
Tracy at at. 1997 
VWhsra6staM999 
Ridkaratal. 1996 
Agawa6atat,1996 
Rokrainan at at, 2000
Ridkaratal. 1966 
Toss at at, 1997 
Havarfcalaatai, 1997
96% or
SOS
24653
246
166
ISO
145
100
61
16
241
381
13675
■M-k- —si. O-- ------m  vno • convMMVVGv mnO* ala^ gl ■ aCUaft(VDP UMII W  QOfGOVVI UHIU)
< £ >  16(66% Cl 16 to 2J)
U  (66% Cl 1.1 to l l )
-  14|86% CI1Jtel3)
0.5
Figure 8 Previous meta-analysis of prospective studies of CRP and coronary heart disease prediction
Latterly guidelines from the American Heart Association/Center for Disease 
Control (2002-03) included the measurement of CRP as a class Ila 
recommendation for stratifying patients with known cardiovascular disease 
(CVD) at a moderate (10-20%) 10-year event risk and a class Hb 
recommendation for patients without known CVD (Figure 9) [383].
High-senativity C-reactive protein is an 
independent marker of risk that may be used 
at the discretion of the physician in patients 
judged by global risk assessment to be at 
intermediate risk (10% to 20% risk of 
coronary heart disease per 10 years) for 
cardiovascular disease. hsCRP may help 
direct further evaluation and therapy in the 
primary prevention of CVD. The benefits of 
such therapy based on this strategy remain 
uncertain.
(Class Ha, Laval of Evidanca: B)
hsCRP is an independent marker of risk and 
may be used at the discretion of the
physician as part of a global coronary risk 
assessment in adults without known CVD. 
The benefits of this strategy remain
uncertain.
(Class lib, Laval of Evidanca: C)
hsCRP levels may be useful in motivating 
patients to improve their lifestyle behaviours. 
The benefits of this strategy remain
uncertain.
(Class lib, Laval of Evidanca: C)
Patients with persistently unexplained 
marked elevation of hsCRP (210 mg/L) after 
repeated testing should be evaluated for 
non-cardiovascular causes.
(Class Ila, Laval of Evidanca: B)
•  Inflammatory markers (cytokines, other 
acute-phase reactants) other than hsCRP 
should not be measured for the 
determination of coronary risk.
(Class III, Laval of Evidanca: C)
hsCRP measurement in patients with stable 
coronary disease or acute coronary 
syndromes may be useful as an 
independent marker of prognosis for 
recurrent events, including death, 
myocardial infarction, and restenosis after 
rcutaneous coronary intervention. The 
nefits of therapy based on this strategy 
remain uncertain.
(Class Ila, Laval of Evidanca: B)
Application of secondary prevention 
measures should not depend on hsCRP 
determination.
(Class III, Laval of Evidanca: A)
Application of management guidelines for 
ACS should not depend on hsCRP levels. 
(Class III, Laval of Evidanca: A)
Serial testing of hsCRP should not be used 
to monitor the effects of treatment.
(Class III, Laval of Evidanca: C)
Figure 9 American Heart Association/Center for Disease Control Guidelines
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The report acknowledged, however, that the epidemiological data to support this 
view were not entirely consistent and recommended that additional larger 
prospective studies be conducted to improve the reliability of the evidence. In 
particular, it remains uncertain whether CRP is an independent risk factor for 
coronary heart disease. For example, in the British Regional Heart Study, the 
odds ratio was reduced from 3.46 to 2.13 after adjustment for baseline 
confounding factors [179]. This substantial reduction suggests that more exact 
adjustment for confounding factors might produce a greater reduction.
This chapter presents data from the largest prospective study so far of CRP 
(Table 9), as well as discussing a subsequent updated meta-analysis [168], to 
help evaluate the relevance of CRP determination in the prediction of coronary 
heart disease. The lead investigator was Professor J. Danesh of the Department 
of Public Health and Primary Care, Institute of Public Health, University of 
Cambridge.
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Table 9 Prospective observational studies of CRP and coronary heart disease: details of study populations (pre-2003)
Reykjavik [168] Iceland Population register/complete birth cohorts 1967-
1991
2 406 18 569 39-59 70 20
ARIC [386] USA Listing of household/random 1987-89 615 15 792 45-64 43 8
W OSCOPS [387] Scotland Population register/complete 1989-95 580 6 595 45-64 100 6
BRHS [179] UK General practitioners list/random 1978-80 506 5 661 40-59 100 16
W om ens H ealth (WHI) [276] USA RN/LPN register/complete 1992-95 371 28 345 45+ 0 8
WHIOS [388] USA 40 clinic lists/complete 1994-98 280 93 724 50-79 0 3
C aerphilly  [389] Wales Electoral rolls/random 1979-83 249 2 512 45-59 100 14
MRFIT [174] USA Industry & government employees/complete 1973-76 246 12 866 35-57 100 10
P h y s ic ian s  Health [177] USA Physicians register/complete 1982 246 22 071 40-84 100 14
Helsinki H eart [390] Finland Industry employees/complete 1981-82 241 4 081 40-55 100 10
AFCAPS/TEXCAPS [273] USA Civilian and military clinics/complete 1990-93 216 6 605 45-73 ns 5
Speedw ell [391] England General practitioners list/complete 1979-82 165 1 690 47-67 100 6
CHS [186] USA Medicine eligibility lists/complete 1989-90 150 5 888 >=65 61 3
Helsinki A ging [392] Finland Population register/random from birth 
cohorts
1989 147 651 75-85 28 10
RHPP [186] USA Medicine eligibility lists/complete 1995 145 3 884 65-79 43 3
G lostrup  [393] Denmark Population register/random from birth 
cohorts
1976-84 133 5 637 30-50 100 12
Q uebec  [394] Canada Population register/random 1985 105 2100 45-77 100 5
K aiser P e rm an en te  [395] USA Health check list/random 1967-79 100 261 ns ns 5
Iowa 65+ [396] USA Population register/complete age 65+ years 1982 74 3 673 65+ 41 4
MONICA A u g sb u rg  [178] Germany Population register/random 1984-92 53 5 069 25-74 100 7
HOORN [397] Netherlands Population register/random 1989-92 24 2 484 50-75 48 5
G btebo rg  In terven tion  [398] Sweden Population register/complete 1993 16 508 50-72 100 3
* Sampling method: random = a randomly selected subset o f eligible persons was invited to participate; complete = all eligible persons in the study population were invited to participate.Eligibility was based on more restrictive criteria in the following studies: WOSCOPS (persons with LDL o f 
174-232mg/dl); MRFIT2 (persons with a high risk for CHD based on blood pressure, cholesterol and smoking profiles); Helsinki Heart (persons with high non-HDL levels); AFCAPS/TEXCAPS (persons with below average HDL); Goteborg Intervention (persons with hypertension). 
ARIC=Atherosclerosis Risk in Communities; WOSCOPS=West o f  Scotland Coronary Prevention Study; BRHS=British Regional Heart Study; WH10S=Womens Health Initiative Observational Study; MRFIT=Multiple Risk Factor Intervention Trial; AFCAPS/TexCAPS=Air Force/Texas 
Coronary Atherosclerosis Prevention Study; CHS=Cardiovascular Health Study; RHPP=Rural Health Promotion Project;.
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10.5 Study Methods
We measured CRP concentrations in about 2400 incident coronary heart disease 
cases and in about 4000 controls “nested” within the Reykjavik prospective 
cohort study of about 19 000 middle-aged men and women without a history of 
myocardial infarction, thereby involving about four times as many coronary heart 
disease cases as the previous largest such study. In addition to reducing random 
error because of its larger sample size, the present study was able to assess the 
impact of within-individual variation of inflammatory markers because serial 
blood samples were taken over several years in several hundred of its 
participants.
10.5.1 Patients and Controls
Iceland has a total population of around 280,000 with over half the population 
living in the capital Reykjavik. The Reykjavik Study is a large population-based 
cohort study that started in 1967 [399-402]. All men bom between 1907 and 
1934 and all women bom between 1908 and 1935 who were resident in 
Reykjavik and its adjacent communities on 1 December 1966 were identified in 
the national population register and then invited to participate in the study during 
five stages of recruitment between 1967 and 1991, yielding 8888 male and 9681
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female participants without a history of myocardial infarction (72 percent 
response rate) [403]. Nurses administered questionnaires, made physical 
measurements, recorded an electrocardiogram, performed spirometry (forced 
expiratory volume in 1 second), and collected fasting venous blood samples for 
measurement of ESR, and for preparation of aliquots of serum, which were 
stored at -20°C for subsequent analysis. Factors measured either by the nurses 
or in the laboratory included systolic and diastolic blood pressure, fasting total 
cholesterol, triglycerides, smoking habits (classified here only either as smoking 
or non-smoking or current/ex-smoker and never smoked), height, and weight, as 
well as assessment for the presence of diabetes. A standard glucose tolerance 
test was performed, with a fasting and 90 minute glucose concentration 
determined [404]. All participants have been monitored subsequently for all 
cause mortality and for cardiovascular morbidity, with a loss to follow up of only 
about 0.6 percent to date [403].
A total of 2459 men and women with available serum samples had major 
coronary events between the beginning of follow-up and 31 December 1995, 
yielding mean durations of follow-up among CHD cases of 17.5 (SD 8.7) years 
and of 20.6 (SD 8.2) years among controls. Among men, 1073 CHD deaths and 
701 non-fatal myocardial infarctions (Mis) were recorded (including 564 
confirmed Mis and 137 possible Mis) and 385 CHD deaths and 300 non-fatal 
Mis among women (including 237 confirmed Mis and 63 possible Mis). Deaths 
from coronary heart disease were ascertained from central registers on the basis 
of a death certificate with International Classification of Diseases codes 410-414,
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and the diagnosis of non-fatal myocardial infarction was based on MONICA 
criteria. We selected 3969 controls “frequency” matched to cases on calendar 
year of recruitment, sex, and age in five year bands from among participants who 
had survived to the end of the study period without a myocardial infarction. A 
national ethics panel approved the study protocol and participants provided 
informed consent.
10.5.2 Laboratory Methods
Laboratory measurements were made without knowledge of the participants' 
disease status, and thus samples (approximately 100 pi volumes) from patients 
and controls were randomly distributed during the assay process. Concentrations 
of CRP were measured by latex-enhanced immunoturbidimetry, with a lower 
limit o f detection of 0.02 mg/1 (Roche Diagnostics) [405], in the Clinical 
Chemistry Department of the Royal Free Hospital. The variation in CRP values 
within runs was less than 1%, and the between-day variability was 1% at a 
concentration of 14 mg/1 and 3.7% at a concentration of 3.8 mg/1 (Table 10).
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Table 10 Quality control data for CRP measurement
Control “SPS-13” “CRP T-S”
n 106 132
Quoted (mg/l) 14.3 3.762
Mean (mg/l) 14.218 3.794
SD 0.1437 0.1407
CV (%) 1.011 3.708
The Wintrobe method was used to measure the erythrocyte sedimentation rate in 
fresh blood samples obtained at the time of base-line venesection [402]. Other 
biochemical and haematologic measurements involved the use of standard 
assays. Previous reports describe these in more detail [399]. To determine self­
correlation for the markers of interest [406], measurements were made in pairs of 
samples obtained from 379 participants a mean of about 11.5 years apart.
10.5.3 Statistical Analysis
For ethical, social and political reasons (e.g. the deCODE project), the issue of 
confidentiality in research in Iceland is topical, and subject to legislation [407- 
409]. This had bearing on how the data was handled by myself and our 
collaborators. As a result the analysis is clearly divided into two sections.
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Baseline analysis: The statistical analysis of the baseline data was performed in 
London using SPSS 10.0 for Windows (SPSS Inc.). Log-transformation was used 
as appropriate for variables not normally distributed. Baseline associations were 
assessed by simple correlation, linear regression, analysis of variance and binary 
logistic regression. Adjustment was based upon gender, smoking status and 
diabetes as fixed factors, with other factors representing covariates (ESR, age, 
FEV1, BMI, fasting glucose, glucose tolerance at 90 minutes, cholesterol, 
triglycerides, systolic BP, diastolic BP, haematocrit, haemoglobin, creatinine). 
% FEV1 was calculated as the FEV1/Predicted FEV1 x 100. Predicted FEV1 for 
men and women was calculated as defined previously [410]. For graphical 
representation the boxes represent the interquartile range around the median 
(horizontal line); whiskers show the highest and lowest values within one 
interquartile interval from the box. Extreme values/outliers are not shown, but 
are included in the analysis. Error bar charts plot the mean and 95% confidence 
intervals for variables. Histograms demonstrate frequency, according to the 
variable/category assigned.
Case-control analysis: The case-control analysis, with access to further aspects 
of the dataset, was performed in Cambridge. Small differences in the datasets 
exist between the baseline and the case-control analysis and reflect independent 
parallel collaborations on going at the same time, but do not affect the overall 
conclusions. The analysis employed unmatched stratified logistic regression 
fitted according to the unconditional maximum likelihood (Stata software, 
version 7). To maximise the ability to compare the results with those of previous 
reports, primary analyses of values of CRP and ESR, were prespecified to
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compare extreme thirds of patients and controls with respect to the distribution of 
values in the controls. Odds ratios were sequentially adjusted for the following 
variables: age, sex, calendar year of enrollment, smoking status, systolic blood 
pressure, total cholesterol level, triglyceride level, body-mass index, forced 
expiratory volume in one second, presence or absence of diabetes, socioeconomic 
status, and the concentrations of ESR.
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10.6 Results
The analysis herein is focussed towards CRP in keeping with our contribution to 
the Reykjavik Study. ESR as the most robust alternative inflammatory marker is 
used for reference where appropriate.
10.7 Baseline data
The important baseline characteristics of our population are shown in Tables 11, 
12, and 13. Nearly 70% of subjects were male, and the rate of active smoking at 
the time of recruitment was just over one-third. The mean age at recruitment was 
just over 55 years old. There were 152 diabetic patients. In keeping with 
previous population studies of CRP, the median CRP was 1.41 mg/l, the 90th 
centile being 5.82 mg/l and the 99th centile 27.14 mg/l. The geometric mean of 
log transformed CRP was 1.45 mg/l. Just over 4% of the individuals had a CRP 
>10mg/l, the cut off previously used to indicate active inflammation. If these 
individuals are excluded the median CRP falls slightly to 1.32 mg/l, with the 90th 
centile being 4.64 mg/l and the 99th centile 8.85 mg/l. However specifically to 
avoid introduction of any extra bias, the data is analysed as a whole, without 
exclusion of patients with a CRP >10 mg/l; the objective of analysis was to 
ascertain baseline associations for CRP in all objectively well individuals.
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Table 11 Summary of population attributes at baseline
Baseflne statistics
Percentiles
Age at bleed (yr) 6760 0 55.68 54.63 9.20 .49 .25 51.25 58.24
CRP (mg/l) •620 140 2 J6 1-41 5.21 •JO 70.90 XT 2X2
log CRP 6620 140 .16 .15 .49 .19 .17 -.07 .36
ESR (mm/1 st hr) 6713 47 9.74 7.00 10.02 2.40 9.32 4.00 10.00
log ESR +1 6713 47 .90 .90 .40 -.20 -.30 .70 1.04
Height (m) 6733 27 1.72 1.72 .09 -.21 -.39 1.68 1.76
Weight (kg) 6731 29 75.69 75.20 13.54 .39 .77 69.60 80.60
Body mass index (BMI) 6720 40 25.65 25.42 3.80 .76 2.60 23.92 26.87
Systofic BP (mmHg) 6735 25 143.33 140.00 22.66 .89 1.40 130.00 150.00
Diastolic BP (mmHg) 6730 30 89.00 88.00 11.85 .63 1.32 84.00 92.00
FEV1 (ml in 1 second) 6632 128 2848.43 2850.00 859.02 -.02 -.45 2450.00 3250.00
Fasting glucose (mmol/l) 6704 56 4.57 4.44 .89 5.79 59.51 4.22 4.66
Glucose tolerance. 90 minutes (mmol/l) 6455 305 5.89 5.55 2.08 2.14 9.67 4.94 6.27
Haemoglobin (mmol/l) 6705 55 9.11 9.18 .81 -.34 .91 8.81 9.43
Haematocrit (%) 6707 53 44.47 45.00 3.55 -.03 1.45 43.00 46.00
Cholesterol (mmol/l) 6752 8 6.58 6.50 1.18 .75 2.86 6.03 6.94
Triglycerides (mmol/l) 6354 406 1.22 1.05 .69 3.76 31.89 .87 1.28
log Triglycerides 6354 406 .04 .02 .20 .49 .70 -.06 .11
Creatinine (Mmol/l) 6704 56 87.98 88.40 15.69 1.56 18.57 79.56 88.40
loo Creatinine 6700 60 1.94 1.95 .07 -.12 3.17 1.90 1.95
Table 12 Gender differences in baseline parameters
Gender
Female Male
Valid No. Mean Median Std Deviation Valid N Mean Median Std Deviation
CRP (mg/l) 1938 2.75 1.35 4.79 4682 2.91 1.44 5.38
log CRP ** 1938 .14 .13 .50 4682 .17 .16 .48
ESR (mm/1 st hr) 1948 14.57 12.00 11.83 4785 7.77 5.00 8.42
Log ESR + 1 * 1948 1.07 1.11 .34 4765 .78 .78 .38
Height (m)* 1954 1.62 1.62 .06 4779 1.76 1.78 .06
Weight (kg)* 1955 66.09 64.70 12.03 4776 79.62 78.70 12.09
Body m ass index (BMI) * 1949 25.26 24.91 4.42 4771 25.82 25.63 3.51
Systolic BP (mmHg) 1953 143.64 140.00 24.42 4782 143.20 140.00 21.91
Diastolic BP (mmHg) * 1952 86.15 86.00 12.00 4778 90.16 90.00 11.59
FEV1 (ml in 1 second) * 1892 2084.26 2100.00 577.73 4740 3153.46 3150.00 757.05
Fasting glucose 
(mmol/l)* 1954 4.42 4.27 .92 4750 4.63 4.50 .87
Glucose tolerance: 90 
minutes (mmol/l) * 1827 6.05 5.66 2.03 4628 5.83 5.49 2.10
Haemoglobin (mmol/l) * 1955 8.42 8.44 .68 4750 9.40 9.37 .67
Haematocrit (%) * 1954 41.69 42.00 3.17 4753 45.62 46.00 3.03
Cholesterol (mmol/0 * 1964 6.95 6.84 1.30 4788 6.43 6.37 1.09
Triglycerides (mmol/0 1948 1.15 1.01 .58 4406 1.26 1.08 .74
log Triglycerides * 1948 .02 .00 .19 4406 .05 .04 .20
Creatinine (pmol/1) 1960 78.00 79.56 14.03 4744 92.10 88.40 14.44
loo Creatinine * 1959 1.89 1.90 .07 4741 1.96 1.95 .06
* P<0.001 for difference between fem ales and males; ** P<0.01 for difference between females and males
Table 13 Breakdown of gender and crude smoking history at baseline
 Crude smoking history_________ Total________ Age
No n-smoker Cu rrent smoker
N (%)___________N (%)__________ %_______Mean (SD)
Male 3337(69.6) 1458(30.4) 69.6 54.67(8.93)
Sex
Female 1093(55.6) 872(44.4) 30.4 58.15(9.39)
% 65.5 34.5 55.68 (9.2)
As with previous studies the distribution of CRP is highly skewed (Figure 10). 
When values are log transformed, the distribution assumes a Gaussian 
distribution. ESR values are less precise by analytical nature and the distribution 
is less skewed (Figure 11). Since ESR values can be zero, in this case the log 
transformation is adjusted by adding 1 to all the values. Triglycerides and 
creatinine distributions benefited in the same way from log transformation.
The cut off points for tertiles in the whole population for CRP were 0.87 mg/l 
and 2.32 mg/l. This differs very slightly from the case-control analysis, wherein 
the tertile cut points relate to the control group only, and therefore are, as one 
would expect, slightly lower (0.78 mg/l and 2 mg/l). Table 14 summarises the 
crude baseline differences for some of the important markers, when classified by 
CRP tertile. This is discussed in detail later.
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Table 14 Summary of differences in baseline parameters according to CRP 
tertiles
DsaCftpttVSS
CRPTsrtMs N Moan Std. Deviation Std. Error
95% Confidence Interval for 
Mean
Lower Bound Upper Bound Minimum Maximum
BUM <067
0.87-2.32
>2.32
Total
2179
2211
2191
6681
24.5823
25.9218
26.4501
25.6542
3.3075
3.5401
4.2597
3.8050
7.086E-02 
7.529E-02 
9.100E-02 
4.691 E-02
24.4433
25.7742
28.2716
25.5622
24.7212
26.0694
26.6286
25.7461
13.40 
14.79 
15.12
13.40
40.13
41.77
53.91
53.91
Systolic BP (mm Hg) <067 2183 1408156 21.1961 .4537 139.4260 1412053 92.00 290.00
0.87-2.32 2215 143.8388 22.3210 .4743 142.9088 144.7689 90.00 240.00
>222 2197 1458061 24.1193 .5146 144.7970 1468152 86.00 276.00
Total 6699 1438280 22.6898 .2794 142.7803 143.8757 86.00 290.00
Diastolic BP (mmHg) <087 2181 87.8446 11.0341 .2363 87.3812 88.3079 28.00 150.00
0.87-282 2214 89.2913 11.8845 .2528 88.7960 89.7866 60.00 142.00
>282 2195 89.8907 12.5625 .2881 89.3648 90.4165 50.00 164.00
Total 6500 89.0121 11.8745 .1463 88.7254 89.2989 28.00 164.00
FEV1 (ml) <087 2152 3027.6380 870.5115 18.7652 2990.8382 3064.4378 500.00 5800.00
0.87-282 2162 28608621 827.4938 17.7148 2825.5224 2895.0019 650.00 5150.00
>282 2160 26568269 841.6344 18.1091 2621.1138 2692.1399 500.00 5200.00
Total 6494 2847.9955 859.9480 10.6713 2827.0763 2868.9147 500.00 5800.00
% FEV1 PrBdctod <087 2150 90.9033 19.6619 .4240 90.0718 91.7349 20.31 220.37
0.87-282 2178 87.9714 19.0793 .4088 87.1696 88.7731 19.51 15662
>282 2154 82.7667 20.4665 .4410 81.9019 83.6315 19.11 154.14
Total 6482 87.2143 200224 .2487 86.7268 87.7018 19.11 220.37
Ags at bissd (yra) <087 2188 53.9667 8.5860 .1836 53.6068 54.3267 33.30 85.80
0.87-2.32 2224 55.8281 9.1319 .1936 55.4484 56.2079 33.38 85.97
>282 2208 57.0977 9.5889 .2041 56.6975 57.4979 33.41 86.29
Total 6620 55.6363 9.2016 .1131 55.4146 55.8560 33.30 86.29
Cholesterol (mmotfl) <087 2186 6.5475 1.1556 2.472E-02 6.4991 6.5960 3.42 12.85
0.87-2.32 2221 6.6426 1.2057 2.558E-02 6.5924 6.6928 2.80 18.96
>282 2205 6.5722 1.1676 2.487E-02 6.5234 6.6209 3.06 12.12
Total 6612 6.5877 1.1773 1.448E-02 6.5593 6.6161 2.80 18.96
Trtglycaildes (mmol/l) <087 2070 1.0690 .5462 1.200E-02 1.0455 1.0925 .15 7.01
0.87-2.32 2063 1.2655 .7465 1.636E-02 1.2335 1.2976 .20 11.29
>282 2078 1.3340 .7461 1.637E-02 1.3019 1.3661 .32 11.29
Total 6231 1.2231 .6653 8.809E-03 1.2058 1.2403 .15 11.29
log Triglycerides <087 2070 -1.34656-02 .1846 4.065E-03 -2.1437E-02 -5.4938E-03 -.83 .85
0.87-Z32 2063 5.188E-02 .1988 4.356E-03 4.333E-02 6.042E-02 -.69 1.05
>282 2078 7.731 E-02 .1966 4.313E-03 6.885E-02 8.576E-02 -.50 1.05
Total 6231 3.865E-02 .1973 2.499E-03 3.375E-02 4.355E-02 -.63 1.05
Fasting glucosa (mmoM) <087 2172 4.4941 .7285 1.563E-02 4.4634 4.5248 .39 15.54
0.87-2.32 2204 4.5657 .8627 1.838E-02 4.5296 4.8017 2.22 15.78
>282 2188 4.6432 1.0509 2.247E-02 4.5991 4.6873 2.39 18.98
Total 6564 4.5678 .8928 1.102E-02 4.5462 4.5894 .39 18.98
Glucoss tolerance: 90 <0.87 2124 5.6198 1.8518 4.018E-02 5.5410 5.6966 .00 21.65
mhutos (mmol/l) 0.87-2.32 2117 5.8851 2.0786 4.518E-02 5.7965 5.9737 2.22 25.86
>282 2074 6.1670 2.2647 4.973E-02 6.0695 6.2645 1.94 22.20
Total 6315 5.8884 2.0820 2.620E-02 5.8371 5.9398 .00 25.86
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10.8 Associations
Previous epidemiological studies have described a number of associations for 
baseline CRP values. The tables below show unadjusted non-parametric (Table 
15) and parametric (Table 16) associations for CRP and log transformed CRP. 
Factors that stand out as being correlated with CRP are increasing age, smoking 
status, reductions in FEV1 and increases in BMI. Other associations include 
gender (male vs. female), fasting glucose, glucose tolerance at 90 minutes, 
triglycerides and systolic blood pressure. ESR values, precisely because they are 
another measure of inflammation, are strongly associated with baseline CRP.
Table 15 Spearman Rank Correlations for CRP
Spearman Rank Correlations
CRP
CRP 1.000
ESR .351**
Age at bleed .146**
Gender .031*
Smoking status .165**
FEV1 -.187**
BMI .202**
Diabetic status .025*
Fasting glucose .068**
Glucose tolerance: 90 minutes .109**
Cholesterol .007
Triglycerides .202**
Systolic BP .101**
Diastolic BP .065**
Haematocrit .080**
Haemoglobin .046**
Creatinine .043**
**. Correlation is significant at the .01 level 
*■ Correlation is significant at the .05 level (2-tailed).
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Table 16 Pearson correlations for CRP
Pearson correlations
log CRP
log CRP 1.000
Log ESR +1 .359**
Age at bleed .149**
Gender .033**
Smoking status .160**
FEV1 -.189**
BMI .199**
Diabetic status .025*
Fasting glucose .067**
Glucose tolerance: 90 minutes .115**
Cholesterol .003
log Triglycerides .182**
Systolic BP .105**
Diastolic BP .072**
Haematocrit .078**
Haemoglobin .050**
loo Creatinine .054**
**• Correlation is significant at the 0.01 level 
*■ Correlation is significant at the 0.05 level (2-tailed).
Simple adjustment for age, gender and smoking modifies the correlations further 
(Table 17). At this stage, other than cholesterol, all the variables appear to have, 
at least statistical association with baseline CRP values. The partial correlations 
are shown for all the other variables in Table 18.
I l l
Table 17 Partial correlations for CRP (adjusted for age, gender, smoking)
log CRP 1.000
log ESR+1 0.388 **
FEV1 -0.169 **
BMI 0.220 **
Fasting glucose 0.060 **
Glucose tolerance: 90 minutes 0.113**
Cholesterol 0.023
log Triglycerides 0.159**
Systolic BP 0.098 **
Diastolic BP 0.095 **
Haematocrit 0.072 **
Haemoglobin 0.047 **
log Creatinine 0.039 **
** Correlation is significant at the 0.001 level (2 tailed)
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Table 18 Partial correlations for all variables (adjusted for age, gender and smoking)
- 0..388* -0.169* 0.220* 0.060* 0.113* 0.023 0.156* 0.098* 0.095* 0.072* 0.047* 0.040+
0.388* - -0.115* 0.066* 0.067* 0.082* 0.135* 0.069* 0.106* 0.078* -0.268* -0.230* -0.046*
-0.169* -.115* - 0.028 -0.024 -0.090* 0.018 -0.067* -0.087* -0.079* -0.116* -0.036+ 0.030
0.220* 0.066* 0.028 - 0.210* 0.164* 0.063* 0.325* 0.239* 0.274* 0.153* 0.202* 0.081*
0.060* 0.067* -0.024 0.210* - 0.588* 0.031 0.161* 0.162* 0.122* 0.014* 0.048* -0.011
0.113* 0.082* -0.090 0.164* 0.588* - 0.022 0.214* 0.158* 0.128* 0.050* 0.092* 0.035+
0.023 0.140* 0.018 0.063* 0.031 0.022 - 0.223* 0.110* 0.106* 0.130* 0.146* 0.036+
0.159* 0.069* -0.067* 0.330* 0.161* 0.214 0.223* - 0.135* 0.162* 0.160* 0.190* 0.180*
0.098* 0.106* -0.087* 0.239* 0.162* 0.158* 0.110* 0.135* - 0.748* 0.168* 0.153* 0.050*
0.095* 0.078* -0.079* 0.274* 0.122* 0.128* 0.106* 0.162* 0.748* - 0.216* 0.210* 0.074*
0.072* -0.268* -0.116* 0.153* 0.014 0.050* 0.130* 0.160* 0.168* 0.216* - 0.828* 0.078*
0.047* -.230* -0.036+ 0.202* 0.048* 0.092* 0.146* 0.190* 0.153* 0.210* 0.828* - 0.076*
0.039+ -0.046* 0.030 0.081* -0.011 0.035+ 0.036+ 0.180* 0.049* 0.074* 0.078* 0.076* -
Two tailed significance indicated at * P<0.001 or + P<0.01.
To further explore the associations three different analyses have been performed: 
simple linear regression, multivariate analysis and finally binary logistic 
regression. Categorical variables are coded 0 and 1 to enable insertion in the 
models. Caution must be exercised in the interpretation of statistical 
associations, as the biological relevance may not be important. Therefore in 
depth discussion of every statistical association is deliberately avoided. The 
different approaches show how changes in models/assumptions can alter 
strengths of associations, but strong associations remain regardless, namely, 
smoking, BMI and FEV1.
10.8.1 Linear regression
When entered into a linear regression model, the correlations adjust further, such 
that diabetic status and blood pressure are no longer significant. Other 
associations become significant, albeit with very low correlations e.g. 
cholesterol. Those with correlations > +/- 0.1 are ESR, age, gender (male), 
smoking, FEV1, BMI, cholesterol, triglycerides and haematocrit. The analysis is 
repeated for males and females separately, with only minor changes to the 
findings (Tables 19, 20 and 21). The comparison for ESR is shown in Table 22 
(gender is assigned to female, as ESR is positively correlated with female sex).
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Table 19 Linear regression analysis for CRP: males and females
Linear regression: coefficients *
Unstandardized Standardized
Coefficients Coefficients 95% Confidence Interval for B Correlations
B Std. Error Beta t Sig. Lower Bound Upper Bound Zero-order Partial Part
(Constant) -2.224 .200 -11.122 .000 -2.616 -1.832
Log ESR +1 .530 .016 .426 32.627 .000 .498 .562 .356 .397 .367
Age at bleed 5.813E-03 .001 .099 7.171 .000 .004 .007 .139 .095 .081
Gender .197 .019 .183 10.384 .000 .160 .234 .040 .136 .117
Smoking status .143 .013 .140 11.385 .000 .119 .168 .166 .149 .128
FEV1 -7.765E-05 .000 -.134 -8.304 .000 .000 .000 -.180 -.109 -.093
BMI 2.146E-02 .002 .164 12.933 .000 .018 .025 .196 .169 .145
Diabetic status -2.926E-02 .043 -.008 -.677 .498 -.114 .055 .031 -.009 -.008
Fasting glucose -2.337E-02 .009 -.038 -2.643 .008 -.041 -.006 .069 -.035 -.030
Glucose tolerance: 
90 minutes 1.297E-02 .003 .055 3.718 .000 .006 .020 .117 .049 .042
Cholesterol -2.988E-02 .005 -.071 -5.923 .000 -.040 -.020 .010 -.078 -.067
log Triglycerides .146 .032 .058 4.598 .000 .084 .208 .179 .061 .052
Systolic BP -6.836E-05 .000 -.003 -.180 .857 -.001 .001 .104 -.002 -.002
Diastolic BP -9.859E-04 .001 -.024 -1.354 .176 -.002 .000 .078 -.018 -.015
Haematocrit 3.070E-02 .003 .222 9.034 .000 .024 .037 .092 .119 .101
Haemoglobin -4.070E-02 .015 -.066 -2.628 .009 -.071
Oor .056 -.035 -.030
log Creatinine .209 .088 .031 2.362 .018 .035 .382 .052 .031 .027
a- Dependent Variable: log CRP
Table 20 Linear regression analysis for CRP: males only
Linear regression: Coefficients *,b
Model
Unstandardized
Coefficients
Standardized
Coefficients Correlations
B , Error Beta t Sig. Zero-order Partial Part
.254 -8.431 .000
.019 .420 28.700 .000 .401 .413 .384
.001 .074 4.540 .000 .132 .072 .061
.015 .130 9.083 .000 .184 .142 .122
.000 -.119 -7.482 .000 -.246 -.117 -.100
.002 .150 9.834 .000 .167 .153 .132
.052 -.022 -1.533 .125 .009 -.024 -.021
.010 -.031 -1.812 .070 .058 -.029 -.024
.004 .054 3.069 .002 .114 .048 .041
.006 -.039 -2.779 .005 .030 -.044 -.037
.036 .040 2.660 .008 .147 .042 .036
.000 -.007 -.326 .745 .104 -.005 -.004
.001 -.010 -.468 .640 .077 -.007 -.006
.004 .246 10.201 .000 .083 .159 .136
.018 -.106 -4.366 .000 .022 -.069 -.058
.107 .028 2.033 .042 .015 .032 .027
1 (Constant) -2.145
Log ESR + 1 .532
Age at bleed 4.375E-03
Smoking status .136
FEV1 -7.712E-05
BMI 2.083E-02
Diabetic status -7.999E-02
Fasting glucose -1.889E-02
Glucose tolerance: „nn • 1.251 E-0290 minutes
Cholesterol -1.739E-02
log Triglycerides 9.660E-02
Systolic BP -1.501E-04
Diastolic BP -4.067E-04
Haematocrit 3.970E-02
Haemoglobin -7.829E-02
 ________log Creatinine______  .217
a- Dependent Variable: log CRP
b- Selecting only cases for which Gender- Male
Table 21 Linear regression analysis for CRP: females only
Linear regression: Coefficients *>b
Unstandardized Standardized
_______ Coefficients____________Coefficients  Correlations_______
Model_____________________________ B________ Std. Error________ Beta___________t_______Sig. Zero-order Partial Part
(Constant) -1.813 .355 -5.113 .000
Log ESR +1 .534 .034 .363 15.806 .000 .378 .361 .325
Age at bleed 8.049E-03 .002 .132 5.185 .000 .179 .126 .106
Smoking status .160 .023 .157 6.885 .000 .151 .166 .141
FEV1 -9.548E-05 .000 -.107 -4.394 .000 -.259 -.107 -.090
BMI 2.247E-02 .003 .192 8.279 .000 .246 .199 .170
Diabetic status 5.891 E-02 .078 .016 .759 .448 .079 .019 .016
Fasting glucose -3.926E-02 .017 -.061 -2.344 .019 .079 -.057 -.048
Glucose tolerance: 
90 minutes 1.590E-02 .007 .064 2.377 .018 .134 .058 .049
Cholesterol -5.441 E-02 .009 -.140 -6.307 .000 -.004 -.153 -.130
log Triglycerides .252 .065 .092 3.869 .000 .250 .094 .079
Systolic BP 8.136E-05 .001 .004 .120 .904 .104 .003 .002
Diastolic BP -1.260E-03 .001 -.030 -.936 .349 .063
COCM©r -.019
Haematocrit 6.752E-03 .007 .041 .959 .338 .084 .023 .020
Haemoglobin 5.252E-02 .032 .069 1.663 .097 .081 .041 .034
loo Creatinine .154 .157 .021 .986 .325 .085 .024 .020
a- Dependent Variable: log CRP
b- Selecting only cases for which Gender = Female
Table 22 Linear regression analysis for ESR
Linear regression: Coefficients
Model
Unstandardized
Coefficients
Standardized
Coefficients Correlations
B Std. Error Beta t Sig. Zero-order Partial Part
1 (Constant)
Age at bleed 
Gender (Female) 
Smoking status 
FEV1 
BMI
Diabetic status
Fasting glucose
Glucose tolerance: 
90 minutes
Cholesterol
log Triglycerides
Systolic BP
Diastolic BP
Haematocrit
Haemoglobin
log Creatinine
2.974 
-5.671 E-03 
5.041 E-02 
4.303E-02 
-4.698E-05 
-4.848E-04 
-1.262E-02 
6.050E-03
4.576E-03
5.310E-02
1.607E-02
1.119E-03
1.335E-03
-3.989E-02
-1.445E-02
-.259
.297
.153
.001
.014
.010
.000
.001
.032
.007
.003
.004
.024
.000
.001
.003
.012
.066
.009
-.120
.058
.052
-.101
-.005
-.004
.012
.024
.158
.008
.064
.040
-.359
-.029
-.048
.370
19.445
-9.373
3.524
4.528
-6.698
-.385
-.390
.913
1.751
14.265
.677
3.937
2.450
-15.912
-1.246
-3.924
32.627
.000
.000
.000
.000
.000
.700
.697
.361
.080
.000
.499
.000
.014
.000
.213
.000
.000
.051 -.123 -.098
.338 .047 .037
.141 .060 .047
-.283 -.088 -.070
.022 -.005 -.004
.012 -.005 -.004
.015 .012 .010
.083 .023 .018
.192 .186 .149
.041 .009 .007
.082 .052 .041
.003 .032 .026
-.380 -.206 -.167
-.363 -.017 -.013
-.203 -.052 -.041
.356 .397 .342
a Dependent Variable: Log ESR + 1
10.8.2 Univariate analysis
Similarly to the linear regression model, a simple univariate analysis for CRP 
(General Linear Model: Univariate; Type IV Sum of Squares) confirms the 
independent associations as smoking, age, FEV1, BMI, fasting glucose (weak), 
glucose tolerance at 90 minutes, cholesterol, triglycerides, haematocrit, 
haemoglobin, creatinine (weak) and ESR; Tables 23, 24 and 25. There were no 
strongly significant interactions between factors, although gender and diabetes 
status was weakly significant, P=0.027. In this analysis, gender was not 
significantly associated with CRP values. By assigning gender to be either 0 or 1 
in the weighted least squares option, analysis restricted to males or females was 
also performed.
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Table 23 Between subject effects for CRP: males and females 
Univariate analysis: Tests of Between-Subjects Effects
Dependent Variable: log CRP
Source
Type IV Sum 
of Squares df Mean Square F Sig.
Corrected Model 387.323® 20 19.366 112.031 .000
Intercept 16.926 1 16.926 97.913 .000
Age bled 8.889 1 8.889 51.423 .000
FEV1 11.917 1 11.917 68.939 .000
BMI 28.681 1 28.681 165.919 .000
Fasting glucose 1.091 1 1.091 6.310 .012
Glucose tolerance: 
90 minutes 2.413 1 2.413 13.960 .000
Cholesterol 6.015 1 6.015 34.794 .000
log Triglycerides 3.514 1 3.514 20.328 .000
Systolic BP 6.841 E-03 1 6.841 E-03 .040 .842
Diastolic BP .304 1 .304 1.758 .185
Haematocrit 14.044 1 14.044 81.243 .000
Haemoglobin 1.202 1 1.202 6.951 .008
log Creatinine .933 1 .933 5.396 .020
log ESR +1 183.471 1 183.471 1061.365 .000
Gender (Male) .562 1 .562 3.249 .072
Smoking status 2.545 1 2.545 14.721 .000
Diabetic status 3.596E-02 1 3.596E-02 .208 .648
Error 982.902 5686 .173
Total 1502.575 5707
Corrected Total 1370.225 5706
a- R Squared -  .283 (Adjusted R Squared ■ .280)
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Table 24 Between subject effects for CRP: females only
Univariate analysis (Females only): Tests of Between-Subjecte Effects b
Dependent Variable: tog CRP
Type IV Sum
Source of Squares df Mean Square F Sig.
Corrected Model 128.178® 16 8.011 44.140 .000
Intercept 4.024 1 4.024 22.171 .000
Age bled 4.851 1 4.851 26.730 .000
FEV1 3.488 1 3.488 19.217 .000
BMI 12.290 1 12.290 67.717 .000
Fasting glucose 1.039 1 1.039 5.725 .017
Glucose tolerance: 1.087 1 1.087 5.990 .01490 minutes
Cholesterol 7.167 1 7.167 39.492 .000
log Triglycerides 2.745 1 2.745 15.126 .000
Systolic BP 3.388E-03 1 3.388E-03 .019 .891
Diastolic BP .157 1 .157 .867 .352
Haematocrit .158 1 .158 .869 .351
Haemoglobin .509 1 .509 2.802 .094
log Creatinine .180 1 .180 .990 .320
log ESR +1 45.168 1 45.168 248.866 .000
Smoking status 1.438 1 1.438 7.922 .005
Diabetic status .223 1 .223 1.227 .268
Error 302.186 1665 .181
Total 455.254 1682
Corrected Total 430.362 1681
a* R Squared = .298 (Adjusted R Squared = .291)
b. Weighted Least Squares Regression - Weighted by Gender: Male -0; 
Female *1
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Table 25 Between subject effects for CRP: males only
Univariate analysis (Male only): Tests of Between-Subjects Effects b
Dependent Variable: log CRP
Type IV Sum
Source of Squares df Mean Square F Sig.
Corrected Model 264.860® 16 16.554 98.619 .000
Intercept 11.487 1 11.487 68.436 .000
Age bled 3.464 1 3.464 20.635 .000
FEV1 9.390 1 9.390 55.941 .000
BMI 16.200 1 16.200 96.509 .000
Fasting glucose .546 1 .546 3.251 .071
Glucose tolerance: 1.582 1 1.582 9.424 .00290 minutes
Cholesterol 1.297 1 1.297 7.725 .005
log Triglycerides 1.185 1 1.185 7.062 .008
Systolic BP 1.748E-02 1 1.748E-02 .104 .747
Diastolic BP 3.712E-02 1 3.712E-02 .221 .638
Haematocrit 17.442 1 17.442 103.911 .000
Haemoglobin 3.199 1 3.199 19.057 .000
log Creatinine .694 1 .694 4.137 .042
log ESR +1 138.235 1 138.235 823.535 .000
Smoking 1.227 1 1.227 7.307 .007
Diabetic status .318 1 .318 1.896 .169
Error 672.764 4008 .168
Total 1047.321 4025
Corrected Total 937.625 4024
a- R Squared -  .282 (Adjusted R Squared = .280)
b. Weighted Least Squares Regression - Weighted by Gender: Male =1 
Female =0
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10.8.3 Multivariate analysis
Table 26 shows a multivariate analysis for CRP and ESR (General Linear Model: 
Multivariate; Type IV Sum of squares). In this analysis, the fixed factors chosen 
are smoking, gender and diabetic status, whilst the other variables are treated as 
covariates. For CRP it is notable that cholesterol, gender, and diabetic status, 
along with creatinine and both systolic and diastolic blood pressure are no longer 
significantly associated. Note this analysis clearly does not include ESR/CRP as 
covariates.
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Table 26 Multivariate analysis for CRP and ESR
Multivariate analysis : Teste of Between-Subjects Effects
Source Dependent Variable
Type IV Sum 
of Squares df Mean Square F Sifl.
Corrected Model log CRP 203.851® 19 10.729 52.312 .000
Log ESR +1 229.837b 19 12.097 105.167 .000
Intercept log CRP 1.174 1 1.174 5.725 .017
Log ESR +1 35.142 1 35.142 305.523 .000
Age Bled log CRP 2.940 1 2.940 14.337 .000
Log ESR +1 5.841 1 5.841 50.784 .000
FEV1 log CRP 29.855 1 29.855 145.566 .000
Log ESR +1 13.912 1 13.912 120.949 .000
BMI log CRP 39.529 1 39.529 192.734 .000
Log ESR +1 3.014 1 3.014 26.200 .000
Fasting glucose log CRP 1.136 1 1.136 5.539 .019
Log ESR +1 1.643E-03 1 1.643E-03 .014 .905
Glucose tolearance: log CRP 4.803 1 4.803 23.417 .000
90 minutes Log ESR +1 1.444 1 1.444 12.552 .000
Cholesterol log CRP 2.674E-02 1 2.674E-02 .130 .718
Log ESR +1 19.270 1 19.270 167.529 .000
log Triglycerides log CRP 5.579 1 5.579 27.203 .000
Log ESR +1 .843 1 .843 7.330 .007
Systolic BP log CRP .440 1 .440 2.146 .143
Log ESR +1 1.986 1 1.986 17.262 .000
Diastolic BP log CRP 2.850E-02 1 2.850E-02 .139 .709
Log ESR +1 .522 1 .522 4.539 .033
Haematocrit log CRP 1.972 1 1.972 9.615 .002
Log ESR +1 20.566 1 20.566 178.801 .000
Haemoglobin log CRP 2.383 1 2.383 11.619 .001
Log ESR 1 .712 1 .712 6.193 .013
log Creatinine log CRP .145 1 .145 .706 .401
Log ESR •>-1 1.225 1 1.225 10.649 .001
Smoking status log CRP 4.501 1 4.501 21.944 .000
Log ESR +1 .983 1 .983 8.545 .003
Gender (Male) log CRP .262 1 .262 1.276 .259
Log ESR +1 .202 1 .202 1.757 .185
Diabetic status log CRP 3.472E-02 1 3.472E-02 .169 .681
Log ESR +1 3.894E-05 1 3.894E-05 .000 .985
Error log CRP 1166.374 5687 .205
Log ESR +1 654.137 5687 .115
Total log CRP 1502.575 5707
Log ESR +1 5132.393 5707
Corrected Total log CRP 1370.225 5706
Loq ESR +1 883.974 5706
a- R Squared = .149 (Adjusted R Squared = .146) 
b. R Squared = .260 (Adjusted R Squared = .258)
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10.8.4 Binary logistic regression
Finally, binary logistic regression, assessing the odds of CRP being in the upper 
third of the population distribution, was performed. Only subtle differences 
result, particularly depending on whether ESR is included as a covariate (Tables 
27 and 28).
Table 27 Binary logistic regression: association with CRP value being in the 
upper tertile of distribution - ESR excluded
Binary logistic regression: ESR excluded
95.0% C.I.fbr 
EXP(B)
B S.E. Wald df Sig. Exp(B) Lower Upper
Smoking status .793 .066 144.247 1 .000 2.210 1.942 2.516
Gender (Male) .622 .101 37.598 1 .000 1.863 1.527 2.272
Diabetic status -.222 .225 .973 1 .324 .801 .515 1.245
Age bled .013 .004 9.472 1 .002 1.013 1.005 1.022
FEV1 .000 .000 75.754 1 .000 1.000 .999 1.000
BMI .085 .009 92.102 1 .000 1.089 1.070 1.108
Fasting glucose -.069 .047 2.155 1 .142 .933 .851 1.023
Glucose tolerance: 
90 minutes .067 .018 13.234 1 .000 1.069 1.031 1.109
Cholesterol -.027 .027 1.003 1 .317 .974 .924 1.026
log Triglycerides .641 .169 14.356 1 .000 1.898 1.363 2.645
Systolic BP .001 .002 .092 1 .762 1.001 .997 1.005
Diastolic BP .001 .004 .033 1 .856 1.001 .993 1.008
Haematocrit .071 .018 14.995 1 .000 1.073 1.036 1.112
Haemoglobin -.292 .085 11.694 1 .001 .747 .632 .883
log Creatinine .163 .470 .121 1 .728 1.178 .468 2.960
Constant -4.064 1.045 15.112 1 .000 .017
a. Variable(s) entered on step 1: SMOK, SEX01, DIABHIST, AGEBLED, FEV1, BMI, GLUFMMOL, 
GLU90MMO. CHOLMMOL, LOGTRI, BPSYS, BPDIA, HCT, HBMMOL, LOGCREAT.
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Table 28 Binary logistic regression: association with CRP value being in the
upper tertile of distribution - ESR included
Binary logistic regression: ESR included
95.0% C.I.for 
EXP(B)
B S.E. Wald df Sig. Exp(B) Lower Upper
Smoking status .644 .071 83.221 1 .000 1.905 1.659 2.188
Gender (Male) .687 .108 40.240 1 .000 1.988 1.608 2.458
Diabetic status -.176 .238 .546 1 .460 .839 .527 1.336
Age bled .026 .005 30.408 1 .000 1.026 1.017 1.036
FEV1 .000 .000 27.808 1 .000 1.000 1.000 1.000
BMI .080 .009 70.696 1 .000 1.083 1.063 1.103
Fasting glucose -.079 .050 2.453 1 .117 .924 .837 1.020
Glucose tolerance: 
90 minutes .051 .020 6.801 1 .009 1.053 1.013 1.094
Cholesterol -.154 .029 28.112 1 .000 .857 .810 .907
log Triglycerides .527 .180 8.619 1 .003 1.695 1.192 2.410
Systolic BP -.002 .002 1.148 1 .284 .998 .993 1.002
Diastolic BP -.002 .004 .252 1 .616 .998 .990 1.006
Haematocrit .167 .020 66.883 1 .000 1.182 1.136 1.231
Haemoglobin -.218 .092 5.577 1 .018 .804 .672 .964
log Creatinine .701 .508 1.901 1 .168 2.016 .744 5.459
log ESR +1 2.482 .106 551.092 1 .000 11.961 9.723 14.715
Constant -11.674 1.175 98.758 1 .000 .000
a- Variabte(s) entered on step 1: SMOK, SEX01, DIABHIST, AGEBLED, FEV1, BMI, GLUFMMOL, 
GLU90MMO, CHOLMMOL, LOGTRI, BPSYS, BPDIA, HOT, HBMMOL, LOGCREAT, LOGESR1.
If the analysis is restricted to males or females the results are as indicated in 
Tables 29 and 30. The only differences of note appear as adjusted associations 
with haemoglobin and haematocrit.
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Table 29 Binary logistic regression: association with CRP value being in the
upper tertile of distribution - ESR included, males only
Binary logistic regression: ESR included, Males only
95.0% C.I.fbr 
EXP(B)
B S.E. Wald df Sig. Exp(B) Lower Upper
Smoking status .618 .084 53.741 1 .000 1.855 1.572 2.188
Diabetic status -.488 .300 2.652 1 .103 .614 .341 1.104
Age bled .019 .006 11.872 1 .001 1.019 1.008 1.031
FEV1 .000 .000 20.111 1 .000 1.000 1.000 1.000
BMI .074 .012 36.128 1 .000 1.077 1.051 1.104
Fasting glucose -.057 .060 .896 1 .344 .945 .839 1.063
Glucose tolerance: 
90 minutes .049 .023 4.487 1 .034 1.051 1.004 1.100
Cholesterol -.109 .036 8.952 1 .003 .897 .835 .963
log Triglycerides .409 .210 3.789 1 .052 1.506 .997 2.273
Systolic BP -.003 .003 1.689 1 .194 .997 .991 1.002
Diastolic BP .000 .005 .002 1 .966 1.000 .990 1.010
Haematocrit .215 .025 76.103 1 .000 1.240 1.181 1.301
Haemoglobin -.365 .110 11.073 1 .001 .694 .560 .861
log Creatinine .575 .627 .842 1 .359 1.778 .520 6.077
log ESR+ 1 2.522 .123 422.876 1 .000 12.458 9.796 15.844
Constant -11.486 1.508 58.040 1 .000 .000
a. Variable(s) entered on step 1: SMOK, DIABHIST, AGEBLED, FEV1, BMI, GLUFMMOL, GLU90MMO, 
CHOLMMOL, LOGTRI, BPSYS, BPDIA, HCT, HBMMOL, LOGCREAT, LOGESR1.
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Table 30 Binary logistic regression: association with CRP value being in the
upper tertile of distribution - ESR included, females only
Binary logistic regression: ESR included, Females only
95.0% C.I.for 
EXP(B)
B S.E. Wald df Sig. Exp(B) Lower Upper
Smoking status .738 .133 30.914 1 .000 2.091 1.612 2.713
Diabetic status .369 .421 .769 1 .381 1.446 .634 3.298
Age Med .039 .009 19.373 1 .000 1.040 1.022 1.059
FEV1 .000 .000 11.222 1 .001 1.000 .999 1.000
BMI .090 .015 34.863 1 .000 1.094 1.062 1.128
Fasting glucose -.145 .096 2.257 1 .133 .865 .716 1.045
Glucose tolerance: 
90 minutes .069 .037 3.423 1 .064 1.072 .996 1.153
Cholesterol -.260 .051 25.483 1 .000 .771 .697 .853
log Triglycerides .686 .360 3.634 1 .057 1.986 .981 4.022
Systolic BP .000 .004 .016 1 .900 1.000 .992 1.007
Diastolic BP -.001 .008 .015 1 .903 .999 .984 1.014
Haematocrit .060 .040 2.256 1 .133 1.062 .982 1.148
Haemoglobin .106 .183 .333 1 .564 1.111 .776 1.591
log Creatinine .850 .891 .909 1 .340 2.339 .408 13.416
log ESR +1 2.474 .219 127.655 1 .000 11.874 7.730 18.240
Constant -10.461 2.065 25.671 1 .000 .000
a. Variables) entered on step 1: SMOK, DIABHIST, AGEBLED, FEV1, BMI, GLUFMMOL, GLU90MMO, 
CHOLMMOL, LOGTRI, BPSYS, BPDIA, HCT, HBMMOL, LOGCREAT, LOGESR1.
Further analysis, with reclassification of some of the variables, again in a binary 
logistic regression model, was performed specifically to calculate the odds of 
having a CRP in the upper tertile of the distribution (Table 31). This shows how 
for example a smoker has twice the chance of having an elevated CRP; similarly 
so for someone who is morbidly obese. The FEV1 and %FEV1 interaction is 
more complex, as the number of individuals with severely impaired FEV1 at 
baseline is small, and FEV1 itself needs to be interpreted with respect to age, sex 
and height. The pooled analysis of %FEV1 shows that those with severely 
impaired lung function have around a two fold increase in likelihood of having a 
raised CRP (one greater than 2.32 mg/1).
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Table 31 Odds ratio of having a CRP in the upper tertile of population 
distribution
Odds ratio (95% Cl) of being in upper third of CRP distribution; 
P<0.001 unless indicated
Smoker vs. Non- 
smoker
2.091
(1.612-2.713)
1.855
(1.572-2.188)
1.905 
(1.659 -  2.188)
Male vs. Female 1.988 
(1.608 - 2.458)
%FEV1 <40 
(Severe) vs. Normal
3.221
(1.676-6.192)
1.656 
(0.765-3.587) n.s.
2.415 
(1.482 -  3.933)
%FEV1 40-60 
(Moderate) vs. 
Normal
1.469 
(1.029 -  2.098)
1.394 
(0.973-1.997) n.s.
1.401
(1.097-1.789)
FEV1 >75th centile 
vs. 25th centile
0.011 
(0 -1414) n.s.
0.609
(0.463-0.803)
0.600 
(0.473 -  0.761)
FEV1 50-75th 
centile vs. 25th 
centile
0.772 
(0.473-1.258) n.s.
0.831 
(0.643-1.075) n.s.
0.787 
(0.638 -  0.972)
BMI > 30 vs. < 25 2.655
(1.814-3.887)
2.006
(1.536-2.620)
2.183
(1.758-2.712)
BMI 25-30 vs. < 25 1.443
(1.114-1.870)
1.356
(1.147-1.603)
1.375
(1.196-1.581)
Age > 70 vs. <50 2.130
(1.225-3.703)
2.210
(1.440-3.392)
2.043
(1.474-2.832)
Age 60-70 vs. <50 2.197
(1.461-3.3041)
1.171 
(0.922-1.488) n.s.
1.42
(1.161-1.737)
10.8.5 Individual associations
Studies such as ours shed detailed light on the factors associated with baseline 
CRP values. Although some associations do not persist after adjustment, it 
nevertheless demonstrates that classical descriptions of what constitutes 
inflammatory states may need to be revised. The following analysis (Figures 12-
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15) shows clearly the associations of age, gender, diabetes, and smoking on 
baseline CRP values. In doing such analysis, it remains important to note that 
association does not imply causality.
10.8.5.1 Age
This study was skewed to patients over 50 (as the object was to investigate future 
cardiovascular events) and therefore does not have an adequate spread of 
individuals across all ages, to hilly address the relationship between age and 
CRP. It is not surprising nonetheless that there was an increase in baseline CRP 
as individuals aged, with a mean difference in age of + 3 yrs when comparing 
individuals in the upper and lower tertiles of CRP distribution (P<0.001); see 
Table 14 and Figure 12. This equates to a mean difference of 0.82mg/l when 
comparing those over 70 with those under 50 (P<0.001). After full adjustment 
age remains correlated with log CRP (P<0.001), and has a partial correlation 
coefficient of 0.1 in the linear regression analysis.
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Figure 12 CRP values and age
10.8.5.2 Smoking
The baseline data categorises individuals into active smokers (includes cigarettes, 
pipes and cigars) and non-smokers. The non-smoker category includes ex­
smokers. Quantification of smoking habits was not available for this part of the 
analysis. Current smokers have 50% greater baseline CRP values as compared to 
non-smokers with geometric means of 1.85 mg/1 (95% Cl 1.77 - 1.94) vs. 
1.27 mg/1 (95% Cl 1.23 -  1.32); P0.001. When fully adjusted for the other 
covariate smokers had a geometric mean CRP of 1.73mg/l whilst for non- 
smokers it was 1.12 mg/1 (P <0.001). It appears the effect of smoking on CRP 
values equates to an active process, since if the analysis is repeated, classifying 
individuals into active or previous smokers and those that have never smoked, 
there is no difference in baseline CRP values. Fully adjusted values reveal for
those that smoke or who have smoked a geometric mean CRP of 1.21 mg/1 vs. 
1.35 mg/1 for those that have never smoked (P>0.05). This is in keeping, for 
example, with another large study recently published [411]. Figure 13 below 
graphically represents some of these associations.
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Figure 13 CRP values and smoking
10.8.5.3 Gender
The effects of gender in this study are not very striking, particularly when fully 
adjusted, as already shown above. The unadjusted geometric mean for men was 
1.48 mg/1 (95% Cl 1.44 -  1.53) and for women was 1.36 mg/1 (95% Cl 1.30 - 
1.44); P = 0.006. Full adjustment reveals a geometric mean CRP for men of 
1.63 mg/1 vs. for women 1.29 mg/1; this is however only just significant with a P
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value of 0.033. Of note our study does not have equal numbers of males and 
females, we lack a complete drug history (information was not recorded on the 
use of aspirin or “statins” and fewer than 5% of the women reported use of 
hormone replacement treatment), and the age range of subjects is limited. It is 
therefore not best placed to formally study any differences in CRP values 
between males and females. The small difference between males and females 
may not be globally relevant and for the sample size involved a P value of 0.03 is 
of course not very convincing. Figure 14 below graphically represents some of 
the associations between gender and baseline CRP values.
CRP Tertiles
|< 0.87
Figure 14 CRP values and gender
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10.8.5.4 Diabetes
The total number of diabetics in this study is small (n=152; M 98 : F 54) but the 
geometric mean CRP for a diabetic patient was 1.74 mg/1 (95% Cl 1.45- 2.04) as 
opposed to 1.44 mg/1 (95% Cl 1.40 -  1.48) for a non-diabetic individual; P= 0.04 
(Figure 15). As noted already on further adjustment, the association does not 
hold for diabetes, but this study has too few diabetics individuals for a truly 
robust analysis of this important subgroup. However interestingly in the 
multivariate analysis there was an interaction noted between diabetes and gender 
(P =0.027), and with full adjustment the estimated marginal geometric mean for 
female non-diabetics is noted to be 1.08 mg/1 (95% Cl 1.01 - 1.15) whilst 
diabetic females had an estimated marginal geometric mean CRP of 1.46 mg/1 
(95%CI 1.00 - 2.11). The significance of this, if any, is unclear.
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80*
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6461 
Not diabetic
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Figure 15 CRP values and diabetes staus
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More involved associations with parameters such as BMI, FEV1 and blood 
pressure have also been described before, and we have found similar 
associations.
10.8.5.5 BMI and fasting glucose/glucose tolerance
Obesity, impaired glucose tolerance and the metabolic syndrome are important, 
modifiable, cardiovascular risk factors. The body mass index (weight/height2) is 
a good marker of adjusted body mass, although it doesn’t distinguish the 
distribution of the weight. The WHO has classified BMI as follows: “normal 
weight” is defined as BMI > 18.5, but less than 25; “overweight” equals BMI > 
25, but less than 30; and “obese” individuals have BMIs > 30. In our study, BMI 
remained significantly associated with baseline CRP values throughout analysis, 
which is in keeping with previous studies. The mechanisms for the association 
between adipose tissue and subtle inflammation are not fully understood; the co­
existence of insulin resistance, endothelial dystunction and increased IL-6 
production by adipose tissue are probably important [236].
In particular, comparing individuals in the upper tertile of CRP with those in the 
lower tertile, there is a 10% difference in BMI. When BMI is modelled in a 
univariate analysis with all the factors studied, after adjustment this difference 
remains (mean difference in BMI 2.287 P < 0.001). This is consistent with the 
adjusted correlation coefficient of 0.22 (Table 17). When looking at glucose and 
glucose tolerance at baseline, before adjustment, the difference between tertiles 
of CRP in fasting glucose is 0.149 mmol/1. After adjustment (not including
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diabetes status or 90 minute glucose tolerance), the adjusted mean difference 
between the upper tertile and lower tertile of CRP in value is 0.026 mmol/1 and is 
not significant. Excluding the small number of diabetics doesn’t change this. 
However the relationship between glucose tolerance at 90 minutes, a dynamic 
physiological challenge, is stronger. At baseline the difference between upper 
and lower tertiles of CRP for the 90 minute glucose tolerance value is 
0.54 mmol/1 (P <0.001). After adjustment (including for the baseline glucose 
value but not diabetic status), the mean difference falls to 0.188 mmol/1 but 
remains highly significant (P = 0.005). If you exclude all diabetics, the 
difference becomes 0.201 mmol/1 (P = 0.002). Whilst the magnitude of the 
change is small, the association of baseline CRP values with a dynamic function 
of insulin sensitivity is intriguing and in keeping with the concept of 
dysregulated inflammation in glucose intolerance and diabetes. More specific 
studies on restricted groups of individuals would be needed to extend these 
observations.
Figures 16- 20 illustrate the associations described above.
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10.8.5.6 FEV1 and %FEV1
Lung function is an interesting association for CRP (Figure 21). Although at first 
thought it may be assumed to just reflect smoking habits, this is not the case, as 
demonstrated in Figures 22 and 23. Other factors must be important, although 
precisely what cannot be ascertained from our studies. To add some clinical 
correlate, %FEV1 has been used, as it allows a crude classification of lung 
function: normal >80%, mild impairment 60-80%, moderate impairment 40- 
60%, and severe impairment <40%. Although the numbers with severe 
impairment are small in this study, it is noteworthy that this is the group with 
elevated CRP values.
Specifically, comparing individuals in the upper tertile of CRP distribution with 
those in the lower tertile, we see that the mean difference in FEV1 is -371 ml 
(P0.001) and for %FEV1 8% (P<0.001). Smoking does affect FEV1 and 
%FEV1 (2662 ml vs. 2945 ml and 81% vs. 90%; P<0.001) but the differences in 
CRP values persists (Table 32 and Table 33). With full adjustment for the other 
covariates a non-smoker in the upper tertile of CRP distribution has an FEV1 of 
2669 ml (95% Cl 2554 - 2784) vs. that of smoker of 2375 ml (95% Cl 2216 - 
2534). This compares with a FEV1 of a non-smoking individual with a CRP < 
0.87mg/l of 2881 ml (95% Cl 2750 -  3013) and that of a smoker 2956 ml (95% 
Cl 2681 -  3231). There is therefore more to the relationship between reduced 
crude lung function and CRP values, than just smoking. Interestingly when one 
reclassifies smokers into those that smoke or have smoked as opposed to those 
that have never smoked, whilst the difference in FEV1/%FEV1 with respect to
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CRP remain, there is no effect of smoking history. Adjusted values for FEV1 for 
example, in those that have never smoked are 2651 ml (95% Cl 2565 -  2737) 
compared to 2715 ml (95% Cl 2602 -  2827) for those that are current or ex­
smokers.
Table 32 FEV1, smoking and CRP distribution
CRP Tertiles vs Smoking status
Dependent Variable: FEV1
95% Confidence Interval
CRP Tertiles Smoking status Mean Std. Error Lower Bound Upper Bound
<0.87
Non-smoker 
Current smoker
3098.329
2821.231
20.969
35.831
3057.223
2750.991
3139.435
2891.472
0.87-2.32
Non-smoker 
Current smoker
2935.392
2709.900
22.010
31.137
2892.246
2648.861
2978.538
2770.938
>2.32
Non-smoker 
Current smoker
2750.625
2539.788
24.266
27.054
2703.056
2486.753
2798.194
2592.823
Table 33 %FEV1, smoking and CRP distribution
CRP Tertiles vs Smoking status
Dependent Variable: % FEV1
CRP Tertiles Smoking status Mean Std. Error
95% Confidence Interval 
Lower Bound Upper Bound
<0.87
Non-smoker 92.743 .484 91.794 93.692
Current smoker 85.525 .828 83.903 87.147
Non-smoker 90.741 .508 89.744 91.737
0.87-2.32
Current smoker 82.433 .719 81.023 83.842
Non-smoker 86.623 .561 85.524 87.722
>2.32
Current smoker 77.970 .625 76.745 79.196
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10.8.5.7 Lipid parameters
Hyperlipidaemia, in particular raised cholesterol is clearly an established major 
cardiovascular risk marker. Our study was able to assess direct relationships 
with total serum cholesterol and triglyceride values (Figures 24 and 25). LDL- 
cholesterol or HDL-cholesterol were not measured for practical reasons.
Unadjusted, there was no difference between cholesterol values for patients in 
the upper or lower tertile of CRP distribution (6.57 mmol/1 [95% Cl 6.52-6.62] 
and 6.55 mmol/1 [95% Cl 6.50 -  6.60]). Partially adjusted, there was no 
correlation between CRP and cholesterol, but with full adjustment in a linear 
regression model cholesterol was weakly, negatively, associated with CRP 
values (B -0.08; P0.001), but the mean difference between extreme tertiles of 
CRP distribution is not significant (6.50 mmol/1 vs. 6.66 mmol/1). The lack of 
any strong association between CRP and cholesterol suggests that they could 
complement each other in cardiovascular risk prediction, if they are representing 
different aspects of the disease process.
Hypertriglyceridaemia is also a risk factor for future cardiovascular disease. 
With respect to serum triglycerides the unadjusted geometric means for upper 
and lower tertiles of CRP were significantly different: 1.19 mmol/1 (95% Cl 1.17 
-  1.22) vs. 0.97 mmol/1 (95% Cl 0.95 -  0.99). Fully adjusted values were not 
however significantly different (1.11 mmol/1 [95% Cl 1.04 -  1.19] vs.
1.03 mmol/1 [95% Cl 0.93 -  1.13]), although when correlated as continuous
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values, and adjusted for other variables, log triglycerides has a regression 
coefficient of 0.06 (PO.OOl). This association with CRP is unexplained, but 
must reflect subtle metabolic and inflammatory changes associated with an 
excess level of triglycerides. Notably the partially adjusted correlations (age, sex, 
diabetes) between triglycerides and BMI is 0.33 (P<0.001).
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10.8.5.8 Blood pressure
Finally blood pressure is another important cardiovascular risk factor, for which 
other studies have reported associations with baseline CRP values [167, 412, 
413]. Certainly in our study, when unadjusted, there is an association with 
baseline values (Figures 26 and 27). An individual in the upper tertile of CRP 
has a systolic BP 5.5 mmHg higher than that of someone in the lower tertile of 
CRP (95% Cl 4.15-6.83), and a diastolic BP 2.05 mmHg higher (95% Cl 1.34 -  
2.75). However neither factor remains independently associated with CRP in the 
regression analyses performed. There is therefore serological evidence of low 
grade inflammation associated indirectly with hypertension but adjustment for 
factors such as BMI, smoking, FEV1, age, gender, eliminate the association in 
our population.
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10.9 Reproducibility
One obvious criticism placed at using CRP in risk prediction has been the wide 
variation in values possible because of its manifest sensitivity to all causes of 
inflammation. This impacts indirectly on the question of how many times one 
should measure an individual’s CRP to determine their “true” baseline value 
[414]. However, within this population study, the reproducibility of CRP values 
in the same patient, when measured more than ten years apart was very good, 
with a Spearman rank coefficient of 0.6 (n=379; PO.OOl); Figure 28. This is in 
keeping with other studies [415, 416].
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The reasonably high decade-to-decade consistency of CRP values recorded 
compares well with other traditional cardiovascular risk factors. The regression 
dilution ratio, a self-correlation coefficient, is shown in Table 34 for the 
important cardiovascular risk factors, based on the reproducibility data from the 
sequential samples.
Table 34 Self-correlation coefficients for cardiovascular risk factors
C-reactive protein 0.59(0.52-0.66)
ESR 0.67(0.61-0.73)
Blood pressure 0.66(0.60-0.72)
Cholesterol 0.60 (0.64-0.66)
- die regression dilution ratio, derived with the help of Professor J. Danesh, describes the ratio of 
die steepness of the uncorrected association to that of the real association. It is derived by relating 
baseline measurements of the risk factor to replicate measurements from a reasonably 
representative sample of study participants after an interval.
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10.10 Case-control analysis: Inflammatory Markers and Incident 
Coronary Heart Disease
The mean age at the time of the coronary heart disease event was 70.2±9.7 years. 
There were significant differences between patients and controls with respect to 
established coronary risk factors, such as smoking status, body-mass index, 
blood pressure, and serum lipid concentrations (Table 35). Information on 
occupation was available for only 1742 cases and 2888 controls respectively 
whilst information on education was available for only 1292 cases and 2157 
controls respectively. There were no significant differences in occupation, 
education beyond high school, or home ownership/nature of house. No 
information on alcohol use was available, nor on physical activity.
As a first observation it remains quite striking that the value of CRP in 
individuals who subsequently go on to have coronary events is, unadjusted, 37% 
higher, than matched controls. Our study, regardless of addressing the 
independent predictive power of CRP, constitutes further evidence of the 
apparent inflammation that accompanies future atherothrombotic events, and 
underscores the need to further understand the processes at play.
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Table 35 Baseline comparison of risk factors: cases vs. controls
Cases
(n=2459)
Controls
(n=3969)
P value
Demographic
Age (years) 55.8 (9.3) 55.7 (9.1) Matched
Male, n (%) 1774(72) 2743 (69) Matched
Questionnaire
Current smokers
(incl. cigarettes, cigars, pipe), n (%) 1417(58) 1941 (49) <0.001
Current cigarette smokers, n (%) 962 (39) 1266(32) <0.001
History of diabetes, n (%) 83(3) 63 (2) <0.001
Physical measurements
Height (m) 1.71 (0.087) 1.72 (0.087) 0.07
Weight (kg) 76(14) 75(14) <0.001
Body mass index (kg/m*) 26 (3.9) 25 (3.7) <0.001
Systolic blood pressure (mm Hg) 146 (22) 141 (20) <0.001
Diastolic blood pressure (mm Hg) 89(11) 87(11) <0.001
Forced expiratory volume (ml/ 1st sec) 2800 (85) 2900 (86) 0.002
Blood sample
Total serum cholesterol (mmol/1) 6.82(1.18) 6.40(1.14) <0.001
Serum triglycerides (mmol/l)t 1.19(0.79) 1.03 (0.62) <0.001
Fasting glucose (mmol/1) 4.6 (1.1) 4.5 (0.8) <0.001
Serum creatinine (pmol/1) 77 (14) 75 (13) <0.001
Haemoglobin (mmol/1) 9.2 (0.80) 9.1 (0.81) <0.001
Haematocrit (%) 45 (3.6) 44 (3.5) <0.001
Inflammatory markers
C-reactive protein (mg/l)t 1.75 (5.3) 1.28 (5.2) <0.001
ESR (mm/1* h)t 7.4 (10.6) 6.3 (9.7) <0.001
Values are mean (SD) unless indicated otherwise.
J Factor log transformed for analysis and presented as geometric mean (SD).
The odds ratio for coronary heart disease was 1.92 (95% Cl 1.68 - 2.18; x2=105, 
with 1 df) among patients with values in the top third (cutoff value, 2.0 mg/1), as 
compared with the bottom third (cutoff value, 0.78 mg/1), of base-line CRP 
concentrations in the control group. The odds ratio fell to 1.45 (95% Cl 1.25 - 
1.68; x2=28, with 1 df) after adjustment for smoking status, other established 
coronary risk factors (systolic blood pressure, total cholesterol, triglycerides,
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body mass index, FEV1, history of diabetes), and indicators of socioeconomic 
status (Table 36 and Figure 29).
Comparisons between the top and bottom thirds of patients and controls with 
respect to ESR gave adjusted odds ratios for coronary heart disease (cutoff value 
of 10 mm/hr for the top third and 4 mm/hr for the bottom third), of 1.30 (95% Cl 
1.13-1.51; x?=13, with 1 df); (Table 36 and Figure 29).
Receiver operator curves (ROC) curves display the relationship between 
sensitivity (true positive rate) and 1-specificity (false-positive rate) across all 
possible threshold values that define the positivity of a disease or condition. 
Summary measures of ROC curves, such as the area under the curve (AUC), can 
summarise into a single statistic the inherent capacity of a test for discriminating 
a diseased from a non-diseased subject across all possible levels of positivity. 
The area under the receiver operating characteristic curve is the most commonly 
used measure of the ability of a biomarker to distinguish between two 
populations. Logistic-regression analysis was used to calculate the areas under 
the receiver-operating-characteristic curve after adjustment for age, sex, and 
period, with data on major established risk factors and inflammatory markers 
added to the model in the order of the strength of each variable’s association with 
coronary heart disease.
In our case we wished to specifically address the question of whether or not our 
study suggests CRP adds information, above and beyond that of standard cardiac
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risk factors. In Figure 29 one can see that the calculated areas under receiver- 
operating-characteristic curves indicate that information on the CRP 
concentration provided comparatively little additional predictive value over that 
provided by assessment of other major established risk factors.
These findings were not materially changed in analyses restricted to the 2083 
patients without evidence of coronary heart disease at base line, to the 2206 
patients with CRP values who had a confirmed myocardial infarction or died of 
coronary heart disease, or to the participants without evidence of acute-phase 
reactions at the base-line examination (i.e. this analysis excluded 132 patients and 
152 controls with a CRP concentration of more than 10 mg/1 or an erythrocyte 
sedimentation rate of more than 30 mm/hr). The findings were also unaffected by 
changes in the cutoff values (e.g. analyses of quarters or fifths, or according to 
increases of 1 SD) (Table 36).
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Table 36 Relative odds o f  coronary heart disease
Factor No. of Cases No. of Controls Odds Ratio (95% Cl) Adjusted For:
(tertile cutoffs) Top Middle Bottom Top Middle Bottom
Age, sex and 
period
Age, sex, period 
and smoking
Age, sex, period, 
smoking and risk 
factors*
Age, sex, smoking, 
risk factors and 
socioeconomic 
status
Age, sex, smoking, risk 
factors, socioeconomic 
status and other 
inflammatory markers
Inflammatory markers All 2459 cases and 3969 controls
C-reactive protein 
(2 and 0.78 mg/I)
1090 742 574 1294 1300 1297 1.92
(1.68-2.18)
1.76
(1.54-2.01)
1.45§
(1.25-1.69)
1.45
(1.25-1.68)
1.36
(1.16-1.58)
ESR 
(10 and 4 mm/hr)
922 733 785 1220 1201 1521 1.64
(1.44-1.87) (1.36-1.78)
1.31
(1.13-1.51)
1.30
(1.13-1.51)
1.18
(1.01-1.38)
2083 cases without evidence of coronary heart disease at entry and 3969 controlst
C-reactive protein 
(2 and 0.78 mg/I)
887 635 520 1294 1300 1297 1.81
(1.58-2.07)
1.65
(1.43-1.89)
1.37
(1.17-1.60)
1.37
(1.17-1.59)
1 ™ 
(1.10-1.52)
ESR 
(10 and 4 mm/hr)
766 633 671 1220 1201 1521 1.53
(1.34-1.77)
1.45
(1.26-1.68)
1.22
(1.05-1.43)
1.22
(1.04-1.42)
1.10
(0.95-1.28)
I Some established CHD risk factors All 2459 cases and 3969 controls
Total cholesterol 
(6.80 and 5.85 mmol/l)
1150 826 482 1309 1320 1334 2.62
(2.29-3.00)
2.68
(2.3-3.08)
2.33
(2.01-2.70) (2.03-2.74)
2.38
(2.05-2.77)
Smoking X 
(current vs. never)
1417 544 498 1941 851 1177 1.74
(1.53-1.98)
1.74
(1.53-1.98)
1.87
(1.63-2.22)
1.87
(1.62-2.16)
1.75
(1.51-2.03)
Systolic blood pressure 
(147 and 131 mm Hg)
1041 742 670 1308 1240 1402 1.72
(1.51-1.96)
1.85
(1.62-2.10)
1.51
(1.32-1.74)
1.50
(1.30-1.73)
1.50
(1.30-1.74)
.  Markers of socio-economic status = non-manual occupation, education beyond high school, home ownership and living in an apartment block.
Systolic blood pressure, total cholesterol, triglycerides, body mass index, smoking (former or current, including number cigarettes per day), FEV1, history of diabetes, f These analyses exclude individuals with ECG evidence of CHD or a history of angina. Individuals with 
a history of Ml were excluded from the baseline survey. J Smoking is not represented as thirds of a continuous distribution: case and control frequencies are tabulated for current-, ex- and non-smokers, and odds ratios are calculated comparing current and never smokers. § 
The adjusted odds ratio of CRP and CHD using alternative comparisons were: 1.55 (1.31-1.84) top quarter vs. bottom quarter; 1.65 (1.36-2.00) top fifth vs. bottom fifth; 1.20(1.12-1.27) per standard deviation (log scale).
Risk factor:
Total cholesterol
Cigarette smoking* 
Systolic blood pressure 
C-reactive protein
Erythrocyte sedimentation rate 
(ESR)
A tm  und*r the  ROC curv* f  
(96% Cl)
0.61 (0.59-0.62)
0.63 (0.61-0.64)
0.64 (0.63-0.65)
0.65 (0.64-0.67)
0.65 (0.64-0.67)
1 2 4
- ■I • 95% confidence intervals
* Current smokers compared to non-smokers
t  Area under the ROC curve for the linear predictor of age, sex and period adjusted 
logistic regression models with sequential addition of risk factors in order of strength of 
association with CHD
Figure 29 Comparison of the strength of associations of several factors with coronary heart disease
- 2459 incident cases and 3969 controls in the Reykjavik study (comparisons involve top third vs. bottom third in the population)
10.11 Discussion and Meta-analysis
CRP is an extremely sensitive marker of classical inflammatory processes such 
as infection or tissue necrosis. This study demonstrates, with great statistical 
power, that serological evidence of low grade inflammation is an important 
accompanying feature of many markers of health and disease, not thought of as 
classically inflammatory processes i.e. active smoking, increased body mass 
index, reduced forced expiratory volume, increasing age, increasing blood 
pressure, increasing triglycerides and impaired glucose tolerance are associated 
with a highly sensitive marker of systemic inflammation. These associations on 
further analysis can be both direct and indirect (as assumed by loss of association 
with adjustment), and reflect the presumed very complicated interaction between 
host genetic factors and variable production of inflammatory mediators.
Whilst association and causation manifestly differ, this study clearly confirms as 
a striking principle, the important association of biochemical evidence of 
inflammation with future coronary artery disease. Healthy individuals, who 
subsequently go on to have coronary heart disease events, are more likely to have 
raised systemic biochemical markers of inflammation, many years prior to 
clinical manifestations of disease.
In some respects it is therefore a secondary question, whether or not CRP is an 
independent marker of cardiac disease, because clinically that will depend on 
how one chooses to use the information gained. However the question is
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important because resources are limited and should be efficiently targeted to 
maximal effect. If we can already identify those at risk then the extra costs of a 
new test are not justifiable, particularly if that cost can be channelled more 
effectively elsewhere.
In order to help put the new data from the present study in context, John Danesh 
and Jerry Wheeler went on to update the meta-analysis of previous relevant 
studies. We reported this in The New England Journal of Medicine [168] (Figure 
30). Twenty-two prospective studies of CRP (including the present study) were 
included, involving a total of 7068 patients, with a weighted mean age at entry of 
57 years and a weighted mean follow-up of 12 years. All studies used high- 
sensitivity assays, and all but two reported adjustment for at least smoking status 
and some other established risk factors for coronary heart disease. There was 
evidence of heterogeneity between these studies ($.=46, with 21 df; P=0.001), 
but with the exception of the date of publication (x?=15, with 2 df; P<0.001), 
characteristics such as sample size (x2=4.0, with 1 df; P=0.04), location (x2=0.3, 
with 1 df; P=0.58), sampling method (x2=5.2, with 1 df; P=0.02), sex of 
participants (x2=3.4, with 2 df; P=0.18), mean duration of follow-up (x2=T.6, 
with 1 df; P=0.20), and sample storage temperature (x?=0.1, with 1 df; P=0.77) 
did not account for much of the overall heterogeneity.
The previous meta-analysis, found the odds ratio for non-fatal myocardial 
infarction or death from coronary heart disease to be about 2.0 in a comparison of 
extreme thirds of CRP values [179], and in a few, relatively small studies, the 
odds ratio was even greater. By contrast, the best current evidence suggests that
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the odds ratio is about 1.5 (95% Cl 1.4 -1.6). A number of studies subsequent to 
ours are now reporting odds ratios of the same magnitude [203, 204]. The 
tendency toward more extreme findings in studies published before 2000 is 
consistent with the preferential publication of positive results in earlier studies. 
For example restriction of analyses to the four studies involving more than 500 
patients, comprising 4107 cases of coronary heart disease, which should limit any 
such bias, yielded a combined odds ratio of 1.49 (95% Cl 1.37 - 1.62; %2=10.6, 
with 3 df; P=0.01). This value is somewhat smaller than the overall odds ratio of
1.58 (95% Cl 1.48 - 1.68) derived from combining all 22 studies.
Moreover, contrary to some earlier suggestions, the current data indicate that 
established coronary risk factors are generally stronger predictors than are CRP 
values. For example, in our study, the adjusted odds ratios among people with 
raised total cholesterol concentrations and among smokers were approximately
2.4 (95% Cl 2.0 - 2.7) and 1.9 (95 % Cl 1.6 - 2.2), respectively.
Further clarification of the predictive ability of CRP in CHD will require the 
pooling of studies based on individual participant data from each of the available 
prospective studies, enabling more complete adjustment for other risk factors, 
more precise quantification of the associations in particular subgroups (such as 
age- and sex-specific associations as well as assessments of combinations of 
inflammatory markers), more reliable characterisation of the shape of any 
dose-response relationship, and more detailed investigation of potential sources 
of heterogeneity.
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Groups of studes No. Cases Odds retto (top third versus bottom third) and 99% conddsnce Interval
Period of publcsSon
ItoyltfMflcStady 2400 ------------- ■ -------------
PubMwtf toelmaa 200002: 11 ahtfaa 2545 -------- ■ --------
PuUWMd tofera 2000:11 aktfee 2230 -------------------- ■ --------------------
Study size
>900 eMK 4 abidtee 4107 ------ ■ ------
«S00caeea: I lS t f N 2001 ------- ■ -------
Geographical location
Wealtm Europe: 11 afci£ee 4820 — ■ —
North Awotai: 11 S i l i i 2840 — a —
Sample framework*
PepuMton/GP wgjrtT. 14 ekidtee 4887 — a —
OttrorOotucHee
Sex of participants*
2211 --------- a ---------
Malt: 12«Miee 4272 — a —
Female: 3 ahidee 1325
Net reported aapamMy: •  ahtfee
Mean duration offoSow-up
1471
%10yeera:3«h)dtoe 4174 — ■ —
<10 ymm  14 efeidtee
Ptaomafeeram storage temperature1
20S4 — a —
•20*C: 7 etudaa 2082 — a —
&-20*C:13«*M*ee 3000 — a —
1 2 4
* The figure is biased on 22 studies, apart from the data under “period of pubfcation’, which lists 23 studies to snow that one study published in two
separata reports, with the first pubished before 2000 and the update published in 2002
t f  “Other* sample frameworks indude participants selected under various criteria (eg, individuals without a history of coronary disease recruited into
randomised trials, individuals identified by their occupation, etc); GP=general practice
t  The Reykjavik Study provided estimates for males and females separately
I Such information was unavailable for 2 studies
Figure 30 Twenty-two prospective studies of CRP and coronary heart disease
10.11.1 Limitations
The validity of this study’s measurements has been demonstrated by the 
reasonably high decade-to-decade consistency of CRP values recorded in paired 
samples in several hundred study participants. This consistency was at least as 
good as that recorded in previous studies based on much briefer intervals 
(ranging from one to five years). Further validation of measurement is suggested 
by the expected baseline associations observed between CRP and other 
inflammatory markers with one another and with established risk factors. Mean 
values and distributions of several established coronary risk factors (and their 
strength of association with CHD) were also generally similar in the present 
study to those seen in other Western European populations. Whilst the 
Reykjavik population’s relative homogeneity will minimise certain residual 
biases (such as differences in socioeconomic status), the findings do have wider 
relevance. Measurements of only total serum cholesterol concentrations (rather 
than of LDL and HDL cholesterol subfractions, which have opposing effects on 
CHD risk) were available in the present study, thereby under-estimating the 
predictive ability of lipid levels (and potentially over-estimating the adjusted 
predictive ability of CRP). Information was not recorded in this study on the use 
of aspirin, “statins”, or hormone replacement treatments, but they were relatively 
uncommonly used in the general adult population of Reykjavik between 1967 
and 1991. The analysis was not altered by comparisons among extreme quarters 
or extreme fifths rather than among extreme thirds. The use of any particular 
cutoff point (such as 3 mg/1), consistently applied among studies, would also
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yield similar contrasts with previous estimates, provided the shape of the 
relationship between CRP values and coronary risk were approximately log- 
linear.
10.12 Sum m ary
Our study confirms the presence of raised CRP concentrations years before 
evidence of coronary artery disease. This does not equate with evidence that 
inflammatory markers should be measured in risk stratification. The data from 
our large prospective study (involving 2406 patients who had non-fatal 
myocardial infarction or who died from coronary heart disease) and from an 
updated meta-analysis of 21 previous reports (including a total of 4662 such 
patients) indicate that the value of CRP measurement in the prediction of the risk 
of coronary disease has previously been overestimated. The best current 
evidence, suggests that the odds ratio is about 1.5 (95% Cl 1.4-1.6). 
Measurement of CRP added only marginally to the predictive value of 
established risk factors: the area under the receiver-operating-characteristic curve 
increased from 0.64 (95% Cl 0.63 - 0.65) to only 0.65 (95% Cl 0.64 - 0.67) when 
it was included. The current data confirm that established coronary risk factors 
are generally stronger predictors than are CRP values. The adjusted odds ratios 
among people with raised total cholesterol concentrations and among smokers 
were approximately 2.4 (95% Cl 2.0 - 2.7) and 1.9 (95% Cl 1.6 - 2.2), 
respectively in our cohort.
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11 C-reactive protein and animal models of disease
11.2 Introduction
An array of studies largely confined to passive administration of CRP or transgenic production of rabbit or human CRP in mice (Table 37), points to a role for CRP in host defence against 
microbial infection and in the physiological and pathophysiological handling of 
autologous constituents; under various circumstances CRP may also function as a 
pro-inflammatory mediator [34]. Indeed the capacity of human CRP to bind to 
phosphocholine and related residues that are widely present in cell membranes 
and bacteria and then to precipitate soluble ligands, aggregate particulate ligands 
and activate the classical complement pathway, all resemble closely the classical 
properties of antibodies. The subtleties of animal models of disease however, 
along with species differences in CRP glycosylation, capacity to activate 
autologous complement, and regulation of basal and acute phase synthesis (the 
acute phase production of murine CRP never exceeds trace amounts and no 
mouse CRP knockout has been made), suggest extreme caution in extrapolating 
from animal models to man. Aware of the limitations of heterologous systems, 
we studied further the in vivo role of human CRP following endotoxin 
administration and in the context of experimental arthritis, making particular use 
of a human CRP transgenic mouse strain, in which CRP production is under the 
control of its human promoter.
168
Table 37 Array of animal studies by 2004 published in the investigation of the biological properties of CRP
Kushner I & Kaplan MH 1961 [417] Immunohistochemical localisation o f Cx-reactive protein in rabbits: association with necrosis Endogenous rabbit
Kushner I et al. 1963 [196] Localisation of Cx-reactive protein in heart in induced myocardial infection in rabbits Endogenous rabbit
Hurliman J et al. 1966 [101 The liver as the site o f C-reactive protein formation Endogenous rabbit
Parish WE 1977 [4181 Cutaneous reactions in rabbits and guinea pigs following intracutaneous injection of aggregated CRP Passive hCRP
du ClosTW etal. 1981 [4191 Localisation of rabbit CRP to inflammatory lesions in experimental allergic encephalomyelitis Endogenous rabbit
Mold C et al. 1981 [10] Protective against S. pneumoniae infection in mice Passive hCRP
Nakayama S etal. 1982 [420] Increase in splenic sequestration of erythrocytes coated with PC Passive hCRP
Nakayama S et al. 1984 [421] Inhibition o f antibody responses to phosphocholine Passive hCRP
Rowe IF et al. 1984 [761 Reduced clearance o f rabbit CRP during acute phase response Passive rabbit CRP
Baltz ML et al. 1985 [4221 Half life o f hCRP ~4hrs in rodents and not increased by CPS, though increased splenic localisation Passive hCRP
Rowe IF et al. 1985 [4231 Rabbit CRP not detected in catheter-induced aortic endothelial injuries in the rabbit Endogenous rabbit CRP
Ciliberto et al. 1987 [741 Inducible and tissue-specific expression of human CRP in transgenic mice hCRPTg
Horowitz J et al. 1987 [4241 Blood clearance of S. pneumoniae Passive hCRP
Renia L et al. 1993 [4251 No protection against infection with Plasmodium yoelii sporozoites Rabbit CRP Tg
du ClosTW etal. 1994 [4261 Decreased autoantibody levels and enhanced survival of (NZB x NZW) FI mice Passive hCRP
Hutchinson W etal. 1994 [26] Hepatocytes are the single major site o f pentraxin clearance and catabolism in vivo Passive hCRP
Lin CS et al. 1995 [731 Expression of rabbit CRP in transgenic mice Rabbit CRP Tg
Szalai AJ etal. 1995 [4271 Protective against fatal S. pneumoniae infection hCRPTg
Ahmed N et al. 1996 [4281 Diminished chemotactic factor-induced alveolitis Rabbit CRP Tg
Weinhold B et al. 1997 [350] Interleukin-6-dependent and -independent regulation of the human CRP gene hCRPTg
Xia D and Samols D 1997 [4291 Resistance to endotoxaemia Rabbit CRP Tg
Szalai AJ et al. 1998 [351] Testosterone and IL-6 requirements for human CRP gene expression in transgenic mice hCRPTg
GrisselliM etal. 1999 [2011 Human CRP is an important mediator of tissue damage in acute myocardial infarction Passive hCRP
Noursadeghi M et al. 2000 [891 Significantly reduced morbidity and mortality in murine endotoxaemia Passive hCRP
Szalai AJ etal. 2000 [4301 Protective against fatal S. enterica serovar typhimurium hCRPTg
Mold C et al. 2002 [4311 Protection from lipopolysaccharide (through interactions with Fey receptors) Passive hCRP
Mold C et al. 2002 [432] Protection from S. pneumoniae infection requires complement (but not Fey receptors) Passive hCRP
Szalai AJ et al. 2002 [4331 Experimental allergic encephalomyelitis is inhibited in transgenic mice hCRPTg
Danenberg HD et al. 2003 [434] Increased thrombosis after arterial injury in transgenic mice hCRPTg
Szalai AJ etal. 2003 [435] Delayed lupus onset in (NZB x NZW)F1 transgenic mice hCRPTg
Gill R et al. 2004 [332] Increases cerebral infarct size after middle cerebral artery occlusion Passive hCRP
Paul A et al. 2004 [4361 Accelerates the progression o f atherosclerosis in apolipoprotein E-deficient transgenic mice hCRPTg
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1 1 3  Endotoxin
The outer leaflet of the outer membrane of Gram-negative bacteria is composed 
primarily of lipopolysaccharides (LPS). These molecules all contain an 
endotoxic lipid A with which the LPS is anchored in the bacterial membrane and 
a polysaccharide unit presented at the cell surface that is specific to the bacterial 
species. The polysaccharide unit consists of the core oligosaccharide and the O- 
specific chain (Figure 31) [437]. Lipopolysaccharides are essential for the 
survival of Gram-negative bacteria, providing a permeation barrier for harmful 
substances. However LPS plays an important role in a number of recognition 
processes and the LPS of Gram-negative bacteria potently induce acute pro- 
inflammatory responses and endotoxic shock [438]. Endotoxaemia has been 
associated with a variety of human diseases, including sepsis [439], 
inflammatory bowel disease [440], liver failure [441], and pancreatitis [442].
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Figure 31 Schematic structure of lipopolysaccharide
11.3.1 Systemic endotoxaem ia
Systemic endotoxin administration to animals generates a lethal model of 
endotoxic shock [443]. LPS binds to the acute phase protein, LPS-binding 
protein (LBP) and CD 14, a glycosylphosphatidylinositol-anchored protein found 
on the surface of monocytes/macrophages, binds the complex of LPS and LBP. 
Recognition of LPS is initialised by the interplay between LBP, the membrane- 
bound or soluble forms of CD 14 and the toll like receptor-4 (TLR4) MD-2 
complex (MD-2 being an 160-amino acid protein associated with TLR4 on the 
cell surface, that enables TLR4 to respond to LPS). This leads to the rapid 
activation of an intracellular signalling pathway, highly homologous to the 
signalling pathway of IL-1, which results in the release of pro-inflammatory 
mediators. The many adverse effects of endotoxic shock are dependent on the
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generation of these endogenous mediators, which include arachidonic acid 
metabolites, platelet activating factor, cytokines such as TNF-a, interferon-y and 
various interleukins, reactive oxygen metabolites, as well as components of the 
coagulation and complement cascades (Figure 32) [97, 438].
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Figure 32 Physiological responses to endotoxaemia
The changes described following endotoxin challenge, represent one very 
specific example of an acute phase response. Although not fully understood, the 
acute phase response is generally assumed to be protective, and CRP has been 
reported to contribute to resistance against the toxicity of LPS; one study in 
transgenic mice expressing rabbit CRP [429], and subsequently also for wild type 
mice passively administered human CRP [89, 431].
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11.3.2 The Shwartzman reaction
Local responses to endotoxin can also be generated. The Shwartzman reaction 
was first described more than 50 years ago and the two types, local and 
generalised, are models of thrombohaemorrhagic skin necrosis and disseminated 
intravascular coagulopathy (DIC) respectively [444]. In the local Shwartzman 
reaction an intra-venous preparatory injection of endotoxin followed by an intra- 
dermal injection of endotoxin 24 hours later, classically elicits a 
thrombohaemorrhagic lesion only at the site of intra-dermal injection of 
endotoxin. In mice the first dose of endotoxin is not necessary to elicit the local 
reaction. Two intravenous injections of endotoxin spaced 24 hours apart induce 
a systemic generalised Shwartzman reaction characterised by coagulopathy, 
petechial haemorrhages, microthrombi, and decreased circulating platelets 
similar to DIC. The thrombohaemorrhagic lesions of the Shwartzman reaction 
only develop at the sites of intra-dermal injections of endotoxin, and the reaction 
has been reproduced by administration of TNF-a and interferon-y [445-447].
The acute phase response and the pentraxins in particular, were studied some 
time ago in the context of the local Shwartzman reaction [353]. Following 
generation of the local Shwartzman reaction in mice, there was a marked acute 
phase response (murine SAP and C3). Neither steroid therapy nor in vivo 
complement depletion had an effect on either the cutaneous lesion or the 
accompanying acute phase response. Interestingly though, administration of 
colchicine at the same time as LPS suppressed both the acute phase response and 
the Shwartzman reaction. Inhibition of the cutaneous reaction by colchicine was
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abrogated by injecting mice with casein, an unrelated acute phase stimulus, the 
day before LPS challenge. We were particularly interested to readdress this 
model, to see if human CRP might increase the size of the lesion, potentially by 
binding to damaged cells and enhancing complement activation.
11.4 Collagen arthritis
Rheumatoid arthritis (RA) is a chronic progressive auto-inflammatory disease of 
the joints associated with significant morbidity, deformity, and impaired quality 
of life [448, 449]. CRP concentrations correlate with disease severity and 
radiographic progression in RA, as well as predicting disease onset, prior to 
clinical signs being evident [450-453]. Complement has been repeatedly 
implicated in the pathogenesis of RA based on studies showing reduced levels of 
native complement components and increased levels of complement metabolites 
in plasma, synovial fluid, and synovial tissue of RA patients; this is thought to be 
secondary to immune complex complement activation [454-456]. Ligand bound 
CRP can activate the complement system in vivo, and complexes between CRP 
and the activated complement components C3d (C3d-CRP) and C4d (C4d-CRP), 
which in part reflect CRP-mediated complement activation, as well as the overall 
levels of activated C3 and C4, have been correlated with disease [457, 458]. 
Finally CRP has been detected immunohistochemically in rheumatoid synovium
[459]. All these lines of evidence, at the least, suggest the possibility of a direct 
pathogenic role for CRP in RA.
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However it is as conceivable that CRP is anti-inflammatory in this auto-immune 
disease. Less appreciated and not as well understood as CRP's ability to bind 
antigen and aid in the elimination of microbes, is its known ability to bind 
autoantigens and presumed capacity to promote clearance of apoptotic cells
[460]. These latter properties of CRP have been suspected to contribute to 
homeostasis and to autoimmune disease. In addition to binding to subcellular 
particles from lysed or permeabilised cells (small nuclear ribonucleoprotein 
particles in particular) [84, 461, 462], CRP binds apoptotic cells in a Ca2+- 
dependent manner [59]. In so doing it appears to enhance opsonisation and 
phagocytosis of apoptotic cells by macrophages. Controversially in lupus, a 
condition characterised by an inappropriate CRP response for the amount of 
tissue damage present [28, 463], there are preliminary observations for a 
protective role for CRP [426]: recent reports for example in human CRP 
transgenic mice, suggested that CRP protected against SLE by increasing blood 
and mesangial clearance of immune complexes and by preventing their 
accumulation in the renal cortex [435], and one study claimed treatment of 
NZB/NZW mice with human CRP prior to disease onset delayed the onset of 
high-grade proteinuria and prolonged survival [464].
Attempting to further understand the role of CRP in arthritis is therefore of 
interest. Collagen-induced arthritis (CIA) is an animal model of autoimmunity 
that has been studied extensively because of its similarities to RA [465, 466]. 
Severe polyarticular arthritis, with synovitis, pannus formation, cartilage and 
bone erosion are hallmarks of CIA and histologically, murine CIA is 
characterised by an intense synovitis that corresponds precisely with the clinical
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onset of arthritis. CIA is induced in genetically susceptible strains of mice by 
immunisation with type II collagen (CII), the major constituent protein of 
articular cartilage, and both T cell and B cell immunity to CII are required for 
disease manifestation. While the direct role of T cells in the pathogenesis of CIA 
is unclear, the B cell response in terms of anti-CII immunoglobulin is critical to 
the development of the disease. This response, predominated by the IgG2 
isotype, requires the activation of the complement cascade. Transfer studies 
have shown that autoantibodies are directly pathogenic and can provoke at least 
some of the manifestations of joint inflammation. Antibodies, particularly as 
constituents of antibody-antigen immune complexes, play a central role in 
triggering inflammation; notably the DBA/1 LacJ mouse strain, which represents 
one of the most sensitive models for the induction of autoreactive joint disease, 
became almost completely resistant to collagen arthritis when rendered congenic 
for C5 deficiency, despite abundant Ig and C3 deposition within the joints [467].
This chapter describes our experiments looking at the role of CRP in vivo, 
following local or systemic endotoxin challenge, and during development of 
collagen arthritis.
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11.5 Results
11.5.1 The local Shwartzman Reaction
Intra-dermal injection of LPS (Salmonella enteritidis) all led to a Shwartzman 
reaction, regardless of whether a second systemic injection of endotoxin was 
given. At doses of LPS as low as 10 |ig the reaction was evident histologically 
on haematoxylin and eosin staining (Figures 33 and 34). Intra-dermal injection 
of 20 (xg LPS was also, as expected, associated with a systemic acute phase 
response at bleed out, with mouse SAP values >150 mg/1.
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Figure 33 Normal histology of murine skin
- a) x5, b) xlO, c) x20 (Objective magnification; Haematoxylin and eosin) 
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Figure 34 Demonstration of local Shwartzman phenomenon: polymorph infiltration, vasculitis and haemorrhage 
- a) and b) x5, c) and d) x 10, e) and f) x 20 (Objective magnification; Haematoxylin and eosin).
11.5.1.1 No effect of passive CRP administration on the local Shwartzman
reaction
The morning following intra-dermal LPS (10 pg), isolated human CRP (1 mg) or 
TC buffer was given intra-peritoneally to one group of age matched female mice 
and repeated 8 hours later. Approximately 36 hours after LPS administration, the 
mice were euthanised and the skins harvested and processed. A simple histology 
score for polymorph infiltration [mild (1), moderate (2) and severe (3)], was 
performed, blinded to treatment, by two observers in the laboratory (MBP and 
myself) and one external expert pathologist (Professor D. Evans). Figure 35 
shows our findings.
The median human CRP concentration at bleed out was 22.97 mg/1 (range 
16.32). No consistent difference between groups was evident. Other histological 
findings of vasculitis were not sufficiently common to meaningfully quantify.
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Figure 35 Passive CRP and polymorph infiltration in the Shwartzman reaction 
- Mice treated with LPS +/- CRP; histology scores of three observers for each mouse
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11.5.1.2 No effect of transgenic CRP production on the local Shwartzman
reaction
The local Shwartzman reaction was also elicited in age matched male human 
CRP transgenic mice (control mice were negative for the transgene). Intra- 
dermal LPS (10 |ig) was administered and 36 hours later the mice were killed 
and bled out. The median CRP at bleed out in transgenic mice was 18.90 mg/1 
(range 19.02). Again, there was no difference in the histological scoring (blinded 
to genotype) of polymorph infiltration (Figure 36). Haemorrhage and occasional 
vasculitis was noted but with no distinguishing pattern between groups and 
insufficiently frequently to score meaningfully.
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Figure 36 Transgenic CRP and polymorph infiltration in the Shwartzman reaction
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11.5.2 Endotoxaemia and C-reactive protein
LPS lethality was generated by systemic administration of LPS to mice. Unless 
indicated the LPS originated from Escherichia coli 0111:34, and was 
administered at a dose of 10 mg/kg intra-peritoneally; sterile acute phase stimuli 
were generated 24 hours prior to endotoxin challenge by administration of either 
0.5 ml 10% w/v casein or 0.25-0.5ml 2% w/v silver nitrate sub-cutaneously. All 
mice were bred on a pure C57BL/6 background, and were age matched. 
Analysis is presented separately for males and females and unless shown no 
significant difference in survival was detected by log Rank or Breslow testing.
11.5.2.1 Baseline and acute phase production of human CRP in transgenic 
mice
The known sexual dimorphism in baseline and acute phase serum concentrations 
of human CRP in the transgenic mice was confirmed before and after stimulation 
by injection of casein, silver nitrate or LPS (Figures 37 and 38). The males had 
dramatically higher values than the females, and mounted acute phase production 
of human CRP that corresponded well with the concentrations seen in human 
disease.
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Figure 37 Production of human CRP in female transgenic mice after stimulation with sterile inflammatory stimuli
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Figure 38 Production of human CRP in male transgenic mice after stimulation with sterile inflammatory stimuli
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11.5.2.2 Systemic administration and effect of acute phase stimulation on 
LD80: On going acute phase responses do not protect against LPS 
lethality
We established that for female wild type (Wt) mice, the LD80 dose of LPS 
needed to be greater than 7.5 mg/kg (E. coli 0111:84). Figure 39 summarises 
our experience of the thresholds for lethality.
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noted
n=10 n=14
5mg/kg unprimed 5mg/kg Casein 5mg/kg 0.25ml Ag 5mg/kg 0.5ml Ag
Figure 39 Lethality in female mice following endotoxin challenge
- priming by pre-existing sterile acute phase responses (s/c casein or silver nitrate; 
pooled results for lethality at 72 hours)
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Mice in which major acute phase responses had been induced by sterile 
inflammation, by sub-cutaneous injection of casein solution (Figures 40 and 41), 
24 hours beforehand, were not protected against LPS lethality. The harsher 
stimulus, silver nitrate did not protect either, and indeed lowers the threshold for 
LPS lethality (Figure 39).
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Male W t: Control (n=8) 
Male W t: Casein (n=9)
Hours following LPS challenge
Figure 40 Casein pre-treatment does not protect against LPS lethality in male mice
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Figure 41 Casein pre-treatment does not protect against LPS lethality in female mice
11.5.2.3 Passively administered human CRP does not protect female 
C57BL/6 mice against E. coli 0111:B4 LPS lethality
In contrast to the previous observation in female Balb/c mice receiving 
Salm. typhimurium LPS [89], and the study of Mold et al. in male C57BL/6 mice 
receiving E. coli 055:B5 LPS [431], we observed no protection by human CRP 
injections in the female C57BL/6 mice challenged here with E. coli 0111:B4 
LPS (Figure 42).
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Figure 42 No effects of passive CRP on survival from lethal LPS challenge
- groups o f female wild type C57BL/6 received an intra-peritoneal injection of isolated 
purified human CRP, either 6 or 50 mg/kg, or buffer alone in controls, 15 minutes before 
intra-peritoneal challenge with 10 mg/kg of E. coli O Hl:B 4  LPS and again 4 hours 
later. The LPS content o f the purified CRP used was extremely low, 0.1 ng o f LPS per 
mg o f CRP; this means that with the highest dose o f CRP administered there was about 
0.2ng o f LPS compared to the lethal challenge dose o f ~200pg.
11.5.2.4 Human CRP transgenic mice are not protected against LPS 
lethality
Both male and female transgenic mice mounted acute phase responses of human 
CRP to the stimulus of LPS injection. However, lethality following challenge 
with E. coli O l l l  :B4 LPS did not differ significantly from that seen in wild type 
controls (Figures 43 and 44). Furthermore, the same absence of protection was 
observed in mice challenged respectively with LPS from E. coli 055:B5 or Salm. 
typhimurium, that were used in previously reported studies (Figures 45 and 46).
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Figure 43 Male mice transgenic for human CRP are not protected against LPS (a) 
- E. coli Ol 11 :B4; lOmg/kg, i/p.
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Figure 44 Female mice transgenic for human CRP are not protected against LPS 
- E. coli Ol 11 :B4; lOmg/kg, i/p.
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Figure 45 Male mice transgenic for human CRP are not protected against LPS (b) 
- E. coli055:B5; lOmg/kg, i/p.
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Figure 46 Male mice transgenic for human CRP are not protected against LPS (c) 
- S. typhimurium; 1 Omg/kg, i/p.
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11.5.2.5 On going acute phase responses in human CRP transgenic mice do 
not protect against LPS lethality
Human CRP transgenic mice that were stimulated by injection of either casein or 
silver nitrate 24 hours before challenge with LPS from E. coli Ol 11 :B4, and that 
were therefore mounting acute phase responses of human CRP at the time of 
challenge with LPS, were not protected against lethality compared to control 
transgenic animals that were not pre-stimulated, or to unstimulated wild type 
controls (Figures 47-52). Indeed, the human CRP transgenic male mice that 
were pre-treated with casein showed greater mortality than the control group 
(Figure 47). We observed the trend to greater mortality in the male not the 
female human CRP transgenic mice, consistent with the fact that the males 
produce abundantly more human CRP than the females. Even though the 
difference was statistically significant one must be very cautious not to over 
interpret this finding because we are very aware of the variability in these 
experiments.
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Figure 47 Male hCRPTg mice are not protected against LPS by casein pre-treatment 
- although the samples size is small, there was significantly greater mortality among 
males pre-treated with casein than in the corresponding control group, PO.Ol (Log 
Rank test).
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Figure 48 Female hCRPTg mice are not protected against LPS by casein pre-treatment
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Figure 49 Silver nitrate (0.25ml) fails to protect male hCRPTg mice from LPS lethality
- 5mg/kg E. coli Ol 11 :B4 LPS
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Figure 50 Silver nitrate (0.25ml) fails to protect female hCRPTg mice from LPS lethality 
- 5mg/kg E. coli Ol 11 :B4 LPS
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Figure 51 Silver nitrate (0.5ml) fails to protect male hCRPTg mice from LPS lethality
- 5mg/kg E. coli Ol 11 :B4 LPS
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Figure 52 Silver nitrate (0.5ml) fails to protect female hCRPTg mice from LPS lethality 
- 5mg/kg E. coli Ol 11 :B4 LPS
11.5.2.6 Human CRP does not bind to LPS from rough or smooth strains of 
E. coli
Loss of human CRP immunoreactivity in the Roche MIRA assay is a sensitive 
test for macromolecular ligand binding by CRP (see section 13.6.3.3), as shown 
by the effect of C-polysaccharide (Table 38). Addition of LPS from the rough 
E. coli strain J5, and from two different smooth strains 0111:B4 and 026:B6, 
however, had no significant effect other than possibly minor inhibition. The 
failure of the LPS preparations to interfere in the assay is thus robust evidence 
that CRP does not bind significantly to LPS, at least via the calcium-dependent 
ligand binding B face of the CRP molecule.
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Table 38 LPS does not block CRP reactivity in the MIRA assay
CRP Concentration measured (mg/l)
C-polysaccharide 0.4* 0.41* 0.46* 0.46* 0.39* 66.10
E. coli 026:B6 LPS 56.54 66.96 69.01 69.52 69.63 63.99
E. coli J5 LPS 65.26 66.01 64.34 64.26 65.28 65.30
E. coli 0111:B4 60.03 63.02 63.33 64.18 65.01 64.20
- all samples had the same concentration of pure human CRP; * masked 
immunoreactivity implying ligand bound CRP
11.5.3 Collagen a rth ritis  in hum an C -reactive protein transgenic mice
Human CRP transgenic C57BL/6 mice were immunised intra-dermally in the 
tail, with chick collagen (complete Freund's adjuvant, day 0), with an identical 
boost on day 21. They were studied clinically over a two month period as well 
as biochemically and histologically. This small pilot study included male CRP 
transgenic negative mice (wt), male CRP transgenic positive mice, and female 
CRP transgenic positive mice. It must be noted that the schedule employed to 
elicit collagen arthritis in the C57BL/6 strain is harsher than traditional methods 
[354] (which employ more genetically susceptible DBA/1 mice), and this was 
visible in some mice with important morbidity, particularly inflamed tails and 
occasional mortality. This concerned us, and is a critical reason for not repeating 
this study in this strain.
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11.53.1 Acute phase response secondary to immunisation
Murine SAP
All animals mounted an acute phase response secondary to the immunisation 
schedule, regardless of the presence or absence of clinical arthritis. Figure 53 
demonstrates the mouse SAP response in all mice, whilst Figures 54-56 
demonstrate the mouse SAP response in the different subgroups. Human CRP 
genotype did not affect the global mouse SAP response, which acted in this case, 
as an independent marker of similar immunisation protocols.
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Figure 53 Murine SAP response to chick collagen immunisation (all animals) 
- complete Freund’s adjuvant Day 0 and 21
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Figure 54 Murine SAP response to chick collagen immunisation: male hCRPtg +ve 
- complete Freund's adjuvant Day 0 and 21
^  100-1 
co
^  75-1
£ a
E
50-
25-
0J
0 6 14 33 43 56 63
Days following immunisation
Figure 55 Murine SAP response to chick collagen immunisation: female hCRPTg +ve 
- complete Freund’s adjuvant Day 0 and 21
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Figure 56 Murine SAP response to chick collagen immunisation: male wt mice 
- complete Freund’s adjuvant Day 0 and 21
Human CRP
When assayed, CRP was not detectable in female positive transgenic mice, 
despite the mSAP response to immunisation, and the use of a sensitive assay 
(MIRA). Interestingly the male mice demonstrated only a modest response 
(Figure 57). This was not consistent with the evident tissue damage in the tails 
of the mice immunised or the mSAP response.
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Figure 57 Human CRP values in male CRP transgenic mice immunised with collagen
11.5.3.2 Collagen antibody production, genotype, and clinical arthritis score
No reference serum was available for this assay. Therefore we used serum from 
a single animal with florid arthritis at the end of the experiment (arthritis score 
11), that contained IgG anti-chick collagen antibodies. Pre-bleed sera did not 
contain any detectable antibody. There was a linear relationship across a wide 
range of dilutions of sera, and antibody production was evident prior to clinical 
signs of arthritis (Figure 58). Bleed out sera from the other animals were then
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tested at a dilution of 1 in 1600 and compared to the reference sera (serial 
antibody titres were not measured).
No difference in antibody titre was seen between groups, and no relationship was 
seen between clinical arthritis and presence of antibody i.e. animals with no 
arthritis had detectable antibody and vice versa (Figures 59 and 60). This may 
simply represent a sampling error with regards the power of our study. 
Alternatively, and worthy of further investigation if this were found to be a 
robust and reproducible effect, it may represent changes in the handling or 
presentation of potential immunogens in CRP transgenic mice.
Animal C41/6 
CRPTg -ve male
Day (Arthritis score)
—  Day 33 (0)
—  Day 56 (10)
—  Day 63 (11)
i—--------------- 1-------------------1
0.0001 0.001 0.01
Serum dilution (log scale)
Figure 58 Linear relationship of anti chick collagen antibodies across a dilution series
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Figure 59 No relationship between clinical arthritis score and collagen antibody titre
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11.5.3.3 Clinical arthritis score and CRP genotype
Figure 61 demonstrates the clinical arthritis score for the study. None of the 
female CRP transgenic positive mice developed clinical evidence of arthritis. 
Indeed severe arthritis was only noticed in male CRP transgenic negative mice. 
There was however variability in the severity of the arthritis (Figure 61, inset), so 
further work is needed before any substantive conclusion can be drawn.
11.5.3.4 Histology
Professor D. Katz kindly reviewed the embedded sections (which had been 
decalcified). No immunohistochemistry could be performed on these sections. 
His findings, showed, where there was clinical evidence of arthritis, histological 
confirmation with synovitis, synovial hyperplasia and soft tissue inflammation as 
well as bone erosion. Where no evidence of arthritis was macroscopicaily seen, 
histology was normal. Representative examples of histology are shown in Figure 
62.
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Figure 61 Clinical arthritis and CRP genotype; b) wide variation in severity of arthritis
- the average arthritis score is calculated from the score for each paw of every mouse, 
with the average for each genotype shown in a) and plotted individually in b).
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Murine arthritisNormal histology
Figure 62 Typical histology from mice with and without clinical evidence of arthritis
- H&E staining; the left sided images show normal histology whilst those on the right demonstrate arthritis, synovitis, inflammation and bone erosion
o■o
11.6 Discussion
Despite many reports of properties of CRP, clear understanding of the actual 
biological functions of this phylogenetically ancient and highly conserved 
protein remains unclear. This reflects a number of important points pertaining to 
CRP, which are in addition to the caveats associated with any individual animal 
model of disease. Examples of the constraints and limitations that need to be 
considered for our work, as well as others before us, include [1,12,326]:
• No deficiency state or protein polymorphism of human CRP has been 
reported. There is thus no information from so called ‘experiments of 
Nature’;
• Mice, the most accessible model for in vivo investigation of the 
physiological and pathophysiological functions of proteins, produce CRP 
only as a trace protein that, although inducible in the acute phase 
response, never exceeds 1-2 mg/1, and no mouse CRP knockout has been 
produced;
• Although CRP is generally conserved, there are nonetheless very 
important differences between CRP in different species [75, 468] with 
respect to key structural and functional properties (demonstrated by 
simple experiments for rabbit CRP in Figure 63 and Tables 39 and 40) 
e.g. fine ligand-binding specificity, presence and nature of glycosylation,
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protomer assembly, capacity to precipitate and aggregate ligands, baseline 
circulating concentrations, behaviour as acute-phase proteins, and 
capacity to activate autologous complement. Experiments in which 
heterologous CRP is administered to mice, or transgenically expressed, 
are not, therefore, necessarily physiological or representative of the actual 
functions of human CRP in man;
Rabbit CRP 
Centre well 200mg/l
C- polysaccharide 
Doubling dilutions from 1 mg/ml 
in top well, clockwise
Human CRP 
Centre well 200mg/l
Indubiose 1%/TC Gel
Figure 63 Rabbit CRP does not precipitate pneumococcal CPS
Table 39 Rabbit and human CRP bind pneumococcal CPS in the fluid phase
- demonstrated indirectly by changes in ability o f CRP (100mg/l) in buffer to bind to 
Sepharose-PE (complexed CRP not being able to bind)
0 80 71
100 78 59
500 60 48
1000 44 37
5 000 32 22
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Table 40 Autologous activation o f complement: rabbit and human CRP
- Despite both rabbit and human CRP binding commercial CPS there are differences in 
complement activation; a sheep red cell haemolytic assay in autologous serum 
demonstrates that rabbit CRP does not activate its autologous complement.
Experiment 1
Buffer Human CRP 1 in 192
CRP-CPS Human CRP <1 in 24
CRP-CPS- Human CRP 1 in 192
RMM*
Buffer Rabbit CRP 1 in 96
CRP-CPS Rabbit CRP 1 in 96
CRP-CPS- Rabbit CRP 1 in 96
RMM*
♦RMM is a specific inhibitor of CRP binding (see Chapter 13)
- hCRP, rCRP, CPS at 165mg/l; RMM at 3.6mM
• Many in vitro studies have been conducted with heterologous systems,
and/or with commercially sourced CRP for which no adequate
characterisation of purity or integrity is reported;
• Very few studies include rigorous controls that are essential for
attribution of observed effects to CRP itself, such as inhibition by
anti-CRP antibodies or by specific affinity chromatography absorption of 
the CRP preparations. The lack of a specific pharmacological inhibitor of 
CRP binding hampers in vivo studies in particular;
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• Transgenic models may demonstrate aberrant protein expression not 
reflected in man e.g. the human CRP transgene is aberrantly expressed in 
our model, with abundant CRP production in the kidney and other tissues 
[435], whilst CRP in humans is produced in significant amounts only by 
the liver.
Chapter 14 discusses these concerns in greater detail.
Specifically we show here that protection of mice against LPS lethality by 
passive administration of human CRP is not a universally reproducible 
phenomenon. Furthermore, human CRP transgenic mice, that mount major acute 
phase responses of human CRP following acute phase stimulation, closely 
resembling events in man, were not protected against LPS toxicity. There are 
also conflicting reports about whether pre-existing acute phase responses protect 
mice against LPS lethality, and we confirm the previous finding that mice 
mounting an acute phase response to a sterile inflammatory stimulus remain as 
susceptible as control, non-pretreated, animals. It has been reported previously 
that human CRP does not bind to LPS, and we confirmed in this study, using a 
very sensitive indirect assay, that there was no evidence of a significant 
interaction between CRP and LPS from one rough and two smooth strains of E. 
coli.
Our present failure to find protection by exogenous human CRP suggests that this
rather artificial phenomenon is unlikely to be of general significance. Apart from
the heterologous nature of the human CRP in the present transgenic mice, they
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represent a much more physiological model, either with or without an ongoing 
acute-phase response before LPS challenge. The previous observations of a 
protective role for CRP were in transgenic mice expressing rabbit CRP under a 
nutritional promoter (and moreover the control animals were not of the same 
strain) [429]. The whole gamut of acute-phase phenomena, including the 
cytokine cascade, acute-phase protein synthesis, and activation of all the 
molecular and cellular pro-inflammatory and defence systems, is engaged in our 
mice, so that any effects of human CRP can be mounted in a milieu that is as 
appropriate as possible. The absence of any protection in such mice therefore 
provides no evidence in favour of human CRP having an important function in 
host defence against LPS lethality. This is consistent with clinical experience, in 
that all patients with septicaemia and with septic shock have extremely high 
circulating CRP concentrations that persist until death, unless there is also 
concurrent severe liver failure. There is thus no evidence from clinical 
observation of a protective effect of CRP in this situation.
With respect to the local Shwartzman reaction we found no effect on the 
histological lesion of either exogenously administered or transgenically produced 
human CRP. Further study in this area might nevertheless be valuable as more 
quantitative histology along with immunohistochemistry looking for CRP and/or 
complement deposition in the skin, might demonstrate subtle differences.
Finally our pilot study in arthritis did not produce any significant conclusions but 
does suggest avenues for further work. Although it is reported that C57BL/6 
mice can be used for collagen arthritis [354], we found that initiation of arthritis
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in this strain was associated with an unacceptable morbidity for the mice (in view 
of the immunisation schedule involving two injections with complete Freund’s 
adjuvant), and occasional mortality. Intriguingly in our hands, in the very small 
numbers studied, all animals had similar acute phase responses and antibody 
titres, but male CRP transgenic positive mice didn’t develop any clinical arthritis 
whilst the male CRP transgenic negative mice did, albeit variably. Larger and 
more appropriate experiments are necessary to take this study further. 
Importantly back crossing the CRP transgene on to a more susceptible strain 
(DBA/1) is necessary followed by a study adequately powered to look for 
differences between genotype as well as gender.
11.7 Summary
The biology of CRP in vivo remains to be clarified. Our attempts to reproduce 
protection against endotoxaemia in the most physiologically relevant model 
available, shows no significant effect of CRP, in either local or systemic 
administration of endotoxin. A pilot study of collagen arthritis in transgenic 
human CRP mice suggested a possible protective role for human CRP but the 
study size and limitations are such that this is not a substantive finding, but one 
that should generate further interesting work.
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12 Transgenic expression of human C-reactive protein
and atherosclerosis
12.2 Introduction
Atherosclerosis is not just the consequence of focal arterial lipid accumulation. Fundamental processes include endothelial injury, intimal cholesterol accumulation, foam cell formation, migration 
and proliferation of smooth muscle cells, expression of an 
extracellular matrix and local thrombus formation, secondary organisation, 
calcification and/or plaque rupture [362]. Although high grade arterial stenoses 
are important, more so are qualitative aspects of plaques themselves, as critical 
factors associated with acute complications. Vessel occlusion occurs due to 
acute plaque rupture and thrombus formation and atherothrombosis supervening 
on unstable atherosclerotic plaques causes most coronary events and stroke. 
Among the functional features of plaques associated with vulnerability, 
inflammation has emerged as a leading pathophysiological mechanism [363, 
364]. The association between circulating concentrations of CRP, an extremely 
sensitive systemic marker of inflammation, and future atherothrombotic events 
has provoked speculation about possible direct pathogenetic roles for this lipid 
binding, complement activating, molecule. This chapter describes the effects of 
transgenic expression of human CRP on atherosclerosis in apoE knockout mice.
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123 Background
Systemic inflammation alters the probability of the occurrence of a 
cardiovascular event and markers of inflammation such as raised white cell 
counts [469], elevated values of CRP and SAA [168, 179], as well as raised 
erythrocyte sedimentation rates [168] are all consistently associated with future 
atherothrombotic disease. Indeed immediately preceding clinical episodes of 
infection and/or inflammation elsewhere in the body are also associated with 
cardiac events [470,471].
The exquisitely sensitive and non-specific nature of the CRP response to 
inflammation, along with its robustness and ease of measurement analytically, 
has focussed much of the recent attention on it rather than other inflammatoiy 
markers. Its use as a prognostic marker has been investigated in detail since the 
1990s, although the association had been studied as long as ago as the 1950s, 
particularly with regards myocardial infarction [472-474]. Notably the European 
Concerted Action on Thrombosis and Disabilities study (ECAT) looked at 
coagulation factors that might predict coronary events in out patients with stable 
and unstable angina, and CRP was included to correct for possible confounding 
by the fact that many clotting proteins are acute phase reactants [475]. Even with 
an insufficiently sensitive assay, CRP values predicted coronary events better, 
statistically, than any of the other markers in the study [173]. With a sensitive 
immunoassay [144] the ECAT investigators demonstrated clearly that raised 
circulating concentrations of CRP were predictors of coronary events in patients
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with stable or unstable angina [176]. When measured in patients with severe 
unstable angina being admitted to hospital, a striking prognostic role for CRP 
was later demonstrated; elevation of CRP (and SAA) at the time of hospital 
admission predicted a poor outcome in patients with unstable angina [172]. The 
Multiple Risk Factor Intervention Trial (MRFIT) then became the first 
prospective study in "healthy but high risk individuals" to document the relation 
between CRP and coronary heart disease mortality (1996) [174]. There then 
followed an explosion of interest in this area. Subsequent studies have 
demonstrated, both for men and women, that elevated values of CRP, albeit in 
the previously thought of as normal range, predict future cardiovascular events in 
patients with and without pre-existing cardiovascular disease. Hence the best 
estimates to date are now of an excess 50% risk of a major cardiac event in an 
otherwise healthy individual whose CRP concentration falls in the top, as 
opposed to bottom tertile (See chapter 10) [168].
The proposal that CRP may not only be a marker of low grade systemic 
inflammation associated with the processes underlying atherosclerosis was 
originally made in the 1980s [110, 111]. As already reviewed in detail in 
Chapter 8, complexed CRP activates complement, and damaged lipoprotein 
particles, including those typically found within atheroma, are potential ligands 
for CRP. Immunohistochemical studies have demonstrated that CRP is found 
deposited in diseased coronary arteries, in association with both lipoproteins and 
complement components. CRP is seen in a diffuse rather than a focal deposition 
in the deep fibroelastic layer and in the fibromuscular layer of the intima adjacent
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to the media and additionally most foam cells below the endothelium stain 
positively for CRP. Furthermore in cell culture studies co-incubation of CRP 
with LDL stimulates foam cell formation, a key process associated with 
atherogenesis (Figure 64). Other in vitro observations, amongst which include 
the demonstration that CRP can upregulate tissue factor production by 
monocytes, have contributed to the suggested role for CRP in atherothrombosis, 
although such in vitro observations are increasingly being questioned.
Figure 64 Foam cell formation: co-incubation of native LDL with human CRP
- in collaboration with Dr X. Ruan, UCL, primary human vascular smooth muscle cells 
(TCS CellWorks) were incubated for 24 hours at 37°C with LDL (200 pg/ml) and CRP 
(100mg/l); Foam cell fonnation was demonstrated by oil red O staining; Objective 
magnification x 20 and x 40.
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CRP may thus be a direct mediator of atherogenesis and in particular 
atherothrombotic events. In vitro studies have inherent limitations, particularly 
with regards the applicability of using isolated human CRP in non-physiological 
settings, and plasma proteins are known to enter the arterial wall by transudation 
and to be detectable in plaques [476-478]. In vivo studies are therefore needed, 
but as discussed in Chapters 11 and 14, with regards CRP, conventional animal 
work is limited because although the evolutionary conservation of sequence, 
subunit organisation and protein fold seen with the pentraxins proteins is strong, 
there are major structural and functional differences between CRP’s of different 
species.
12.4 ApoE K nockout m ice
Mice were traditionally viewed as an atherosclerosis-resistant species until the 
studies of Paigen et al. demonstrated that certain strains of mice, such as the 
C57BL/6, could be induced to form fatty streaks in the aortic sinus with addition 
of fat, cholesterol, and cholate to the diet [479, 480]. However, since the lesions 
are largely restricted to the aortic sinus and don’t progress much past the fatty 
streak stage this approach cannot contribute to modelling advanced stages of the 
disease. In the early 1990's the development, by homologous recombination in 
embryonic stem cells, of apolipoprotein (apo) E-deficient mice revolutionised the 
use of murine models in the study of cardiovascular disease [481,482].
ApoE, a glycoprotein [483], is a structural component of VLDL synthesised by
the liver and intestinally synthesised chylomicrons. It is also a constituent of a
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subclass of HDLs involved in cholesterol transport activity among cells. One of 
the most important roles of apoE is to mediate high affinity binding of 
chylomicrons and VLDL particles that contain apoE to the LDL receptor and a 
hepatic chylomicron remnant receptor. This allows for the specific uptake of 
these particles by the liver which is necessary for preventing the accumulation in 
plasma of cholesterol rich remnants. The homozygous inactivation of the apoE 
gene results in animals that are devoid of apoE in their sera [484]. The mice 
appear to develop normally, however they exhibit five times the normal serum 
plasma cholesterol. The elevation of plasma lipid values seen in apoE'7' mice 
reflects a marked increase in the plasma concentration of remnant chylomicron 
particles along with a modest elevation of VLDL and LDL [481]. There is a 
subsequent predilection for spontaneous development of atherosclerotic lesions 
particularly in the aortic root, at the lesser curvature of the aortic arch, the 
principal branches of the aorta, and in the pulmonary and carotid arteries (Figure 
65). Monocyte attachment to endothelial cells has been observed by 6 weeks of 
age and foam cell lesions develop as early as 8 weeks, and after 15 weeks 
advanced lesions (fibrous plaques) are observed. The latter consist of a fibrous 
cap containing smooth muscle cells surrounded by connective tissue matrix that 
cover a necrotic core with numerous foamy macrophages. These spontaneous 
lesions progress and can cause severe occlusion of the coronary artery ostium by 
8 months, although without functional consequence (Figures 66 and 67) [485, 
486].
In order to directly investigate the possible role of human CRP in atherogenesis 
in vivo, we have studied normal diet fed apoE knockout mice with and without
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transgenic expression of human CRP as they spontaneously develop 
hypercholesterolemia and atherosclerosis.
Figure 65 View of the heart and proximal vessesl in an apoE ' mouse (1 year old)
- this demonstrates the regions of interest in the mouse heart, aorta, and proximal 
branches (Courtesy of Dr M. Kahan, UCL)
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Figure 66 Typical Oil Red O stained lipid lesions in a 20 week old apoE' * mouse
- 10 |liM sections through the aortic sinus (a-d) as quantified in this study; Objective 
magnification x2.5
x 2.5 x 20
Figure 67 Advanced lesions of an apoE''mouse at one year of age
- note coronary artery involvement (right hand image); Oil Red O staining for lipid deposition; 
Objective magnification x 2.5 and x 20
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12.5 Results
12.5.1 Measurement of human CRP in hyperlipidaemic serum
Matrix effects on CRP assay and recovery of isolated pure human CRP spiked 
into apoE+/+ and apoE'^ sera were studied in parallel using the Dade-Behring 
BNII microparticle-enhanced turbidimetric immunoassay and the Roche MIRA 
method. The BNII and Roche MIRA assays are both specific for human CRP; 
neither detect anything significant in sera of mice that are not transgenic for 
human CRP.
The Spearman rank correlation coefficient for CRP determination of identical 
hyperlipidaemic murine serum samples (20-30 mg/1 hCRP) on different 
occasions on the MIRA was 0.943 (P=0.005; n=6), with the absolute values of 
the second reading being 18.2% (SD 5.3%) higher than the first. When the same 
samples were measured both on the MIRA and the BNII the Spearman rank 
correlation between the two assays was 1.00 (P0.0001; n=4), with the BNII 
giving absolute values 19.5% (SD 5.2%) lower than those of the MIRA. The two 
different CRP assays, therefore give consistently comparable results.
Moreover there was identical recovery of CRP when apoE_/'-hCRP+ serum was 
diluted 1:4 in either lipaemic apoE'/_ serum or normal apoE+/+ mouse serum: the 
Spearman rank correlation coefficient (comparing dilution in lipaemic as 
opposed to normal serum) for both assays was 0.9 (P=0.037; n=5). Furthermore,
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both assays showed similar recovery when isolated pure human CRP was spiked 
into normal human serum, typically hyperlipidaemic apoE'7" mouse serum, or 
Tris buffered saline containing 4 g/1 bovine serum albumin (Table 41).
Table 41 Analytical recovery of pure human CRP 
- comparison of different assays (MIRA and BNII) and diluents
0 1.44 1.01
5 Normal human serum* 5.66 6.04
10 10.47 11.5
0 0.34 <0.16
5 apoE'7* serum 5.2 4.5
10 10.24 10.4
0 0 <0.16
5 4% TCB 4.86 5.08
10 10.53 9.4
♦CRP concentration 0.88mg/
12.5.2 Circulating human CRP is not complexed and is cleared 
normally in apoE'7' mice
CRP can bind to phospholipids by virtue of its specific, calcium-dependent 
reactivity with phosphorylcholine residues. However, prior studies of acute- 
phase human serum by gel filtration and density gradient ultracentrifugation 
showed that human CRP is in a free, uncomplexed form, despite the coexistent
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presence of the various classes of serum lipoproteins, all of which contain 
phospholipids [78, 111]. In contrast, when isolated CRP is aggregated by 
immobilisation at a sufficient density on a solid phase and then exposed to 
normal human serum, it selectively binds LDL and traces of VLDL [111]. Native 
human CRP in solution also forms complexes with the abnormal lipoprotein p- 
VLDL in serum of patients with type III hyperlipoproteinaemia as well as 
complexes in sera from individuals with type IV and type V 
hyperlipoproteinaemia [ 109].
Importantly when sera from apoE'/'-hCRP+ mice and from apoE'7' or apoE+/+ 
mice spiked with pure human CRP, were analyzed by size exclusion 
chromatography, the elution volume (12.65 ml) and profile of the human CRP 
were constant and completely distinct from the fractions containing cholesterol 
(elution volume 7.75 ml). There was thus no evidence for complex formation 
between human CRP and any lipoprotein or other macromolecular ligand in the 
lipaemic apoE knockout serum (Figures 68 and 69).
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Figure 68 Gel filtration profile of ex-vivo apoE‘/'-hCRP+ serum 
- demonstrating non-overlapping elution profiles for cholesterol and human CRP
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Figure 69 Gel filtration profiles of human CRP spiked apoE'/_ serum
- hCRP spiked to 200mg/l; demonstration of non-overlapping elution profiles for 
cholesterol and human CRP
In addition the plasma clearance of intra-venously injected trace radiolabelled 
human CRP was identical in apoE /"-hCRP+ and apoE+/+-hCRP+ mice (Figure 
70).
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Figure 70 Plasma clearance of 125I-hCRP in apoE '^-hCRP4^ and apoE+/+-hCRP+ mice
- each point represent the mean (SD), in 4 mice per group, of radioactivity remaining in 
the blood after intra-venous injection of 1 pg tracer at time 0
:+/+
12.5.3 Acute phase response to inflam m ation in apoE"7" and apoE+/+
mice
Following sub-cutaneous injection of casein, the peak acute phase concentration
of transgenic human CRP at day 2 was significantly greater in apoE'7' than
apoE+/+ mice: median (range) 42 (41-63) mg/1, n=5, compared to 19 (7-24) mg/1,
n=9, (PO.Ol). Values fell thereafter with no difference between the groups on
days 4 and 7 (Figure 71). In contrast the acute phase response of mouse SAP
was the same in these two groups as well as in apoE" " and apoE+/+ mice without
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transgenic human CRP. Median SAP values rose from a baseline of 3-7 mg/1 to 
peak at 67-86 mg/1 on day 2, falling to 16-20 mg/1 on day 4 and 9-13 mg/1 on day 
7 (Figure 72). The mouse C3 response was also the same in all four groups, 
rising from 300-400 mg/1 before stimulation to a peak of around 600 mg/1 at day 
2-4, and falling back to only slightly above normal by day 7.
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Figure 71 Expression of human CRP following casein administration in apoE_/‘ 
and apoE+/+ human CRP transgenic mice
228
200n
§
5  1 5 0 H
o) 10(H 
E 
a.
^  SO- C0  0 U i
0 J
■ apoE"7' 
•  apoE+/+
Pre 2 4 7
Days following s/c casein
Figure 72 Expression of mouse SAP following casein administration in apoE'7' 
and apoE+/+ human CRP transgenic mice
12.5.4 Identical hyperlipidaem ia in apoE knockout mice in the
presence and absence of transgenic human CRP expression
The apoE deficient mice developed the same characteristic progressive 
hypercholesterolemia and hypertriglyceridaemia, irrespective of whether they 
were transgenic for human CRP or not. The median (range) serum cholesterol 
concentration was around 2.7 (1.9-3.5) mmol/1 in the apoE /+ and apoE+/+-hCRP+ 
mice at all ages tested up to 56 weeks, and was around 11 (7-17) mmol/1 in both 
apoE'7' and apoE‘7'-hCRP+ groups at 8 weeks, rising to around 17 (9-21) mmol/1 
at one year of age. The median (range) serum triglyceride concentration was
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around 1.0 (0.5-1.5) mmol/1 in the apoE+/+ and apoE+/+-hCRP+ mice at all ages 
tested up to 56 weeks, and was around 1.5 (0.7-5) mmol/1 in both apoE_/' and 
apoE'/‘-hCRP+ groups at 8 weeks, rising to around 2.0 (1.2-5) mmol/1 at one year 
of age (Figures 73 and 74).
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Figure 73 Changes in serum cholesterol and triglycerides in apoE'7' mice with and without the human CRP transgene
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Figure 74 Changes in serum cholesterol and triglycerides in apoE+/+ mice with and without the human CRP transgene
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There was no difference in weight between groups with and without transgenic 
human CRP, for example at one year the mean (SD) weights were: 
apoE'/'-hCRP+, 35.2 (1.8) g and apoE"A, 34.9 (3.0) g, n=16 in each group, while 
all apoE+/+-hCRP+ (n=3) and apoE+/+ mice (n=6) weighed 33.0 g at this age. 
There was also no difference in morbidity between any of the groups, regardless 
of their apoE or human CRP status, and they all showed the same low mortality, 
<5 per 100 at 1 year, as the normal wild type apoE+/+ controls.
12.5.5 Circulating concentrations of mouse SAP and human CRP
The inflammatory markers mouse SAP and human CRP were measured serially 
in one cohort at 8, 12, 16 and 20 weeks of age. Another cohort was bled at 52 
and 56 weeks of age. Figures 75 and 76 show the values for SAP for these 
bleeds, according to apoE and transgenic CRP genotype.
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Figure 75 Mouse SAP concentrations in apoE+/+ and apoE'7' mice, wildtype for 
transgenic human CRP
- median values indicated; broken line represents values >12mg/l; * separate cohort
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Figure 76 Mouse SAP concentrations in apoE+/+ and apoE"/_ mice expressing 
transgenic human CRP
- median values indicated; broken line represents values >12mg/l; * separate cohort
Male C57BL/6 mice have an unavoidable tendency to fight with each other 
[487], leading to minor injuries and inflammation and thus to acute phase 
responses that may complicate assessment of inflammation related to 
development of atherosclerosis in the apoE' * mice. However, in contrast to its 
human homologue, which is a stable constitutive plasma protein, mouse SAP is 
an exquisitely sensitive acute phase reactant, as responsive to bacterial 
lipopolysaccharides as the pyrogen test [488]. In this regard we have used mouse 
SAP to control for systemic evidence of inflammation.
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Baseline values in healthy normal C57BL/6 animals are 2-10 mg/1, and mice, in 
this experiment, with serum SAP values greater than 12 mg/1 all showed signs of 
fighting with ruffled, non-glossy coats and occasionally frank wounds. These 
clinical signs and the raised SAP concentrations were all transient and affected 
only a minority of different mice at the different time points. No mice had 
sustained increased values of SAP and samples with transiently increased SAP 
values were therefore excluded from the analysis of acute phase reactants.
With this proviso, mice of the four different genotypes, apoE+/+, apoE+/+-hCRP+, 
apoE'7' and apoE'/'-hCRP+, had circulating mouse SAP values within the normal 
range at all time points between 8 and 52 weeks (Table 42).
Table 42 No increase in mouse SAP production in apoE'7' mice
- intercurrent inflammation is accounted for by exclusion of mice in whom mouse SAP 
values were greater than 12mg/l
Age mSAP mg/l (median; range)
8 wk 5 (4-7) 9(5-12) 9(5-12) 9(5-12)
n=4 n=8 n=21 n=11
12 wk 6(3-10) 6(1-8) 6(3-11) 6(4-11)
n=7 n=18 n=17 n=17
16 wk 6(2-11) 6(3-12) 6.5(3-11) 6(4-11)
n=7 n=20 n=18 n=13
20 wk 6 (1-7) 4(1-11) 5 (3-12) 4.5(1-12)
n=5 n=17 n=27 n=28
52 wk* ND ND 3(2-4) 3 (2-7)
n=16 n=13
* Separate cohort
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None of the 16 apoE"/_-hCRP+ animals that were killed at 56 weeks had SAP 
concentrations outside the normal range (Median 3 mg/1, range 2-7; n=16). 
Mouse SAP assays thus provided no evidence of a systemic inflammatory 
response associated with either hyperlipidaemia or the development and 
progression of atherosclerosis in apoE’7' mice, regardless of whether they 
expressed transgenic human CRP or not.
12.5.6 Increased circulating concentrations of human CRP in apoE"7" 
mice
The known widely variable baseline circulating CRP concentration among male 
human CRP transgenic mice, was observed here in both the apoE'/_ and apoE+/+ 
background, even after exclusion from the analysis of samples containing acute 
phase values of mouse SAP. However, from 12 weeks onwards, the CRP values 
were consistently higher in the apoE"/'-hCRP+ mice compared to the 
apoE+/+-hCRP+ controls, but did not change significantly after that time (Figure 
77 and Table 43). CRP values were not surprisingly correlated reasonably 
closely with mouse SAP values (Figure 78; r2 values consistently between 0.4 
and 0.8) and there was a suggestion of a correlation with increasing 
hypercholesterolaemia and age (Figures 79 and 80; r2 values of 0.5-0.9). 
However the absolute number of mice studied, the difficulty of controlling for 
extraneous sources of inflammation, as well as the likelihood of numerous 
confounders mean that further statistical analysis of any such interaction cannot 
yield rigorous information.
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Figure 77 Transgenic human CRP expression is increased in apoE'7' mice
- * separate cohort
Table 43 Transgenic expression of human CRP is increased in apoE'7' mice
- even when intercurrent inflammation is accounted for by exclusion of mice in whom 
mouse SAP values were greater than 12mg/l
Age hCRP mg/l (median; range)
8 wk 11.1 (3.0-17.7) 
n=8
10.9(2.0-22.8) 
n=11
12 wk 7.8(1.1-13.7)
n=18
17.1 (3.8-36.1) 
n=17, P<0.005
16 wk 6.2(1.2-14.2)
n=20
24.0 (9.8-31.2) 
n=13, P<0.0001
20 wk 9.1 (1.3-12.6) 
n=17
20.9(1.8-41.1) 
n=28, P<0.0001
52 wk* 8.27(1.7-10.9)
n=3
31.4 (20.8-50.0) 
n=16, P<0.0001
* separate cohort
238
apoE+/+ 8 weeks 
201
8 10 12 14 16 18 20
SAP (mg/I)
20 weeks
SAP (mg/I)
Figure 78 Correlation between human CRP and mouse SAP production 
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These differences in CRP values between the apoE'7' and apoE+/+ groups were not 
due to interference in the CRP immunoassay by the progressive 
hypercholesterolemia of the apoE'7' mice, as shown above and similarly 
circulating human CRP is not complexed and is cleared normally in apoE'7' mice. 
Thus the higher CRP concentrations in the apoE'7"-hCRP+ mice appear to reflect 
increased CRP synthesis.
12.5.7 Human CRP and mouse C3 are found immunohistochemically 
within atherosclerotic plaques
There was specific immunohistochemical staining for mouse C3 in all the 
plaques, with the same intensity regardless of the presence or absence of human 
transgenic CRP expression. In apoE"7‘-hCRP+ mice, CRP was also demonstrable 
within the plaques (Figure 81). No staining for mouse SAP was observed in 
tissues from any of the groups, nor did the anti-human CRP antiserum stain 
tissues from mice that were not transgenic for human CRP (not shown).
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Figure 81 Typical atherosclerotic plaques in the aortic sinus at 20 weeks
A , oil red O stain (inset,polarised light); B, haematoxylin and eosin stain; C, immunostain with anti-human CRP antibody; D, immunostain with anti-mouse C3 antibody, E, immunostain with 
anti-human CRP antibody preabsorbed with immobilised pure human CRP. showing complete absence o f staining observed in C; F, anti-mouse C3 antibody preabsorbed with immobilised mouse
C3, showing complete absence o f staining observed in D. Original magnification x320. 
to  
u>
There was also no difference seen morphologically in the lesions between 
animals expressing human CRP and those wildtype for the transgene, with 
typically advanced lesions comprising a necrotic core (with cholesterol clefts) 
surrounded by proliferating smooth muscle cells and varying amounts of 
extracellular matrix (fibrous cap), including collagen and elastin (Figures 82 and 
83).
Figure 82 Low and high power views of a typical lipid rich lesion 
- Haematoxylin and eosin; Objective magnification x 10 and x 40
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Figure 83 Verhoeff Van-Gieson staining of elastin in a typical lesion
- Objective magnification x 20
12.5.8 Identical aortic atherosclerotic plaque size in apoE knockout 
mice in the presence and absence of transgenic human CRP 
expression
Three separate cohorts of mice were killed at 12, 20 and 56 weeks of age 
respectively, for estimation of the extent of atherosclerosis in the aortic sinus. 
Wild type animals had no atheroma, regardless of the presence or absence of 
transgenic human CRP (not shown). All the apoE deficient mice had substantial 
atherosclerotic plaques which increased in size with time, but there was no
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difference at any time point between the groups with and without transgenic 
human CRP (Figure 84). All animals in each group are included in this analysis, 
but exclusion of those that were mounting an acute phase response of SAP, 
indicative of intercurrent pathology as discussed, did not affect the result at any 
of the time points tested.
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Figure 84 Atherosclerotic lesion area within the aortic sinus of apoE’'-hCRP' and apoE''-hCRP+ mice
- lesion size (mean area plotted for each mouse studied) increased progressively with age but there was no significant difference between the animals with and 
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12.6 Discussion
Mouse CRP is a trace plasma protein, the concentration of which does not exceed 
1-2 mg/1 even at the peak of the acute phase response [72, 489], whereas the 
plasma concentration and acute phase behaviour of human CRP in human CRP 
transgenic male C57BL/6 mice are comparable with these features of CRP in 
humans. These mice are thus an appropriate model for investigation of the 
in vivo effects of human CRP. Female mice express the human CRP transgene 
only at very much lower levels and were therefore not studied here [350, 351, 
427, 490]. In the present experiments there was no difference in aortic sinus 
atherosclerotic plaque size between male apoE'7" and apoE'7‘-hCRP+ mice at any 
of the time points analyzed up to 56 weeks of age. In most mice the initial serum 
concentrations of human CRP were in the range associated in epidemiological 
studies with higher risk of future coronary events, -2.5 mg/1 or more (Table 43), 
but lower baseline values in a few animals were not associated with any 
difference in eventual atherosclerotic plaque size.
Inflammation, stress and infection are all known to be pro-atherogenic in apoE'7' 
mice. In studying the possible specific actions of human CRP it is therefore 
essential to be aware of, and if necessary exclude, intercurrent inflammatory 
pathology, such as the effects of occasional fighting that is inevitable among 
male C57BL/6 mice, or subclinical intercurrent infections that may occur in 
mouse facilities. Measurements of mouse SAP, which is an exquisitely sensitive 
acute phase reactant, are uniquely valuable in this respect. However, the minor 
transient acute phase responses caused by fighting in some mice in the present
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study had no effect on atherogenesis. Also, very notably, the development of 
atherosclerosis in the apoE’7’ mice proceeded without sufficient inflammation to 
be reflected systemically, even by mouse SAP.
Nevertheless at 12 weeks of age the concentrations of human CRP were 
generally higher in apoE*7'-hCRP+ than in apoE+/+-hCRP+ mice, although they did 
not change significantly thereafter. We excluded the possibility that the higher 
CRP values were an assay artefact related to measurement by optical techniques 
in lipaemic serum. We also found no evidence for significant binding of human 
CRP to the abnormal murine lipoproteins in apoE"7' serum. The plasma clearance 
of intravenously injected human CRP was identical in apoE'7' and apoE+/+ 
animals, so the higher serum CRP values must reflect increased transgenic 
human CRP production in the apoE'7' mice. Expression of this human CRP 
transgene in the mouse is under strong sex hormone control, and it was therefore 
notable that when testosterone and oestradiol were measured later for us by Dr 
S.J. Whiting and Dr G.L. Jones (Clinical Chemistry Department, Royal Free 
Hospital), there was a marked reduction in circulating oestradiol concentration in 
apoE'7' mice compared to apoE+/+ controls at around one year of age. Insufficient 
serum was available from earlier time points to assay these hormones, but 
oestrogen/testosterone imbalance related to apoE deficiency and/or its metabolic 
consequences, such as hypercholesterolaemia, is a possible explanation of the 
raised human CRP values (Table 44). Measurement of murine SAA, not 
performed in these experiments, might also help in further understanding the 
differences noted for CRP and SAP.
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Table 44 Serum concentrations of oestradiol and testosterone 
- at one year in apoE'7' and apoE+/+ mice with and without transgenic 
human CRP [491]
Testosterone (nmol/1)
Median
(range)
1.6
(0.6-151.2)
2.4
(0.6-116.8)
1.6
(0.2-79.2)
2.6
(0.2-49.2)
0.34
Oestradiol* (pmol/1)
Median 486 471 102 99 0.0001
(range) (324-664) (344-720) (49-300) (99-268)
n(%)
undetectable
values
0 0 9
(47.4)
11
(73.3)
0.0001
*Kruskal-Wallis test
^Oestradiol assay had sensitivity of 50 pmol/1. Serum samples were of limited volume and had to 
be diluted 1:1 or 1:2 for measurement. Values for samples that were undetectable at these 
dilutions are replaced by the cut-off multiplied by the dilution minus 1 (e.g. <50 when diluted at 
1:2 is replaced by 99, when diluted at 1:1 it is replaced by 49). The P values obtained by non- 
parametric analysis are not significantly changed by using a different replacement value.
In addition, there may be different regulation of the human transgene compared 
to autologous murine SAP and C3, which showed no increased production. It is 
known, for example, that the transgene is aberrantly expressed in this model, 
with abundant CRP production in the kidney and other tissues, whilst CRP in 
humans is produced in significant amounts only by the liver. Baseline CRP 
concentration in humans shows a strong positive relationship with obesity, and 
although at one year the weights of the apoE'7' mice were only about 6% greater 
than those of the apoE+/+ animals, a difference that was not statistically 
significant, there may perhaps be differences in their adipose tissue. In particular
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macrophage accumulation and pro-inflammatory cytokine production are more 
marked in obese adipose tissue, which might be more extensive in apoE'7' mice, 
and may conceivably be reflected more sensitively by human CRP than mouse 
SAP.
The presence of human CRP within the atherosclerotic plaques of the human 
CRP transgenic apoE-7' mice, and of mouse C3 in the plaques in all apoE'7' 
animals, is not informative about whether these proteins are having either 
beneficial or harmful local effects. Although our findings provide no evidence 
for a pro-atherogenic role of human CRP in vivo, it is essential to recognise that 
the transgenic human CRP is in a murine rather than human environment of 
lipoproteins, complement, extracellular matrix, tissue and inflammatory cells, 
cytokines, mediators, and cellular receptors. For example, the lipoproteins that 
are pivotal in pathogenesis of atherosclerosis differ greatly between mouse and 
human, as do their respective complement systems. We have confirmed that 
human CRP complexed with its highest affinity ligand, C-polysaccharide, does 
activate C3 in mouse serum (see Figure 108, Chapter 13), but the effects of 
human CRP binding to potentially important endogenous murine ligands, such as 
lipoproteins, apoptotic cells, and cellular debris, are not known. Also mouse 
complement C5-9 has much lower activity than the human terminal sequence, 
and is not required for atherogenesis in apoE knockout mice. Therefore any 
extrapolation to human pathophysiology from this or similar models must be 
guarded.
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Using frozen sections specifically cut and stored for future work, Dr G. Tennent 
and Professor A. Dhillon (UCL) have gone on to immunostain for Mac-3 (a 
mouse macrophage differentiation antigen) and VCAM-1 (vascular cell adhesion 
molecule-1) within the atherosclerotic lesions (Figure 85). The staining 
increased progressively in intensity from 12 to 20 to 56 weeks in both groups of 
apoE'7" mice, but was not different between apoE'7' and apoE'7’-hCRP+ animals, 
confirming the initial observation of no difference in lesion morphology 
secondary to transgenic human CRP production.
Figure 85 Intimal macrophages (Mac-3) and expression of VCAM-1 
- aortic atheromatous lesions in 20 week old apoE'7' mice with (C/D) or without (A/B) 
transgenic human CRP; x20 Objective; A) and C) Mac-3; B and D) VCAM-1 (Courtesy 
of Dr G. Tennent).
A recent study, using essentially the same model as here, concluded that human
CRP accelerated progression of atherosclerosis in apoE'7' mice [436]. Female
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and male animals were used and some received turpentine injections to induce 
inflammation and acute phase responses. Difference in lesion size was observed 
only in males, and only at the end of the study, at 29 weeks. In the unstimulated 
mice the difference was of marginal statistical significance that could be 
abolished by elimination of a single outlier. The difference in the turpentine 
treated group cannot be ascribed specifically to human CRP as turpentine is a 
major non-specific inflammatory stimulus. Also the baseline and acute phase 
human CRP concentrations reported in male mice by Paul etal. are 
extraordinarily high (100-500 mg/1), suggesting, if the values are correct, the 
presence of active intercurrent inflammatory pathology in the animals studied, 
for which no controls were reported. This is important because, as cited above, 
inflammation, stress and infection are all proatherogenic in apoE'/_ mice. 
Paul et a l also reported increased collagen deposition and increased abundance 
of VCAM-1 and angiotensin type 1 receptor in the plaques of human CRP 
transgenic mice, and decreased plasma C3 concentration. In contrast we have 
detected no differences in plaque histology or morphology in our cohorts and no 
difference in C3 values; nor was there any difference in presence, distribution or 
abundance of either VCAM-1 or of the macrophage marker, Mac-3, in the 
lesions at any time point.
In contrast to the above study, two other independent groups have found results 
similar to ours. Reifenberg et a l have studied transgenic rabbit CRP production 
in apoE knockout mice and show no effect on lesion development [492] whilst 
Trion et a l [493] found no effect of human CRP on early lesion development in 
apoE * 3 -Leiden/hCRP transgenic mice.
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One group has now reported the effects of passively administered human CRP in 
apoE knockout mice [127]. They compared native and modified CRP 
administration, using saline controls and claim that modified CRP and native 
CRP have opposite effects on atherosclerosis in apoE’7' mice: native CRP 
increased whereas modified CRP reduced atherosclerosis. The study lacks 
appropriate controls, administers CRP weekly (the half life of human CRP in the 
mouse is 4 hours [422]) and attempts to study modified CRP, which as already 
discussed, is not established widely as having a physiological role. Regular 
administration of a foreign protein in this way may also of course generate an 
antibody response that could interfere significantly with any findings. The 
results reported cannot therefore, as claimed by the authors, explain the 
conflicting reports for CRP in models of atherogenesis.
Clinical evidence about an association between CRP values and the necessarily 
indirect surrogate indices of overall burden of atherosclerosis in humans is 
conflicting. The significant epidemiological association of increased baseline 
circulating CRP concentration is with atherothrombotic events, rather than with 
the underlying atherosclerosis. Also, CRP values are not increased, even in 
patients with severe coronary atherosclerosis, when they experience variant 
angina caused by coronary spasm rather than acute coronary syndromes that 
presage occlusive atherothrombotic events. Thus, since normal diet fed apoE’7" 
mice do not develop unstable coronary plaques or suffer from spontaneous 
atherothrombotic events, despite their severe atherosclerosis, the convincing 
negative result of the present study does not preclude a role for CRP in man. 
More complex plaques have been reported in the innominate artery of aged fat
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fed apoE'/_ mice, with evidence of intra-plaque haemorrhage and 
atherothrombosis [494]. These lesions merit further investigation in the human 
CRP transgenic model, especially in view of the initial, but yet to be repeated, 
report that arterial thrombosis is increased after vascular injury in human CRP 
transgenic mice [434].
This new transgenic mouse strain may also offer insights to other related 
biological processes. It is known that statins for example reduce CRP production 
in humans but the precise mechanism is not clear. One in vivo study in apoE+/+- 
hCRP+ mice found evidence of a direct suppressive effect of statins and PPARa 
activators on hCRP expression independent of cholesterol lowering [271], 
although a further study looking at low dose atorvastatin use in hyperlipidaemic 
mice found no effect on transgenic human CRP production [495]. If the effects of 
statins in this transgenic strain can be further clarified, not only might it unravel 
the stimuli generating the increased CRP production, but it may also suggest that 
this in vivo model could be used to investigate changes in a potentially clinically 
relevant surrogate marker during the of development of novel therapies.
Recently it has been shown that LDL receptor7’ mice immunised with S. 
pneumoniae have high circulating titres of oxLDL-specific IgM that are cross­
reactive with pneumococcal determinants and that immunisation decreased the 
extent of atherosclerosis [496]. Studies dating back to the 1980s showed that 
pretreatment of mice with human CRP prior to immunisation with S. pneumoniae 
resulted in a dose-dependent inhibition of the antibody response to PC [421], and 
it is known that the spectrum of ligand recognition by CRP closely resembles
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that of E06, an autoantibody to oxidised LDL, which is a T15 clono specific 
anti-PC antibody with specific binding to PC on oxidised but not on native 
phosphatidylcholine [112]. Clinically circulating levels of oxidised LDL 
(measured using the monoclonal antibody E06) are strongly associated with 
angiographically documented coronary artery disease [497]. There is a thus an 
intriguing association between CRP and the innate immune response to 
atherosclerosis [498] that this strain of mice might have the ability to shed further 
light on. For example measuring the titre of antibodies against oxidised LDL 
would ascertain whether or not the transgenic production of human CRP impacts 
on antibody production. Similarly does the presence of transgenic human CRP 
alter the level of oxidised LDL particles in this model?
12.7 Summary
We show that transgenic expression of human CRP had no effect on 
development, progression or severity of spontaneous atherosclerosis, or on 
morbidity or mortality, in male apoE deficient C57BL/6 mice up to 56 weeks, 
despite deposition of human CRP and mouse complement component 3 in the 
plaques. Extrapolation to human pathology, from this xenogeneic combination 
of human CRP with apoE deficiency-mediated mouse atherosclerosis, must be 
guarded. Nevertheless the present results do not suggest that human CRP is 
either proatherogenic or atheroprotective in vivo. In the context of CRP which 
predicts atherothrombotic rather than atherosclerosis burden, a variety of models 
will be required to robustly and conclusively address its role in cardiovascular 
biology.
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13 Novel inhibitors of pentraxin binding
13.2 Introduction
Whilst of course the correlation of circulating CRP concentrations with the severity, extent and progression of many different pathologies, and the prognostic significance of 
these associations, are consistent with CRP being a marker of disease, it is an 
intriguing concept that it may also contribute to pathogenesis. A definitive way 
to test this concept will be the development and use of novel drugs that 
specifically block CRP binding and its potential pro-inflammatory effects in vivo 
[34, 326]. Suitable compounds may be bound by CRP and thereby block the site 
of interaction between CRP and the target ligand, may bind to CRP to alter its 
structure thereby to inhibit or prevent binding to the ligand, or may bind to the 
ligand and in so doing mask it, preventing its recognition by CRP. Alternative 
strategies affecting upstream hepatic production, or downstream clearance of 
CRP, are also conceivable.
Our approach, inhibition of ligand binding at the phosphocholine binding site, is 
first put into context by briefly discussing the details of the ligand binding 
properties of CRP and the consequent, complement activation that occurs, before 
expanding on our specific strategy for rationally designing a CRP inhibitor.
257
133 Ligand binding properties of C-reactive protein
CRP is a calcium dependent ligand binding protein, the ligand to which it binds 
with greatest affinity being phosphocholine residues (Figure 86). The first 
described reactivity of CRP, was the calcium-dependent binding to C- 
polysaccharide (CPS), the peptidoglycan cell wall, teichoic acid, synthesised by 
Streptococcus pneumoniae. Teichoic acids are short chain polymers (10-30 units 
long) consisting of sugar alcohols (primarily glycerol and ribitol), phosphate, and 
a side group; teichoic acid links directly to the peptidoglycan while lipoteichoic 
acid is hydrophobically anchored through its fatty acids to the plasma membrane. 
An important component of the cell wall is the PC on the teichoic acid (two 
choline residues may be covalently added to each carbohydrate repeat), and these 
PC residues present on CPS probably provide the major reactive group for the 
binding of CRP (Figure 86) [4,36,37,39].
a)
o NON
b) :—c—o— Glycerol teichoic acid
H H H
II
Ribitol teichoic acid
II
Figure 86 Structure of phosphocholine (a) and teichoic acid (b and c)
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In the context of drug design, structural understanding can help rational synthesis 
of inhibitors. Each of the five identical noncovalently bound subunits of human 
CRP has the same orientation in the pentamer, with a PC binding site located on 
one face of each subunit (the binding, B, face). The PC binding site consists of a 
hydrophobic pocket formed by residues Leu64, Phe66, and Thr76, and two calcium 
ions which are bound to CRP by interactions with the side chains and main chain 
carbonyls of amino acids from different parts of the primary structure [32, 118]. 
Crystallographic analysis of CRP-PC complexes (Figure 87) has demonstrated 
that the phosphate group of PC directly coordinates with the two calcium ions. 
The choline moiety of PC lies within the hydrophobic pocket. The exposed face 
of Phe66 provides hydrophobic interactions with the methyl groups of choline,
A l
while the side chain of Glu , which is located on the other side of the pocket, 
interacts with the positively charged quaternary nitrogen of choline. Mutational 
analyses of Thr in CRP has confirmed the significance of the hydrophobic 
pocket for PC binding [119,120].
CRP also binds a variety of other ligands that include both autologous (e.g. 
native and modified plasma lipoproteins, damaged cell membranes, a number of 
different phospholipids and related compounds, and small nuclear 
ribonucleoprotein particles) and extrinsic structures (e.g. many glycan, 
phospholipid and other components of micro-organisms, such as capsular and 
somatic components of bacteria, fungi and parasites, as well as plant products) 
[38,44, 84, 106, 110, 111, 461,499-503].
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b) Ribbon diagram of the x-ray crystal structure 
of CRP-Phosphocholine complex
Only one of the five subunits bound to PC is shown. 
The side chains of Phe66 (blue) and Glu81 (brown) a re  
highlighted. The two calcium ions are  in black. Yellow, 
the phosphate group of PC; red, the three methyl 
groups of choline; green, the choline nitrogen.
Figure 87 Structural analysis of CRP-Phosphocholine binding
- the major interactions between CRP and phosphocholine occur at either end of the phosphocholine molecule and involve an interaction between the calcium ions and two of the 
phosphate oxygens at one end and an interaction between the positively charged quaternary nitrogen of phosphocholine and Glu 81 at the other end.
toOnO
There is of course clear evidence suggesting a very important role for the 
abnormal deposition of LDL, a major class of plasma lipoprotein, in arterial 
walls in the pathogenesis of atherosclerosis. Oxidation of LDL, entrapped in the 
arterial intima is believed to be of critical importance, because the lipoprotein is 
converted to a ligand of scavenger receptors [362, 364, 504]. LDL is derived by 
metabolism of very low density lipoproteins, and both these classes of 
lipoprotein particles, as well as high density lipoprotein, consist of apoproteins 
together with varying proportions of phospholipid, triglyceride, esterified, and 
nonesterified cholesterol [505]. Although CRP binds phospholipids by virtue of 
its specific, calcium-dependent reactivity with PC residues, analysis of acute- 
phase serum by gel filtration and by density gradient ultracentrifugation shows 
that human CRP is in a free, uncomplexed form, despite the coexistent presence 
of the various classes of serum lipoproteins, all of which contain phospholipids 
[78]. However isolated CRP, when aggregated by immobilisation, does 
selectively bind LDL and VLDL [110]. In vitro interestingly, Ca2+-dependent 
formation of a complex between CRP and VLDL accounts for a ‘biphasic 
transmittance waveform' seen in coagulation assays [358], whilst CRP, also 
causes agglutination (creaming) of intravenously administered lipid suspensions 
[506].
All of the constituents of LDL, including phospholipids, cholesterol, fatty acids,
and apolipoprotein, can be subject to oxidation and might contribute to the effects
observed with oxidised LDL. Non-oxidative modifications of LDL can also
generate potentially atherogenic molecules, and enzyme modified LDL (ELDL)
261
shares characteristics with lipoproteins isolated from atherosclerotic lesions, 
including particle size, an important and relevant capacity to be bound by CRP 
and to activate complement [360]. E-LDL consists of heterogeneously sized 
fused LDL particles with diameters of 25 to 500 nm, formed after treatment with 
trypsin and cholesterol esterase (with or without neuraminidase treatment). The 
apolipoprotein B is extensively degraded, with a ratio of free to esterified 
cholesterol of -1:1. Tissue proteases degrade the lipoprotein B "shell", rendering 
underlying lipids accessible to cholesterol esterase. Release of fatty acids 
increases the relative content of free cholesterol, and neuraminidase removes an 
important complement inhibitor from the particles. Potentially relevant ligand 
binding sites for CRP are subsequently also more accessible than in the native 
lipoprotein particle [113, 187, 505, 507]. The interactions between CRP and 
lipoproteins may therefore play a part in the normal function of CRP as well as a 
role in lipoprotein pathophysiology [56, 508]. In particular, because of the long 
speculation as to the role of CRP in atherogenesis, inhibition of the interaction 
between CRP and lipoproteins represents a specific patho-physiologically 
relevant target for our studies.
13.4 Complement activation by ligand bound C-reactive protein
The interaction between CRP and the complement cascade is robust and well 
established. When CRP is ligand bound it becomes capable of activating the 
classical pathway of complement via Clq and achieving activation and fixation of 
C3, the main adhesion molecule of the complement system, as well as
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engagement o f the terminal lytic phase, C5-C9 [47-49, 51, 53, 55]. Much of the 
published work (see Table 37) that directly examines the role of CRP in 
experimental models of disease indicates that CRP may have an anti­
inflammatory role that down-regulates infiltration of inflammatory cells and 
reduces tissue damage. This would be consistent with the finding that complexed 
CRP is relatively inefficient at generating the terminal phase of complement 
activation [55, 56] and that involvement of CRP down-regulates other potentially 
inflammatory aspects of complement activation (Figure 88). Recent work in 
different models involving handling of apoptotic cells also indicates that CRP 
has anti-inflammatory properties [59].
The association of increased CRP production with disease conditions has 
generally been interpreted on the basis that CRP production reflects the severity 
of the underlying disease and/or the presence of intercurrent complications. This 
was broadly seen in the context of the predominant, although not necessarily 
consensual, view that the role of CRP in vivo was anti-inflammatory. However 
activation of the complement cascade can no doubt be a pro-inflammatory 
process and CRP could under certain circumstances have significant 
pro-inflam m atory effects [191]. By binding to ligands exposed on cells or other 
autologous structures as a result of infection, inflammation, or ischaemia, and 
triggering complement activation, it may exacerbate tissue damage leading to 
more severe disease. Indeed the enhancement seen in myocardial infarction size 
in rats treated with human CRP was complement dependent [201]. Therefore an 
important aspect of our strategy was the need to specifically demonstrate 
inhibition of complement activation as a parameter in drug development.
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Figure 88 CRP and the complement cascade
- ligand bound CRP binds Clq which is most efficient at early classical pathway activation (Cl, C4, C2). There is however evidence that CRP inhibits the alternative 
pathway/Lectin pathway; it seems to decrease alternative complement pathway C3 and C5 convertase activities. The inhibitory effects are mediated by CRP binding to factor H, 
factor H binds C3b to promote degradation by factor I and binds to the alternative C3 convertase and both C5 convertases to accelerate their decay. Abbreviations: MBL -  
Mannose binding lectin and MASP -  MBL associated serum protease [55]
13.5 Strategies for developing a C-reactive protein inhibitor
We have focussed our efforts on inhibitors that are specifically bound in the 
calcium dependent ligand binding site of CRP, in particular those that comprise 
palindromic molecules of the general formula X-Y-X. In this formula X is a 
structure specifically recognised and bound by the calcium dependent ligand 
binding site present on the so-called “B”, or binding, face of each protomer 
within the intact pentameric CRP molecule, and Y is a linker structure of suitable 
length and physical and chemical properties to enable the compound to be bound 
by two CRP molecules lying B-face to B-face, and for up to five such 
palindromic compounds to be bound between two CRP molecules to provide an 
interaction of maximal avidity. Our initial studies have revolved around a 
simple, but novel, bisphosphocholine substance, we have called RMM (Figure 
89).
QT I 'O
Figure 89 Structure of RMM
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The rationale for compounds that are capable o f cross-linlking two native 
pentameric CRP molecules to create a face-to-face, “B-B” deo&mer, is derived 
from previous work on the very closely related protein, SAP P4], SAP is the 
other member o f the pentraxin family of plasma proteins and il shares extensive 
amino acid sequence homology, secondary, tertiary and quaternary structure with 
CRP. Thus it has a closely similar assembly of identical pnattomers, arranged 
with cyclic pentameric symmetry in a disc-like configuratioai with a calcium 
dependent ligand binding site located on the B face of each proHcwner. The ligand 
specificity of SAP overlaps but is clearly distinct from that off CRP, but is as 
important for the pathophysiological functions o f SAP as it is far these functions 
of CRP. SAP is a therapeutic target in amyloidosis and Alzheimer's disease, and 
a large collaborative effort has shown that compounds with the general structure 
X-Y-X, but specific for binding by SAP, are highly potent inhibitors of SAP 
binding and very effective in blocking SAP function in vivo. SBuch compounds, 
specific for SAP, for example, (R)-1 -[6-(R)-2-Carboxy-pyrrcItidin-1 -yl]-6-oxo- 
hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC), form complexes with SAP in 
which SAP is held as a decamer crosslinked by 5 drug nraoclecules and the 
structure has been solved at atomic resolution by X-ray crystallography (Figures 
90 and 91). Furthermore, in the presence of such SAP-specifia compounds that 
cause decamerisation of SAP, SAP molecules are very rapidly cleared from the 
plasma in vivo and catabolised [94].
OH
HO
Figure 90 Structure o f the D-Proline palindromic inhibitor of SAP, C®!HPC
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Figure 91 Decamerisation of human SAP by CPHPC
- two SAP pentamers cross-linked via their B faces by five molecules of CPHPC (blue) 
viewed perpendicular to the five-fold axis. A face helices are shown in red. The two 
calcium ions bound to each SAP subunit are yellow [94].
On the basis of the previous structural studies by Professor S. Wood [94] it was 
known that in the CRP phosphocholine complex, a phosphocholine molecule is 
positioned parallel to the pentamer surface on each of the five CRP subunits and 
oriented with the choline moieties, pinned between Glu81 and Phe66, towards the 
five-fold axis. Two oxygen atoms of the phosphate group of phosphocholine 
directly co-ordinate the two bound calcium ions of CRP but the third is oriented 
away from the protein surface, providing a suitable exit point to direct a cross
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linking chain towards a putative 2-fold axis related subunit of an adjacent CRP 
pentamer. On this basis it was decided to select a six carbon linker to connect 
the phosphate groups, generating two phosphocholines with a hexane linker, 
expecting a greater separation between binding sites of a putative CRP decamer 
caused in part by rotation of -20° of each CRP subunit towards the five-fold axis 
of the pentamer compared to SAP.
Drugs that inhibit the binding of CRP to its ligands in vivo, and/or reduce its 
availability for such binding, may block the contribution of CRP to pathogenesis 
of disease [34]. Such compounds have the potential to shed significant light on 
the in vivo functions of CRP, and perhaps in the fixture the potential for use in the 
prevention and/or treatment of atherosclerosis and its complications, including 
cardioprotective effects in acute myocardial infarction, stroke and peripheral 
vascular disease in particular. Moreover they may provide a powerful tool for 
determining whether increased CRP production merely reflects atherosclerosis or 
does indeed participate in its pathogenesis and complications. It is conceivable 
that other diverse inflammatory conditions could also be targets for such 
compounds.
The present chapter therefore describes our studies, from screening assays 
onwards, of compounds capable of inhibiting the binding of CRP and in 
particular the innovative work on RMM in vitro and in vivo.
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13.6 Results
13.6.1 C3 cleavage and CRP ligands
As discussed complement activation is one major final pathway through which 
pro-inflammatory effects of human CRP may be important. The effects of CRP- 
ligand binding in vitro on C3 cleavage were therefore assessed by crossed- 
immunoelectrophoresis, including where appropriate its inhibition.
13.6.1.1 Cobra venom factor and normal serum
Isolated cobra venom factor, which functions as an unregulated C3b molecule, 
activating and depleting C3 and C5 via the alternative pathway, was used to 
demonstrate the standard changes seen in migration of C3 cleavage products in 
human and mouse serum (Figures 92 and 93).
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▲
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Cobra venom factor
Figure 92 Demonstration of C3 cleavage products in human serum
- generated by incubation with Cobra venom factor at 37°C for 120 minutes; note the 
change in electrophoretic mobility with C3 activation (*).
Figure 93 Demonstration of C3 cleavage products in mouse serum 
- generated by incubation with Cobra venom factor at 37°C
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13.6.1.2 Modified lipoproteins and C3 cleavage when ligand bound to CRP
Native and modified lipoproteins are important potential ligands for CRP and we 
therefore modified LDL enzymatically as well as oxidatively, to generate 
potentially physiologically relevant ligands. When fresh ELDL is co-incubated 
with CRP, C3 cleavage occurs in keeping with effective ligand binding (Figure 
94).
NHS ♦ Control ELDL 
(Incubatod without enzymes) + TC 
37°C 2hr
NHS + Control ELDL 
(incubated without enzymes) + 
CRP 
37°C 2hr
Figure 94 Activated human C3 cleavage profiles
- enzyme modified LDL (~40mg/l total protein) and human CRP (20mg/l) were 
coincubated in human serum bled for complement; * indicates activated C3 profiles
However this effect is not seen to any great extent with either oxidised LDL or 
VLDL (cf positive control *; Figures 95 and 96). VLDL was provided by Miss 
N. Marshall (University of Liverpool).
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NHS + TC 37°C 2hr , NHS + TC 4°C 2hr
NHS + Control LDL + TC 37°C 2hr NHS + Oxidised LDL + TC 37°C 2hr
NHS + Control LDL + CRP 37°C 2hr NHS + Oxidised LDL + CRP 37°C 2hr
Figure 95 Copper oxidised LDL incubated with CRP does not generate C3 cleavage 
products
- Copper oxidized LDL (40 mg/1 total protein; prior oxidation with 100 jiM CuS04) or native 
LDL (40 mg/1 total protein) was incubated with human CRP (20mg/l)
NHS+ VLDL24334 37°CNHS+ CRP 37°C
NHS+ CRP + VLDL24334 37°CNHS+ CRP + VLDL"”*"4 37»C
Figure 96 Co-incubation of VLDL with human CRP does not activate 
complement
- VLDL (normal and acute phase serum [VLDL24334] was co-incubated with human CRP 
(20mg/l) in normal human serum, for 2 hours at 37°C. CPS-CRP (CPS at 400mg/l) 
complexes acted as a positive control for C3 activation (*).
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13.6.2 Plate assays for CRP binding and its inhibition
13.6.2.1 ELDL based assays
Having demonstrated that ELDL in our own hands was indeed a CRP ligand we 
proceeded to choose it as a physiologically relevant ligand to which a plate based 
assay could be developed. Coupling to commercial stripwell plates of ligands, 
was initially based on hydrophobic interaction, but then subsequently we used 
covalent association.
The binding properties, under varying conditions were studied using purified 
human CRP iodinated with I125 (-125 ng human CRP offered per well unless 
otherwise stated), as this allows for very sensitive assays, without recourse to 
secondary means to measure the amount of CRP bound to immobilised ligand. 
After gel filtration, >95% of the radioactivity was precipitable with 10% w/v Tri- 
Chloro-Acetic acid and functional integrity was confirmed in each case by 
demonstrating retained intact specific ligand-binding activity for 
phosphoethanolamine immobilised on carboxyhexyl Sepharose. On average 
radiolabelled CRP bound to Sepharose-PE with greater than 90% efficiency and 
the final specific activity was 0.75-1 microcuries/microgram protein.
Table 45 summarises for hydrophobic plates the properties of immobilised ELDL
(in carbonate buffer pH 9.0). There was an increased absolute amount of CRP
bound as the concentration of ELDL (as estimated on the basis of the initial
protein concentration of LDL) offered to the hydrophobic plate was increased.
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Background binding was very low and calcium chelation clearly inhibited CRP 
binding back to background levels. Similarly PC and competition by “cold” 
CRP returned binding to background rates. There is therefore clear 
demonstration of specific binding through the calcium dependent ligand binding 
sites of human CRP to immobilised ELDL.
Table 45 Summary of binding properties of hydrophobically immobilised ELDL
300 pg/ml 4.0 +/- 0.9 [3]
100 pg/ml Tris-Ca2+ 2.2+/-1.1 [16]
10 pg/ml Tris-Ca2+ 1.9+/- 0.8 [6]
0 pg/ml
(2% BSA)
Tris-Ca^ 0.2 +/- 0.0 [8]
100 pg/ml Tris-EDTA 0.3 +/- 0.0 [3]
0 pg/ml
(2% BSA)
Tris-EDTA 0.2+/-0.1 [3]
100 pg/ml 40mM PC
(Tris-Ca2+)
0.4+/-0.1 [5]
100 pg/ml 1 mg/ml cold CRP
(Tris-Ca2+)
0.4 +/- 0.0 [2]
Control LDL
(~170 ng/ml)
Tris-Ca2+ 0.5 +/- 0.0 [4]
In modifying the assay, the relative amount of offered protein to that bound was 
assessed, and Figure 97, demonstrates how as expected, the lower the total
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concentration of CRP offered, the greater the relative proportion bound. This is 
relevant to optimising the assay properties.
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Figure 97 Binding of CRP to hydrophobically immobilised ELDL
Figure 98 demonstrates how there is a clear dose dependent relationship between 
PC and inhibition of CRP binding. In this experiment the IC50 was calculated 
(one site competition model) to be approximately 17 pM. This is within 
expectations [36, 39, 45, 509-511] as CRP is reported to have a binding affinity 
(K) to phosphocholine around 1-10 pmol/1.
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Figure 98 Inhibition by PC of CRP binding to hydrophobically immobilised 
ELDL
Although effective, hydrophobic interaction was not very efficient. We therefore 
assessed the effects of covalently coupling to N-oxysuccinimide surface amine 
binding plates (Figure 99).
9, *}
♦ R2“NH2 ^
<>♦' "
DNA-BIND Surfaco Blomolacule Immobilization
RiaSpaeor arm R2d)MA, ProHin, Ele.
Figure 99 Biochemistry of the covalent attachment of ligands to strip-well plates
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Table 46 summarises the binding properties of the now covalently immobilised 
ELDL. Once again calcium dependence is clear as is inhibition by free PC. 
Importantly the plates were stable over time.
Table 46 Summary of binding properties of covalently immobilised ELDL
300 pg/ml Tris-Ca2+ 7.0 +/- 0.3 [4]
150 ng/ml Tris-Cai+ 7.9 +/- 0.0 [3]
0 |ag/ml
(PBS)
Tris-Ca2+ 0.2 +/- 0.0 [3]
300 pg/ml Tris-EDTA 0.2 +/- 0.0 [3]
150 pg/ml lOmM PC
(Tris-Ca2+)
0.1+/-0.0 [3]
150 pg/ml
one week storage +4°C
Tris-Ca2+ 12.5 +/- 0.0 [4]
All with ELDL in 
PBS pH 9.0
For reference we assessed whether or not changes in the buffer used for ELDL 
coupling affected the properties of the assay (Table 47). Although perhaps not 
greatly significant it did appear that a pH 8.0 borate buffer was most optimal, and 
therefore this was chosen for further experiments. As with the hydrophobic 
plates the effect of varying the concentration of CRP offered, under different 
conditions, was also documented (Figures 100 and 101).
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Table 47 Effects of variation in ELDL buffer and concentration on CRP binding
150 |ig/ml PBS pH 7.3 6.1 +/- 0.6
75 pg/ml 6.4+/. 0.2
37.5 pg/ml 5.6 +/- 0.2
18.8 pg/ml 5.2+/-0.1
9.4 pg/ml 4.1 +/- 0.5
4.7 pg/ml 2.0+/-0.1
150 pg/ml PBS pH 8.0 5.4 +/- 0.3
75 pg/ml 5.2 +/- 0.0
37.5 pg/ml 5.0+/-0.1
18.8 pg/ml 4.9 +/- 0.8
9.4 tig/ml 3.2 +/- 0.1
4.7 pg/ml 1.7+/-0.1
150 fig/ml PBS pH 9.0 5.0+/-0.1
75 pg/ml 4.9 +/- 0.4
37.5 pg/ml 4.3 +/- 0.3
18.8 pg/ml 3.6 +/- 0.5
9.4 pg/ml 2.5 +/- 0.2
4.7 fig/ml 1.4+/-0.1
150 pg/ml Boric acid pH 8.0 8.8 +/- 0.5
75 fig/ml 7.7 +/- 0.3
37.5 pg/ml 7.3 +/- 0.3
18.8 pg/ml 6.6 +/- 0.7
9.4 pg/ml 4.4 +/- 0.4
4.7 pg/ml 2.3 +/- 0.1
150 pg/ml Carbonate pH 9.0 6.3 +/- 0.7
75 pg/ml 6.0+/-0.5
37.5 pg/ml 5.1 +/- 0.3
18.8 pg/ml 4.5 +/- 0.3
9.4 pg/ml 3.3 +/- 0.2
4.7 pg/ml 2.1+/-0.1
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Figure 100 Binding of CRP to covalently immobilised ELDL: PBS buffer
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m
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Boric acid pH8.0 
B.DL 75no/rri 
Triplicates
Figure 101 Binding of CRP to covalently immobilised ELDL: Borate buffer
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Specific chemical substances were then shown to inhibit ligand binding. The 
compounds chosen were phosphocholine, which is known to be the best natural 
ligand for CRP, phosphoethanolamine (PE), to which CRP is also well known to 
bind, and phosphoserine (PS), a related phosphorylated molecule the binding to 
which o f CRP has not previously been reported. These were compared with 
hexadecyl-phosphocholine (HDPC), which we initially investigated as a 
proprietary candidate inhibitor of CRP binding; it being more widely known as 
Miltefosine, and used in the treatment of visceral leishmaniasis [512, 513]. 
CPHPC and phosphorylcholine oleoyloxyethyl ester (oleoyl) along with acetyl- 
L-camitine hydrochloride (carnitine) were also assayed.
10-1
PC C50 3.2mM 
HDPC IC50 34.9|iM3 0  
O  CO
I —
T
0.0001 mM 0.001 mM 0.01 mM 0.1 mM 1mM 10mM
Cone. Inhibitor (mM)
Samples in triplicate 
ELDL 150nfl/ml
Figure 102 Inhibition of CRP binding to covalently immobilised ELDL by PC and 
HDPC
- borate buffer pH 8.0
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Figure 103 demonstrates the structure of the potential ligands whilst figures 104 
and 105 show how in this assay PC had an IC50 of between 3-10pM whilst 
HDPC was less efficient with an estimated IC50 of around 20-35 pM. 
Phosphoethanolamine had an IC50 of approximately lOOpM. The other ligands 
were not very efficient, if at all, inhibitors of CRP binding. Of relevance for 
experiments discussed later, CPHPC inhibited binding with an IC50 of nearly 
ImM.
Phosphoethanolamine
N
Phosphoserine
Hexadecylphosphocholine
o
Acetyl-L-Camitine H3C— N+—c— cji— <
Figure 103 Structure of relevant ligands
The IC5 0S quoted are approximations, and are included as markers of efficacy. 
Different methods, such as calorimetry or equilibrium dialysis, not appropriate in 
a screening setting, would be needed to study the binding interactions further.
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Figure 104 Inhibition of binding of CRP to covalently immobilised ELDL 
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Oxidised LDL (thermal and copper generated) was also assessed as a potential 
ligand in a plate assay. However (Table 48) in keeping with the C3 cleavage 
studies earlier, oxidised LDL was not a very efficient ligand (although calcium 
dependent binding was evident), and was not pursued further in this context.
Table 48 CRP binding to covalently immobilised copper oxidised LDL
Ligand (-100fig/ml) % offered bound +
mean +/- SD [N=3]
Control LDL (4°C) 1.4+/- 0.0 0.3 +/- 0.0
OxLDL (24hr 37°C) 1.2+/-0.2 0.4+/- 0.1
OxLDL (48hr 37°C) 1.5+/- 0.0 0.4 +/- 0.0
CuOxLDL (500nM / 24hr 37°C) 1.5+/-0.3 0.3+/- 0.1
CuOxLDL (5pM / 24hr 37°C ) 2.3+/- 0.1 0.3 +/- 0.1
CuOxLDL (50pM / 24hr 37°C) 2.4+/- 0.1 0.2 +/- 0.1
CuOxLDL (lOOpM / 24hr 37°C) 2.6 +/- 0.2 0.3+/-0.1
Buffer PBS pH7.4 + ~100ng CRP offered
13.6.2.2 C-polysaccharide based approaches
Whilst the above work clearly demonstrates that ELDL can be a robust ligand for 
a screening assay, technically it is not convenient to use, requiring lengthy 
isolation of the purified LDL, prior to careful and timely enzymatic modification 
followed by prompt coupling. Pneumococcal C-polysaccharide, the archetypal 
ligand, is more stable and robust and using a commercial source (Statens Serum 
Institut, Denmark) I proceeded to investigate its properties when covalently 
bound to plates as a ligand to facilitate the screening of inhibitors of CRP
binding.
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CRP effectively binds this commercial CPS, as evident by precipitation in a 
simple Ouchterlony, and the complex generates C3 cleavage products (*), both in 
mouse and human serum (Figures 106, 107 and 108).
o ; o
CPS Centre well (1 (JOgg/ml) CRP Centre well (200|jg/ml)
Doubling dilution CRP outer wells (Intlal Doubling dilution CPS outer wells
Cone. 6.45mg/ml) (Initial conc. 1 mg/ml)
c CPS Centre well (50pg/ml) CRP Outer wells (500mg/l)
Figure 106 Double diffusion precipitation between human CRP and CPS
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NHS 4°C
NHS + CPS 37°C
NHS 37°C NHS + CRP + CPS 37°C
Figure 107 CRP-CPS complexes lead to human C3 cleavage 
- activated profiles indicated by *; CRP 20 mg/1 and CPS 200 mg/1
NMS + hCRP lhr 37°CNMS lhr 37°C
NMS + CPS +HCRP lhr 37«CNMS + CPS lhr 37°C
Figure 108 CRP-CPS complexes lead to mouse C3 cleavage 
- activated profiles indicated by *; CRP 20 mg/1 and CPS 200 mg/1
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It proved a very efficient ligand for our plate based assays and inhibitors of 
binding were readily assessed (Table 49 and Figure 109).
Table 49 Summary of CRP binding to covalently immobilised CPS
100 pg/ml Tris-Ca2+ 42.9+/- 1.1
10 pg/ml Tris-Ca2+ 9.2 +/- 0.6
100 pg/ml Tris-EDTA 0.5+/- 0.1
10 pg/ml Tris-EDTA 0.6 +/- 0.1
All with CPS in 
Borate pH 8.0
50-i
•o
§ S'
o  <n m
Ig  25" 
“  «
i
0.001
I
0.10.0001
PC IC50 -11 nM 
HDPC IC50 ~63|iM
Cone, of inhibitor (mM)
Samples in triplicate 
Boric acid pH 8.0 
CPS lOOpG/ml 
EDTA binding O.Sng 
No inhibitor 42.9ng
Figure 109 Inhibition of CRP binding to covalently immobilised CPS 
- ligands PC and HDPC studied
Binding was calcium dependent and the IC50 values for PC (~10 pM) and HDPC 
(-60 pM) were of the same magnitude of those from the ELDL plate assays.
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13.6.3 A novel bisphosphocholine C-reactive protein inhibitor
A t this stage we were therefore ready to assess our novel CRP inhibitor, having 
established assays for screening compounds presently and in the future if  needed. 
As described in the introduction the previous observation o f decamerisation o f 
human SAP proved to be the platform for rational drug design o f a novel 
bisphosphocholine inhibitor o f  CRP binding. This molecule was initially 
synthesised by Professor R. Ganellin (UCL) and then using a novel and more 
efficient pathway in greater quantities in the laboratory o f Professor S. Ley 
(University o f  Cambridge). The final product’s structure and molecular integrity 
were confirmed by NM R and HPLC.
The final synthetic pathway used is summarised below (Figure 110) as well our 
proposed mechanism o f action (Figure 111).
OH Hexane 1,6-dtol
(li) AcetemlbHe/Trlmethytamlne
V
oo
l,6-Bls[{[(trimethylammonlum)ethoxy]phophiny1}-oxy]hexane
Mw 448
F igure  110 Synthesis o f bisphosphocholine, RMM
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Figure 111 Proposed mechanism of action of RMM
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13.6.3.1 Demonstration of efficacy in vitro
In TC buffer (Figure 112), RMM (IC50 ~ 2 pM) was a very effective inhibitor of 
CRP binding to covalently immobilised CPS, being the first ligand tested that 
inhibited binding with greater efficacy than PC (IC50 -19 pM). Interestingly in a 
serum based assay this efficacy was muted (Figure 113), and this is probably a 
result of a different bioavailability. Prior to animal experimentation, a fluid 
phase assay was also undertaken in order to demonstrate inhibition of ligand 
binding in mouse serum, as well as importantly to also confirm efficacy in a 
different assay/context (Figure 114).
0.20
Phosphocholine 
ICgo-19 |iM
£  0 .1 0 -
jd 0 .05 -
0.00
1010.10.010.0010.00010
C oncentration  of Inhibitor (mM)
Figure  112 Inhibition of CRP binding to immobilised C-polysaccharide 
- experimental conditions as in Figure 109
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F igure  113 CRP binding to covalently immobilised CPS and its inhibition in 
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Figure 115, importantly confirms that complement activation (C3 cleavage), is 
inhibited when CRP is ligand bound to RMM. Using a classic haemolytic assay 
of complement activation, Table 40 (section 11.6), we also confirmed this 
finding.
Control positions C3 cleavage by CRP -CPS
1 i
NHS + CRP + RMM 37°C NHS + CRP + CPS 37°C
NHS + CRP + PC 37°C N*18 + CRP + CPS + RMM 37°c > * Inhibition of
ic | C3 cleavage
NHS + RMM 37°C NHS + CPS + RMM 37°C
Figure 115 RMM inhibits C3 cleavage by CRP-CPS complexes in human serum 
- CRP 15mg/l; PC 6 mM ; RMM 0.3 mM; CPS 30 mg/1; Incubation at 37°C for 2 hours
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13.6.3.2 Demonstration of structural effects
A  number o f  independent techniques were used to investigate the effects o f 
RM M  on the molecular assembly o f CRP.
Gel filtration chromatography
Gel filtration chromatography separates proteins, peptides, or oligonucleotides on 
the basis o f  size. Both molecular weight and three dimensional shape contribute 
to the degree o f  retention. Using a calibrated gel filtration column, under varying 
buffer conditions, we were able to clearly demonstrate the predicted structural 
changes associated with CRP binding to RMM (Table 50). Previous studies have 
shown that in a  Tris-EDTA solution hSAP elutes as a decamer whilst hCRP 
elutes as a  pentamer; the formation o f stable decamers by isolated SAP in the 
absence o f  calcium is an in vitro artefact, resulting from pentamer pentamer 
interactions, which are largely electrostatic [357, 514]. When run in a  PC 
containing solution CRP eluted as a pentamer, whilst the change to RMM led to 
immediate decamerisation. At vast excess o f drug CRP eluted once again as a 
pentamer. In the presence o f both ligands, an excess o f 10 fold RMM to PC was 
needed to decamerise CRP. Multimeric CRP, presumed as evident by elution in 
the void volume, occurred in the presence o f  HDPC, consistent with the micellar 
structure this compound assumes in aqueous solution. This series o f experiments 
therefore confirmed decamerisation as a specific, calcium dependent, PC-ligand 
binding site phenomenon related, to the palindromic structure o f RMM (Figure 
116).
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Table 50 Molecular assembly of pentraxins by gel filtration: effect of ligand binding
Blue dextran 7.87* 2000000
Thyroglobulin 8.67 669000
Ferritin 9.95 440000
Catalase 11.73 232000
Aldolase 12.03 158000
Human albumin 13.28 66500
hSAP - Tris-EDTA 11.09 Decamer
hCRP - Tris-EDTA 12.58 Pentamer
hCRP - Tris-Ca2+ 13.06 Pentamer
hCRP x 10 PC Tris-Ca2+ 12.9 Pentamer
hCRP x 1 RMM Tris-Ca2+ 11.61 Decamer
hCRP x 10 RMM Tris-Ca2+ 11.57 Decamer
hCRP x 1000 RMM Tris-Ca^ 11.81 Decamer
hCRP x 10000 RMM Tris-Ca2+ 12.85 Pentamer
hCRP x 10 RMM Tris-EDTA 12.6 Pentamer
hCRP x 200 RMM/x 10 PC Tris-Ca2+ 11.71 Decamer
hCRP x 100 RMM/x 10 PC Tris-Ca2+ 11.79 Decamer
hCRP x 50 RMM/x 10 PC Tris-Ca2+ 12.17 Mixed
hCRP x 10 RMM/x 10 PC Tris-Ca2+ 12.86 Pentamer
hCRP x 10 HDPC Tris-Ca2+ 6.94 Multimeric (void)
hCRP x 10 HDPC Tris-EDTA 12.61 Pentamer
100 mg/l Molar excess with 
respect to CRP protomer
* Void 
volume
Column: Superdex 200 HR10/30
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CRP is a PENTAMER in TC and TE Native state
CRP is a PENTAMER in TC/ PC Native state/single binding site per PC
CRP is a DECAMER in TC/RMM Palindromic molecule brings two pentamers together
CRP is a variable mixture of PENTAMERS and RMM and PC compete for the 
DECAMERS in TC/RMM/PC same binding site
CRP is a PENTAMER in TC/RMM Decamerisation cannot occur if all
when the drug is in vast excess (xlOOOO) the PC binding sites are occupied
CRP is a PENTAMER in TE/RMM Decamerisation is calcium dependent
CRP is MUL7IMERIC in TC/HDPC The specific palindromic structure is key for decamerisation
Figure 116 Representation of molecular assembly of CRP with different ligands as revealed by gel filtration
Electron microscopy
Osmand [61] studied CRP by negative-stain electron microscopy and confirmed 
that the protein was composed o f five subunits arranged in cyclic symmetry. 
Using electron microscopy we studied the effects o f RMM on CRP assembly and 
demonstrated visually (Figure 117) the decamerisation o f CRP in the presence of 
RMM.
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Pentameric CRP 
(xl80K and x360K)
Decameric CRP 
(xl80K)
Transmission electron microscopy o f  2% aqueous uranyl 
acetate negatively stained pure human CRP in the 
presence or absence o f  RMM (1000 fold excess).
Figure 117 Electron microscopy: face on and side views of drug induced CRP decamers
Tandem electrospray mass spectrometry
With appropriate sample desolvation and instrument pressures nanoelectrospray 
ionization mass spectrometry can be used for the analysis and mass measurement 
o f non-covalent protein complexes, such as the protomeric assembly o f the 
pentraxins, since it is possible to preserve native structure and higher-order non- 
covalent interactions. In the present study, we used the technique with Dr A. 
Aquilina and Professor C. Robinson o f the University o f Cambridge to study the 
effects o f the presence o f RMM on the higher-order structure o f CRP.
Figure 118 demonstrates a calcium dependent decamerisation o f  CRP by the 
addition o f RMM. The drug induced decamer differs from the non-ligand 
decamer by a mass equivalent to approximately 5 drug molecules (Figure 119); 
the non-ligand decamer is an A:A face artefact and there remains a very minor 
amount o f non-ligand decamer in the +RMM spectrum. The extra mass observed 
beyond that calculated from multiples o f  the mass o f a protomer o f CRP arises 
from residual solvation o f  the protomers by water molecules and buffer salts, a 
feature often observed for non-covalent interaction o f macromolecular 
complexes in the gas phase. The stability o f  the structure can be assessed by 
dissociation o f monomeric CRP from the pentamer/decamer by increasing the 
sample cone voltage and notably in the presence o f RMM, there is marked 
stability o f  the decamer (Figures 120 and 121).
298
299
aa280212 5 (0.185) Sm (Mn, 2x16.00); Cm (1 51) 
10 0 ,
A : Drug “induced” decamer 
(B:B face + 5 drug molecules)
6890 38
TOF MS ES+ 
A L L
233649.53±60 86
0
i28
100
1mM Ca2+ 
1mM RMM
6499.56
1024.67
709812
9187 37
k j 1797 002576 45 4687.10
6318.44 f, 884014 l
7319.93 \
Iwliy'uv
) 9575 18 10665 38
TOF MS ES+ _223.aa 0211 9 (0.318) Sm (Mn, 2x16.00); Cm (1:26) 4612 08
No Ca2+ 
1mMRMM
A : Pentamer
4804 87 
4824.84 
501406
192141
2306 07
tV.
5242.02
B: Decamer (A:A face)
i im ,
6806.78 7234.48
115312.01*23 38 
231415.52±56 92
aa280210 8 (0.282) Sm (Mn, 2x16.00); Cm (1:12)
100 461507
A : Pentamer
No Ca2+ 
No RMM
4437 32
4807 69
501717
B: Decamer (A:A face)
6789.20
r  ' | ' i
TOF MS ES+
480
A: 115393 86*12 02
»• .,?Q§K 4g±42 3.;
m/z0
1000 2000 3000 4000 5000 6000 7000 8000 9000 10000 11000 12000 13000 14000 15000
Figure 118 Mass spectrometry and CRP-drug interactions 
- lOpM hCRP [pentamer] in 200mM ammonium acetate pH 8
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A .
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MOO0200
Figure 119 Calculated molecular weights of CRP decamers in presence and absence of RMM 
- the difference in weights equals the mass of ~5 RMM molecules
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Figure 120 Effect o f increasing cone voltage on the structure o f native pentameric CRP 
- lOpM hCRP, 1mm Ca2+, 200mM ammonium acetate, pH 8
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Figure 121 Drug induced decamer formation markedly stabilises the structure of human CRP 
- lOpM hCRP, ImM RMM, 1mm Ca2+, 200mM ammonium acetate, pH 8
u>
X-ray Crystallography
Finally crystallography (performed and analysed by Professor S. Wood and 
colleagues, Southampton University) confirms decamerisation (Figure 122). 
Having previously designated the two planar faces of the human pentraxin 
molecules as A, bearing the single small a-helix present in each protomer, and B, 
bearing the calcium dependent ligand binding pocket of each protomer, the X-ray 
crystallographic structure of the CRP complex with RMM, confirms the 
arrangement of two native pentameric CRP molecules lying B face to B face and 
cross linked by 5 palindromic RMM molecules with their phosphocholine head 
groups located in the calcium dependent ligand binding pockets on each 
protomer.
Figure 122 X-ray crystallography of drug induced CRP decamerisation 
- View of complex perpendicular to five-fold axis and along the local two-fold axis 
relating pairs of subunits; calcium ions are yellow; drug molecules are red.
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13.633 Ligand bound C-reactive protein loses immunoreactivity in the 
MIRA
As there was no direct assay available to measure RMM concentrations we 
sought a robust and reliable method o f demonstrating CRP binding o f RMM, and 
indirectly presumed decamerisation. It is already known that the calcium 
dependent binding site o f CRP is a  major epitope for antibodies raised against 
CRP [515, 516], and simply its occupation by ligand may affect reactivity 
greatly. Certain monoclonal antibodies may bind CRP only in the presence o f 
calcium, and the calcium dependent binding can be inhibited by PC, indicating 
that the antigenic determinant is at or near the PC-binding site o f CRP [516].
The Roche MIRA assay is a microparticle enhanced turbidimetric assay for 
human CRP. The assay uses two microparticle types differing in size and 
reactivity o f the coated antibodies, which provides accuracy and precision across 
a wide range o f CRP concentrations [343, 344]. The in house monoclonal 
antibodies, with different epitope specificities, are designated 36F12 and 21F12, 
and the binding o f 21F12 to CRP is calcium ion dependent (Dr S. Eda, Personal 
communication, Roche Diagnostics, Basle; the assay buffers being accordingly 
adjusted to 2 0 mM CaCh). The so called high reactive antibody, 36F12, is coated 
on large 221nm microparticles and the low reactive antibody, 21F12, is coated on 
small 127nm microparticles. The high reactivity antibody on large particles 
dominates the immunoreaction at low analyte concentration and provides the 
desired high analytical sensitivity; the low reactivity antibody coated to smaller 
microparticles provides less analytical sensitivity but tolerates very high analyte
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concentrations. The optimised reaction mixture is a  ratio o f 9:1, small to large 
particles.
With this in mind we demonstrated that ligand bound CRP was not detected in 
this particular automated CRP assay, although it was clearly detected in other 
assays: the Dade Behring BNII Nephelometer, a different and independent 
automated latex enhanced immunoassay, as well as by traditional 
immunoelectrophoresis, in which a polyclonal anti-human CRP antibody is used 
in the presence o f  EDTA. Tables 50 and 51 demonstrate the loss o f MIRA 
reactivity with different ligands, which is not mirrored in the BNII assay whilst 
Figure 123 demonstrates the effect in buffer or serum. Figure 124 confirms the 
presence o f CRP by electroimmunoassay despite masking in the MIRA.
The MIRA assay thus provided a method o f demonstrating ligand binding by 
CRP.
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Table 51 Ligand binding and loss of MIRA reactivity
^T ris-C ?^ - 100
CPS 62.5 mg/1 0.6
CPS 250 mg/1 0.7
CPS 500 mg/1 0.6
21F12 1000mg/l 0
21F12 100 mg/1 65.5
21F12 10 mg/1 90.2
21F12 1 mg/1 92.4
21F12 0.1 mg/1 93.6
21F12 0.01 mg/1 93.8
PC 4.34 mM * 6.9
RMM 4.34 mM * 4.1
* approx. 1000 fold 
excess with respect to CRP 
protomer
100mg/l CRP spiked
Table 52 No loss of immunoreactivity in the BNII assay 
- 100mg/l CRP spiked
T f i ^ r 99.1 104.5
RMM (4.34mM) 4.3 105
PC (4.34mM) 7.3 105.5
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Figure 123 RMM masks MIRA CRP immunoreactivity in serum and aqueous buffer, at high and low CRP concentrations 
- Normal assay a) in buffer (100mg/l CRP) and b) in serum (100mg/l CRP); and c) high sensitivity assay (5mg/l CRP)
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Figure 124 Rocket immunoelectrophoresis plate to visually confirm no loss of CRP antigen 
- despite the loss of MIRA reactivity under varying conditions, immunoreactivity in a different assay persits
u>ooo
The formation by RMM of CRP dimers in which the calcium-dependent ligand 
binding site is occluded, clearly masks a relevant epitope needed by the 
particular antibody in question (21 FI2) and this makes the CRP-RMM complex 
undetectable (Figure 125).
. ^ 7r*av -v* av
& ^0 ^0
a) Normal immunoreactivity
»>-• -<•
5 -r
SjX&J- YXxvV S S  b) Masked immunoreactivity
#
Figure 125 Diagrammatic representation of masking of immunoreactivity
By increasing the relative concentration of RMM to CRP, but accounting for the 
absolute amount of CRP (Table 53), we demonstrated that the relative loss of 
MIRA reactivity falls. Greater blockade of MIRA reactivity at RMM: CRP 
molar ratios that produce decamers is presumably related to the complete 
occlusion of the B face, in B-B dimers. When all the binding sites are occupied, 
RMM-CRP pentamers are formed and the antibody can presumably access its 
epitope again; experimentally this is seen as a lower rate of masking relative to 
the amount of CRP present.
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Table 53 Indirect evidence of saturation binding of RMM to CRP 
- relative reversal of loss of MIRA reactivity by presence of vast excess of drug
163.75 100 1.5 99.08 1000 32.42 80.20
95.38 200 0.71 99.26 2000 21.98 76.96
41.75 400 0.49 98.83 4000 13.75 67.07
17.83 800 0.48 97.3 8000 8.62 51.65
7.26 1600 0.12 98.35 16000 5.31 26.86
2.07 3200 0.05 97.58 32000 2.03 1.93
13.6.3.4 In vivo activity of RM M
We had three goals at the outset of our in vivo mouse studies. Firstly to 
demonstrate efficacy in terms of in vivo decamerisation and loss of ligand 
binding properties, secondly to consider the effect of RMM on CRP turnover and 
finally to demonstrate a tangible reversible of a biological phenomenon mediated 
by CRP recognising a natural ligand. The first two questions were addressed by 
combining the loss of MIRA reactivity for CRP, with ex vivo assessment of CRP 
binding to immobilised phosphoethanolamine. By administering the drug not 
only as an intra-venous bolus with CRP, but also following continuous sub­
cutaneous absorption from surgically inserted osmotic pumps (7 days), we were 
also able to demonstrate true in vivo interaction between human CRP and RMM.
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Unlike CPHPC, which causes a dramatic enhancement in SAP turnover, there 
was no enhanced turnover of passively administered human CRP in vivo with 
RMM in the limited experiments performed, although there was clear evidence 
of circulating decamers, along with the abolition of ligand binding ex vivo 
(Figures 126 and 127; Table 54). Further work interestingly now suggests that if 
delivered at an appropriate concentration and duration, RMM does enhance CRP 
turnover (Personal communication, Professor M.B. Pepys).
250 Clearance of human CRP alone or after premixing with RMM in C57BI6 mice
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Figure 126 RMM masks MIRA CRP immunoreactivity in vivo 
- intra-venous administration of human CRP (215 pg) +/- RMM (18 micromoles)
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Figure 127 RMM has no effect on immunoreactivity by electroimmunoassay
- intra-venous administration of human CRP (215 jig) +/- RMM (18 micromoles); 
measurement by electroimmunoassay demonstrates no difference in turnover of CRP
Table 54 Ex vivo inhibition of binding of human CRP
% CRP bound to 
Sepharose- 
phosphoethanolamine
Time post 
CRP injection
CRP alone CRP + RMM
3 min 96 17
1 hr 92 46
Continuous delivery of drug by osmotic pumps gave similar results, with a 
therapeutic level inferred of drug, which was functional (Tables 54 and 55). 
Whilst as yet we have not completed formal toxicology studies, no adverse 
effects were noted in the mice.
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Table 55 Demonstration of in vivo complexing of CRP and RMM
-  in vivo complexing and subsequent loss of MIRA reactivity and functional binding, 
following i/v CRP (215 pg ; n=3) to mice having received RMM via an osmotic pump 
(0.78M, 1 pl/hr for 7 days)
3 min 11.37 210 95 57
lhr 29.86 105 72 71.3
4hr 23.72 63 62 92.2
* Acute phase Tg hCRP serum: 92% binding
T able 56 Osmotic delivery of RMM or vehicle and in vivo loss of MIRA 
reactivity
-  in vivo complexing and subsequent loss of MIRA reactivity following i/v CRP (215 
pg; n=3) to mice having received RMM via an osmotic pump (0.78M, 1 pl/hr for 7 days)
RMM TC % masked reactivity
3 min 62.77 212.97 70.5
1 hr 82.72 137.48 39.8
4 hr 75.53 90.65 16.7
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In vivo human CRP is known to be protective against lethal Streptococcus 
pneumoniae challenge in mice [100, 103]. Abrogation of this effect would be an 
important proof of principle for effectiveness of RMM, whilst awaiting other, 
more technically complex, in vivo models (e.g. rat myocardial infarction). This 
model in particular is important because it is presumed that the protective effect 
of CRP arises precisely because of the avid ligand binding interaction that occurs 
between it and the C-polysaccharide in the S. pneumoniae cell wall.
Preliminary work was necessary to establish the best conditions in which to test 
RMM. Tables 57, 58, 59 and 60 demonstrate the binding of CRP to different 
S. pneumoniae strains in vitro (in buffer, as well as serum, using direct and 
indirect measures of CRP binding) and how this binding is inhibitable with 
calcium chelation, as well as by ligands including RMM.
Table 57 Calcium dependent CRP binding to S. pneumoniae strains Wt and D39- 
6
Wt No 3.5
(R6, unencapsulated strain) Yes 1.2
D39-6 No 7.3
(Type 2 encapsulated serotype) Yes 1.4
Pelleted ~5 x 107 bacteria
Offered 64ng radiolabelled hCRP
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Table 58 RMM inhibits CRP binding to S. pneumoniae strain D39-6
D39-6 No No 2.5
D39-6 Yes No 0.3
D39-6 No Yes 1.6
Pel leted ~2.5 x 106 bacteria
Offered 64ng radiolabelled hCRP
Table 59 CRP binds to both S. pneumoniae strains WU2 and A66.1
- as evident by loss of recovery of offered CRP (MIRA determination of supernatant)
Pellet ~
WU2 Type 3 16 0.06 4.5 x10s
A66.1 Type 3 16 2.9 9x  107
Table 60 CRP binds specifically to strain WU2 in serum
- S. pneumoniae WU2: pellet 2.5 x 108; normal human serum spiked to ~200mg/l human 
CRP; inhibition of CRP binding by calcium chelation, PC and RMM.
No Tris-Buffer 218
Yes Tris-Buffer 122
Yes EDTA lOmM 202
Yes PC 8.69mM 220
Yes RMM 8.69mM 202
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When given passively human CRP did not protect against lethality from i/p 
administration o f strain D39-6 into female C57/BL6 mice, despite adjustments in 
the dose o f  bacteria and the amount o f  human CRP injected at baseline (Table 
61).
Table 61 In vivo lethality with strain D39-6 o f  S. pneumoniae 
- no protection by human CRP (as compared to vehicle); n= 10 per group of age and 
weight matched female C57/BL6 mice; CRP or buffer (TC) i/p at -15 minutes
5 x 103 bacteria i/p = LD100 at 72hrs
No protection from 80|ig hCRP i/p
Partial protection with 5 xlO2 bacteria and 800pg hCRP i/p 
(Log rank P =0.02 at 72hrs)
Using strain WU2 and age/weight matched female C57/BL6 mice (8 week old /
20-25g), intra-peritoneal administration o f CRP, 15 minutes prior to
administration o f bacteria, significantly protected against the lethal effects o f
intra-peritoneal S. pneumoniae (Figures 128 and 129). Moreover RMM given
passively significantly abrogated this effect (Figures 130 and 131). In the first
experiment (Figure 130) with RMM employing 1000 organisms per mouse,
survival was enhanced by CRP as compared to buffer (P=0.02; Breslow) whilst
the RMM treatment reversed this; the difference between the RMM + CRP
treated group and the CRP alone treated group being highly significant (P=0.02
Log Rank and P= 0.01 Breslow). In the second experiment (Figure 131) with
RMM employing 100 organisms per mouse, survival once again for the CRP
treated group as compared to buffer was significantly improved (P=0.03 Log
Rank and P=0.01 Breslow). Once again RMM treatment reversed this; the
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difference between the RMM + CRP treated group and the CRP alone treated 
group being highly significant (P= 0.03 Breslow).
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Figure 128 Protective effect of human CRP in S. pneumoniae lethality - Experiment 1
- n= 10 per group of age and weight matched female C57/BL6 mice; CRP or buffer (TC) 
i/p at -15 minutes
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Figure 129 Protective effect of human CRP in S. pneumoniae lethality - Experiment 2
- n = 12 per group of age and weight matched female C57/BL6 mice; CRP or buffer 
(TC) i/p at -15 minutes
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Figure 130 RMM abrogates the protective effect of human CRP in S. pneumoniae lethality - Experiment 3
- RMM (lOOpl, 200mM solution) was administered i/p at -15 minutes, 2 hours, 4 hours and 6 hours following inoculation with WU2; CRP or buffer (TC) was
given i/p at -15 miniutes; n= 10 per group of age and weight matched female C57/BL6 mice 
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Figure 131 RMM abrogates the protective effect of human CRP in S. pneumoniae lethality -Experiment 4
- RMM (lOOpl, 200mM solution) was administered i/p at -15 minutes, 2 hours, 4 hours and 6 hours following inoculation with WU2; CRP or buffer (TC) was
given i/p at -15 miniutes; n= 10 per group of age and weight matched female C57/BL6 mice u>►—iVO
13.6.4 Mixed pentraxin assembly
Having successfully demonstrated clear proof of principle with RMM we 
extended our studies to further novel pentraxin interactions. We hypothesised 
that perhaps the ability of CPHPC to enhance clearance of SAP could be 
harnessed whilst inhibiting the ligand binding properties of CRP. We speculated 
that such mixed pentraxin decamers should be able to be generated both in vitro 
and in vivo. To address this, further studies on CPHPC and its interaction with 
CRP were performed as well as specifically asking our synthetic chemistry 
colleagues to create a hybrid of CPHPC and RMM (Figure 132). The product, 
AJC042, is a D-proline-PC hybrid, and sufficient quantities were produced and 
validated, to test its in vitro properties; namely was it a ligand for CRP and SAP 
and could it generate SAP-CRP decamers (as assessed indirectly in the first 
instance)?
O
AJC042
Figure 132 Structure of AJC042
In the absence of a ligand, isolated human SAP auto-aggregates and precipitates 
in the presence of calcium [357]. Inhibition of aggregation of SAP in the
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presence of calcium can therefore be used to screen for SAP ligands. Table 62 
shows how AJC042 prevented calcium induced aggregation of SAP.
Table 62 AJC042 prevents calcium induced aggregation of pure human SAP
- as assessed by spectrophotometry; using an extinction coefficient of 1.71 for 1 mg/ml; 
100mg/l starting concentration of human SAP
Tris Buffer No 0.0052 92.6
Tris Buffer Yes 0.1780 11.3
AJC042 Yes 0.0027 104.4
* ~4mM AJC042 vs ~4pM SAP protomer
As already demonstrated loss of MIRA reactivity can be used to screen for CRP 
ligands and AJC042 in TC buffer, spiked with human CRP, behaved similarly in 
vitro (Table 63).
Table 63 AJC042 is a CRP ligand as demonstrated by loss of MIRA reactivity 
- CRP (100mg/l) spiked TC buffer with either AJC042 or PC
Tris Buffer 105.73
4mM AJC042 9.37
4mM PC 9.56
I hypothesised that co-incubation of SAP and CRP with AJC042 should therefore 
lead to further loss of MIRA reactivity, if as predicted, mixed SAP-CRP 
decamers are formed, and behave like CRP decamers ‘immunologically . Tables
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64 and 65 demonstrate this precise effect, with enhanced loss of MIRA reactivity 
when both SAP and CRP are present (with a graded effect as the concentration of 
SAP is increased), supporting our prediction, for both buffer and serum. Note 
that alone SAP does not interfere with the MIRA assay.
Table 64 AJC042 and loss of MIRA reactivity with SAP and CRP in buffer
- CRP (100 mg/1) spiked buffer in presence of calcium, measured on the MIRA, with 
drug (or vehicle) and increasing concentrations of human SAP. The increased loss of 
MIRA reactivity in the presence of CRP, SAP and drug is taken to imply co- 
decamerisation.
Tris-Buffer 0 103.72
Tris-Buffer 100 102.34
AJC042 100 15.23
AJC042 50 27.85
AJC042 20 40.28
AJC042 10 39.52
AJC042 0 39.38
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Table 65 AJC042 and loss o f  MIRA reactivity with SAP and CRP in serum
-CRP (100 mg/1) spiked into previously SAP/CRP depleted serum, measured on the 
MIRA, with drug (or vehicle) and increasing concentrations of SAP. The increased loss 
of MIRA reactivity in the presence of CRP, SAP and drug is taken to imply co- 
decamerisation.
Tris-Buffer 200 97.83
Tris-Buffer 0 92.84
AJC042 : 8mM 200 35.85
AJC042 : 8mM 0 60.33
AJC042: 4mM 200 51.96
AJC042 : 4mM 100 65.76
AJC042: 4mM 0 75.50
AJC042 : 400|iM 200 71.56
AJC042 : 400pM 0 101.59
In our plate assay CPHPC was shown to inhibit CRP binding to immobilised 
ligand with an IC50 in the millimolar region (see Figure 104). Our collaborators 
at Southampton Univerisity (Professor S. Wood), using isothermal calorimetry, 
estimate a Kd of 15pM for SAP/D-proline and 4pM for CRP/PC (c/ 400nM for 
CRP/RMM and lOnM for SAP/CPHPC). Whilst testing AJC042, we also 
studied CPHPC and intriguingly, under certain conditions it avidly cross links 
CRP and SAP, as demonstrated by the robust technique of size exclusion/gel 
filtration chromatography. The presence of PC reverses the effect and using
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immunoassays on the relevant elution fractions, co-elution of mixed decamers 
was confirmed immunochemically (Tables 66 and 67).
Thus although CPHPC in itself is not an avid CRP ligand, presumably when 
bound to SAP, the ligand binding properties change such that mixed decamer 
formation is favoured; most likely the binding of multiple CPHPC molecules by 
each SAP pentamer creates an array of ligands for CRP which although 
independently weak, provide sufficient avidity to favour formation of a stable 
decamer.
Table 66 Mixed pentraxin assembly with CPHPC as assessed by gel filtration
“Decamer” “Pentamer”
Yes Yes No No TE 11.15 12.78
No Yes Yes No TC 13.01
Yes No Yes No TC 10.70
Yes Yes Yes No TC 11.02 *
Yes Yes Yes Yes TC 10.65 13.05
Column: Superdex 200 HR10/30
Table 67 Co-elution is confirmed by immunoassay of the appropriate (*) 
fractions
IBHH
Relevant fraction hCRP hCRP hSAP
(MIRA; mg/1) (BNII; mg/1) (mg/1)
Masked immunoreactivity No masking Rocket Immuno­
electrophoresis
B ll 0.92 9.16 12
B12 1.01 17.90 24
B13 0.97 10.70 15
B14 0.63 5.11 8
B15 0.23 1.16 3
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Once again utilising the loss of MIRA reactivity, also allows for the 
demonstration of this novel effect. Furthermore competition for ligand binding 
sites can be inferred by co-incubation of both AJC042 and CPHPC (Table 68).
Table 68 Effect of CPHPC and AJC042 on MIRA reactivity in spiked serum
- CRP (100 mg/1) spiked CRP/SAP depleted serum
Tris-buffer 0 112.98
Tris-buffer 200 113.26
AJC042 : 4mM 0 85.47
AJC042 : 4mM 200 58.38
CPHPC : 800 pM 0 107.82
CPHPC : 800 pM 200 10.99
CPHPC : 800 pM 400 1.54
AJC042 (4mM) and 
CPHPC (800pM)
200 82.78
These are important in vitro observations of the ability for mixed decamers to 
form with two compounds, one a D-proline palindrome, the other a D-proline-PC 
compound. However CPHPC has been given in vivo to patients with human 
amyloidoses [94]. Was there evidence of mixed decamer formation ex-vivo? 
The BNII assay for human CRP is not influenced by ligand bound CRP in the 
same way as the MIRA assay, and we used this to study the very limited serum 
samples available from patients who had been given high dose CPHPC. Table 
69 suggests the effect demonstrated above occurs in vivo, with preliminary
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evidence furthermore of the loss of binding properties for CRP that is complexed 
with SAP. Data with respect to SAP concentration and CPHPC concentration 
was available within the laboratory and is included for reference [94],
Table 69 MIRA reactivity and binding to immobilised ligand in patients receiving 
CPHPC
- evidence of in vivo mixed decamer formation (loss of MIRA reactivity) and loss of 
ligand reactivity ex-vivo (reduced binding to Sepharose-PE) in patients on a continuous 
CPHPC infusion.
JB TO 0 37 6.2 5.5 57
JB T 6hr 165 7 2.9 5.4 0
PA/TO 0 67 3.4 2.8 53
PMT 6hr 52.1 3 1.4 2.8 26
13.6.5 RM M  and ligand binding to a m onoclonal IgA (kappa) 
recognising phosphocholine
Phosphocholine is a target of a number of the autoantibodies present in the
conditions of systemic lupus erythematosus and primary antiphospholipid
syndrome. Whilst the role for anti-phospholipid antibodies in the disease
manifestations are debated (which intriguingly include a very high
cardiovascular mortality), finally we speculate that a bisphosphocholine
molecule may have applications in removing or preventing the potentially
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deleterious effects of such antibodies. Albeit with now limited supplies of 
RMM, and TEPC-15 a mouse monoclonal IgA (kappa) that recognises PC, 
preliminary work presented below does indeed suggest that RMM has the 
potential to cross link this antibody. TEPC-15 was predominantly either 
tetrameric or dimeric at least by Native-PAGE, whilst SDS-PAGE clearly 
revealed the heavy and light chains (Figures 133 and 134). I looked for changes 
in structure by size exclusion chromatography after incubation with either RMM 
or PC (with no discernible effects being present by Native-PAGE). In buffer 
alone TEPC-15 interacts with the column (perhaps because of trapped lipid or 
specific/non-specific binding interactions with the column). The presence of PC 
seems to overcome this, suggesting some specificity in the interaction with the 
column (Figure 135). However quite clearly with RMM, as compared to PC, the 
gel filtration profiles are indicative o f an effect whereby (Figure 136) increasing 
concentrations of RMM lead to multimeric complexing of TEPC-15.
These are preliminary and limited observations but merit further work.
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Tetrameric IgA
Dimeric IgA
Thyroglobulin (669K), Ferritin (440K), C atalase (232K), Lactate D ehydrogenase (140K) and Albumin (67K).
Figure 133 Native PAGE for TEPC-15
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Figure 134 Denatured/Reduced SDS gel for TEPC-15
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Figure 135 Gel filtration profiles for TEPC-15 in the presence and absence of PC 
- a) Tris-NaCl, b) PC 133pM and c) PC 13.3mM; TEPC-15 at 200mg/l
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Figure 136 Clear graded effect of increasing concentrations of RMM on the elution volumes of TEPC-15
- a) 133nM, b)1.3mM and c)13.3mM RMM; TEPC-15 at 200mg/lU)u>
13.7 Discussion
Understanding the biological properties of the ligand binding protein CRP 
remains a challenge for many investigators, and has been made more pressing by 
the evidence, both epidemiological and experimental, that inhibition of CRP- 
binding and its effects, may actually be an important therapeutic target.
Harnessing and extending an established platform, based on previous research 
with human SAP, has led to our synthesis of an entirely novel and unique 
inhibitor of CRP ligand binding. This chapter outlines how this was 
accomplished by:
• Generating robust platforms for testing potential inhibitors
• Clearly demonstrating inhibition of CRP ligand binding, and its 
downstream effects, in vitro, to immobilised and fluid phase 
physiological ligands
• Studying and confirming, by a number of independent methods, the 
predicted mode of action of our lead compound
• Documenting in vivo activity in a biologically meaningful model
• Extending our observations to other novel drug molecules and protein 
targets
All work has limitations and drug development is a lengthy process. We remain 
at an early stage and throughout have been limited physically by available drug.
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Sufficient quantities are required for formal pharmaco-kinetic, -dynamic, and -  
toxicological studies. We are unable to measure the concentration of drug at 
present and poorly appreciate its turnover in vivo. Although structural work, 
including now X-ray crystallography and latterly isothermal calorimetry is more 
advanced, greater detail of the bioenergetics and biophysics of the interaction 
between RMM and CRP would be desirable, not just for completeness sake but 
also to guide improvements in future drug molecules. Equilibrium dialysis 
studies, density ultracentrifugation and computer modelling could all throw light 
on the interactions taking place, as well as suggesting possible modifications. 
Much of the data above is by its very nature indirect, particularly using the so- 
called “MIRA effect”, which cannot be further clarified without the ability to 
directly alter the assay properties (not something we as end users can readily 
achieve). Nevertheless it represents a very effective and efficient automated tool 
that might aid screening other similar ligand binding inhibitors o f CRP.
With respect to the present inhibitors described, it has been known for some time 
that after binding of the divalent calcium cation, CRP binds phosphate 
monoesters with a stochiometry of one mole per mole of CRP subunit [45]. 
Replacement of the phosphate monoester group by other acidic groups or by 
conversion to a phosphodiester markedly diminishes or abolishes the ability to 
bind. Our findings from our plate assays are fully in keeping with this. PC is 
bound by CRP with much higher affinity than other phosphate monoesters, as 
assessed indirectly in inhibition assays.
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We estimated that RMM had an IC50 approximately 10 times less than that of 
PC, and again calorimetry studies, that measure the related but distinct binding 
affinity, confirm this qualitative ballpark figure (Kd for CRP/RMM 400nM). 
The enhanced affinity of a bisphosphocholine ligand is fully expected for a 
molecule with the structure of CRP, as it is already known that the binding 
affinity of a ligand increases tremendously when multiple PC residues are 
present on a macromolecular structure. The dimerisation of CRP by RMM, and 
the increased stability of this entity, is in keeping with this. Changing the chain 
length or structure may, or may not, also of course generate a more avid inhibitor 
of CRP and this is something currently being addressed. Finally a CRP mutant 
incapable of binding to PC has been described in the literature [120], and this 
would certainly be an interesting protein with which to study in the context of 
our inhibitor, as a final proof of specificity.
All in vivo models are beset with confounders (from technical aspects to animal 
heterogeneity) and lethality experiments are no exception. Further refining of the 
model to include continuous drug delivery or use of a human CRP transgenic 
strain would of course be ideal. Finally extending the in vivo data to a rat 
myocardial infarction model is a priority as Streptococcal lethality in mice was 
chosen as the simplest biological model for the initial proof of principle.
The ability of the pentraxins to co-decamerise is interesting. The fact that 
CPHPC has a low affinity for CRP alone, but a clear affinity when ligand bound 
to SAP is quite intriguing, but probably just shows that despite distinct 
differences between pentraxins, sufficient similarity exists in the structure and
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binding properties, for interactions to occur in, albeit experimental, settings. No 
immediate physiological role for this effect is apparent.
Whether or not the concept of mixed dimers can be extended to decamers of SAP 
with other unrelated proteins (or even CRP) remains to be seen. Unlike SAP, 
CRP turnover was not increased by decamerisation in these initial experiments, 
and this fits with a previous study investigating turnover in vivo with CPS [422]. 
Later experiments (Personal communication, MBP) do seem to demonstrate 
increased turnover, where the delivery rate and concentration of drug was higher 
(and in rats not mice). Although both proteins are cleared via the hepatocyte 
[26], different subtleties may exist. Further work in mice and rats with RMM 
will clarify this as will in vivo testing of AJC042 where the effect on clearance of 
a mixed decamer can be studied.
13.8 Summary
In summary, this chapter describes from laboratory bench to animal house, the 
development of a novel palindromic CRP inhibitor that through binding to the 
phosphocholine binding sites, decamerises an important human protein and in so 
doing inhibits its biological functions.
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14 Discussion
-reactive protein, the archetypal acute phase reactant continues to 
attract an enormous amount of interest (Figure 137), not only within 
scientific circles but within the media, especially in the America.
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What CMP is and why you used to be 
concerned about it 
■
What to do if your CUP level is high 
■
Ufesaving information on nutrition, 
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Figure 137 Cover page of a general health book on CRP 
- http://www.amazon.com
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As attempts are made to further understand its function as a molecule, and 
mediator within the complexities of the acute phase response, we must be wary 
of premature and unsubstantiated claims becoming de facto truths, particularly 
under the influence of the substantial publicity surrounding this ancient 
molecule. The title and purpose of this thesis was to address the question of 
whether CRP may enhance tissue damage, and therefore be a potential 
therapeutic target. In addressing the question this thesis has started with an 
epidemiological approach to the problem, before focussing on animal models of 
disease and finally developing a rational and unique pharmacological approach. 
The findings presented in this thesis demonstrate clearly:
1) A strong association between increased values of CRP and future 
coronary heart disease, but not one that necessarily exceeds that of 
traditional risk factors. Independently CRP has a modest association with 
future coronary heart disease events;
2) A failure to confirm, in a transgenic setting, a protective role for CRP 
following local or systemic endotoxin challenge;
3) A lack of causality for human CRP in a transgenic mouse model of 
atherosclerosis, despite clear up-regulation of the protein, and evidence of 
its deposition in advanced plaques;
4) An exciting development of a low molecular weight inhibitor of CRP 
binding that specifically dimerises the protein efficiently preventing 
ligand binding, opening the way for pharmacological manipulation of 
CRP.
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There is often a loss of clarity in the discussions regarding CRP. Certain 
potential areas of interest within cardiovascular medicine have driven research 
priorities recently, and each area does not necessarily overlap clinically or 
pathophysiologically. For this reason conclusions drawn from one study 
addressing one topic do not necessarily impact on another focus of interest. 
Broadly then within the spectrum of cardiovascular disease CRP has attracted 
attention for its:
1) Predictive power for future cardiac events in otherwise healthy 
individuals;
2) Predictive power for future cardiac events in individuals post myocardial 
infarction;
3) Predictive power for future cardiac events in individuals with acute 
coronary syndromes, including those undergoing interventions;
4) Utility in targeting individuals (both within primary and secondary 
cardiovascular disease prevention programmes) who may benefit from 
HMG CoA-reductase inhibitors in particular, despite “normal” lipid 
parameters;
5) Potential direct pathogenic role in atherosclerosis;
6) Potential direct pathogenic role in myocardial infarction (and other 
similar inflammatory conditions);
7) Potential to therefore be a therapeutic target, such that a CRP inhibitor 
may be a novel anti-inflammatory drug.
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With colleagues I started by addressing in the largest and most rigorous 
evaluation so far, the predictive value of CRP in coronary disease in the general 
population. The large size of our study provides excellent power and precision in 
its estimates and our conclusion was that the prognostic value of CRP has been 
overstated by overestimation of its predictive power, and underestimation of 
established risk factors.
In reply Dr. Paul Ridker of Brigham and Women's Hospital was widely reported 
as saying our study was “creating controversy where none existed”. Moreover 
he went on to say that “I would never want to be a patient in Great Britain...I 
suppose in Great Britain they don't want people to be healthy...This is about 
public health and letting patients and their primary physicians know there is 
overwhelming evidence that the test works." 
(http://www.missouri.edu/-ohemrg/current_news/Article_Inflammation.html)
Such criticism appears based on firm opinion rather than evidence. We were 
attempting to answer a specific question, namely what does CRP determination 
add to our understanding of heart disease risk? Everyone agrees that coronary 
heart disease risk prediction is important because intervention prior to an event 
has the potential to save many lives. However whilst inflammation is clearly 
involved in the processes we study as end points, this does not mean to say that a 
measure of inflammation adds to any of the known risk factors. The recently 
published INTERHEART study (Yusuf and colleagues study of risk factors for 
myocardial infarction in 52 populations worldwide [374]) shows that more than 
80% of the global burden of coronary heart disease, irrespective of the ethnic
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origin, can be attributed to five main conventional cardiac risk factors—abnormal 
lipids, diabetes mellitus, cigarette smoking, hypertension, and lack of exercise. 
Including other important factors such as abdominal obesity, alcohol intake, 
psychosocial factors and lack of consumption of fruits or vegetables, then 
accounted for most, if  not all, of the population attributable risk of myocardial 
infarction. The effect of the risk factors were particularly striking in young men 
(population attributable risk about 93%) and women (population attributable risk 
about 96%), indicating that most premature myocardial infarction is preventable, 
with already measured risk factors. American studies have also confirmed this, 
casting significant doubt on the so called "only 50%" hypothesis [371-373]: a 
frequently cited concept that individual major risk factors for coronary heart 
disease are absent in perhaps >50% of those with CHD. Thus long term follow 
up from three prospective cohort studies (Chicago Heart Association Detection 
Project in Industry, Multiple Risk Factor Intervention Trial, and the Framingham 
Heart Study) found that for fatal coronary heart disease, exposure to at least one 
clinically elevated major risk factor ranged from 87% to 100% i.e. suboptimal 
levels of cholesterol, raised blood pressure, cigarette smoking, and diabetes 
[371].
It seems likely then that the explanatory power of the major, established 
cardiovascular risk factors has been systematically underestimated. So those that 
criticised our work for over adjustment by factors that tend to reduce the 
predictive ability of CRP, are correct, but miss the essence of the study; new
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markers of risk should not simply be added to global risk scores because they are 
currently fashionable [517-520].
Of course our conservative analysis and estimation of increment in risk, an odds 
ratio for CRP of 1.5 (a 50% increase in risk), may still be a significant finding 
from a clinical and a public health perspective and one that may be clinically 
important. The problem remains though that there is a likelihood that further 
larger long term studies, with even better adjustment for confounding factors, 
will reduce this odds ratio further. As an example there was much interest in the 
effect of a polymorphism in the angiotensin converting enzyme gene and risk of 
coronary restenosis after percutaneous coronary intervention, as well as in 
myocardial infarction. However weaker associations between the angiotensin 
converting enzyme DD genotype and restenosis were found in larger and more 
rigorous studies than in other earlier, smaller studies [521]. Other putative 
associations with cardiovascular disease have also largely fallen by the wayside, 
as studies increase in size and are pooled e.g. Chlamydia pneumoniae [522] and 
Helicobacter pylori infection [523]. Publication bias or detection biases can 
produce artefactual associations and adequately powered investigations are 
needed to properly address important questions relating to association/causation. 
It is a well recognised phenomenon in epidemiology, that early publication bias 
favours positive papers, and as larger studies appear there is the so called 
“regression to the mean or truth” and often the association disappears.
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To ultimately answer the question all are in agreement that no single study alone 
is sufficient. We acknowledge that our study could be criticised for its 
geographical location, its failure to measure lipid parameters such as LDL- 
cholesterol and HDL, and its time frame which meant that most patients were not 
using aspirin or statins. Additionally we could not for practical reasons measure 
other inflammatory markers such as SAA, total white cell count or pro- 
inflammatory cytokines (although ESR, a less specific but summative marker of 
inflammation was assessed and its predictive power was similar to that of CRP, 
suggesting that inflammation per se and not CRP itself is relevant). It was also 
telling that the odds ratio in the Iceland study was very similar to that of the up to 
date meta-analysis, again suggesting that the data was robust. We accept that we 
couldn’t and didn’t fully address the role of CRP and the metabolic syndrome 
nor was the study powered to look at CRP and diabetes directly or specific 
gender differences. We also only addressed the role of CRP in prediction of 
future coronary heart disease risk and not in the management of patients with 
acute coronary syndromes or those whom might benefit from statin treatment. 
Further collaborative research continues therefore to be needed, with long term 
follow up, significant groups of individuals as cases and appropriate controls, 
and critical appraisal of the results [524,525].
Finally it may be the case that CRP does have a practical role to play but 
traditional risk factors must not be underutilised, and any use of CRP must be 
justified for the correct reasons. Hence perhaps it will prove to be the case that 
CRP has a very significant role in day to day practice, if it can be shown that in 
“live use” clinicians prefer CRP based algorithms to those already followed.
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CRP could for example be used as a good global marker of risk, which patients 
and physicians may more easily understand and utilise as a target for 
interventions.
There are many features o f CRP the molecule, not the analyte, which suggest it 
may contribute to some processes in atherosclerosis. However whilst it remains 
the most studied of inflammatory markers it is somewhat self fulfilling to 
conclude that because CRP has stood out as a risk marker it must have a 
pathological role in the disease as well. CRP was measured because it is robust 
and relatively easy to measure. However we know that diverse markers of 
inflammation such as ESR [168], total white cell count [17] and SAA [179] also 
predict cardiovascular disease. In testing for causation rather than just 
association, it is however not as easy to manipulate experimental paradigms for 
these inflammatory markers; whilst one can easily design an experiment to see 
the effect of CRP in vitro or in vivo this is not a meaningful strategy for ESR or 
total white cell count.
The remainder of this thesis attempted to experimentally address the role of CRP 
in vitro and in vivo. Its strength lies within our grasp of the problems one faces 
when you turn to such experimental work. So we are very much aware of the 
areas of controversy that exist for CRP and the experimental hazards inherent in 
studying this molecule. There are many pertinent questions (not all with 
adequate answers) and issues worthy of thought including:
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1) Reliability and plausibility of in vitro studies
a. Contamination of CRP preparations with immunoglobulins and 
endotoxin
i. Is recombinant CRP made in E. coli the same as 
recombinant CRP made in insect cells and the same as 
isolated human CRP from ascites/serum? Are in vitro 
reports therefore that CRP is pro-inflammatory merely a 
result of contamination? Hence the conclusion of one 
group who carefully investigated a wide range of effects 
on endothelial cells ascribed to CRP and found that azide 
(see below) and LPS, but never CRP itself, were 
responsible for the cell activation events [526]. Injection 
into animals of different CRP preparations, with 
subsequent assessment of inflammatory responses has 
shown acute phase responses and pro-inflammatory effects 
induced by commercially available recombinant human 
CRP produced in E. coli, with no such effects using 
genuine human CRP isolated from human subjects [527].
ii. Can low concentrations of immunoglobulins in the 
preparations explain the reported binding to cell surface 
receptors? Hence work showing that the apparent binding 
of human CRP by Fey receptors on human cells is 
artefactual and reflects either use of whole IgG anti-CRP 
antibodies, or contamination of commercial CRP 
preparations with traces of IgG. When recombinant
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human CRP or highly purified human CRP was used, or 
CRP binding was sought using F(ab)2 anti-CRP antibodies, 
no binding of CRP by Fc receptors on human cells was 
detected [296]. This has been confirmed by others [297, 
298].
iii. Are adequate steps taken to demonstrate specificity of 
effects described? Accordingly in our own in vitro studies 
of the effects o f CRP on vascular reactivity [304], we 
demonstrated specificity in a number of ways (notably pre­
absorption of CRP by pure ligand and inhibition of 
binding with RMM), but still concluded that despite 
demonstrating specific, direct effects on vascular function 
in vitro further clarification of the effect, if  any, of CRP on 
vascular reactivity in humans in vivo would require 
clinical studies using specific inhibitors of CRP.
b. Presence of azide in CRP buffers
i. Have adequate steps been taken to remove the cellular 
toxin and nitric oxide donor, sodium azide from CRP used 
experimentally? Independent groups are now reporting 
that many findings claimed for CRP are in fact artefactual.
0.1% NaN3 is the preservative used for commercially 
available CRP and a potential source of NO; the acute 
vasoactive properties of commercially available CRP 
preparations have now been clearly attributed to NaN3 and 
subsequent production of NO by catalase [526, 528-531].
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c. Has the quality and specificity of other reagents used, not only the 
purified CRP, but antibodies for example been adequately 
confirmed? Have the assays employed to measure CRP been 
calibrated appropriately?
d. Design o f meaningful experiments
i. Can you explain the functions of an acute phase serum 
protein with a dynamic range of 10000 fold by studying it 
out of the context of an acute phase response? Is the 
absence of serum proteins and/or acute phase cytokines in 
the experimental milieu acceptable? How do you model 
the time course of the acute phase response, and hence 
CRP production, in an in vitro setting?
ii. Are experiments with modified CRP, which has to be 
generated by exposure of the protein to 6M urea, 
biologically meaningful?
iii. Are cell culture studies generally inappropriate in the 
context of this particular serum protein, and prone to 
misleading conclusions? It is recognised that CRP binds 
to necrotic and apoptotic cells (particularly through PC 
recognition), but might out of context binding generate 
artefactual phenomenon?
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2) Reliability and plausibility of in vivo studies
a. Specificity of transgenic production of CRP, or passive 
administration of protein, across species boundaries
i. Is the regulation of synthesis of transgenic human CRP in 
mice, including sites outside of the liver, sufficiently close 
to man to generate genuine transferable results?
ii. Is the turnover of transgenic human CRP either in normal 
or hyperlipidaemic murine serum representative of man?
iii. Is there a biological cost to the mouse of transgenic 
production of a human protein?
iv. Are the consequences of ligand binding comparable for 
human CRP in human serum with human CRP in mouse 
serum? Is mouse or rat complement sufficiently similar to 
man to contemplate studying the effects of CRP in vivo? 
Are the intricacies of complement regulation mirrored 
adequately enough to allow conclusions about CRP to be 
drawn? It is known for example that human CRP requires 
human C lq to activate guinea pig complement [48] and 
similarly rat CRP appears not to activate its own 
autologous complement when ligand bound, but human 
CRP does activate rat complement [75, 201] (although 
some dispute the idea that rat complement doesn’t activate 
its own complement [532]).
v. Are other models any better? Is there intrinsic value in 
studying rabbit CRP expressed under a nutritional
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promoter in mouse serum? Should a mouse CRP 
knockout be generated even though murine CRP is not the 
predominant pentraxin acute phase protein in mice? Might 
targeted transgenic expression of human CRP be 
informative?
vi. Why are there such profound differences in CRP across 
species in terms of regulation of production and effects of 
ligand binding? Do such differences have an effect on 
experimental models of CRP function? Are such 
differences insurmountable experimentally? Is a 
pharmacological approach, in man, the only logical 
approach?
b. Design of meaningful experiments
i. The peak acute phase response in terms of CRP production 
is approximately 48 hours after an insult or injury. Could 
passive use of CRP in experiments mean that peak values 
are achieved at time points undergoing different 
pathophysiological effects than normal? Could CRP be 
exposed therefore to non-physiological ligands at non- 
physiological times? Could such binding effects of CRP 
be displacing/competing with other ligands and so 
generating an artificial pro-inflammatory effect?
ii. Do the present animal models reflect the important 
pathophysiological mechanisms that CRP appears to 
predict epidemiologically i.e. events rather than disease
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itself? Is the apoE knockout mouse simply a model of 
atherosclerosis with little bearing on atherothrombosis? Is 
a rat coronary artery occlusion study really synonymous 
with human myocardial infarction with staggered coronary 
artery occlusion? Would ischaemia-reperfusion models be 
better?
iii. Are sufficient experiments performed to overcome chance 
in the results? Are the effects seen reproducible in 
independent laboratories?
iv. Are the correct animals being studied; is there a 
compelling argument for CRP researchers to use large 
animals, where CRP biology is more closely related to 
man [12, 533]?
3) Commercial pressure to utilise CRP
a. Is there undue emphasis from outside the clinical arena (Figure 
138) on the adoption of CRP into clinical practice?
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By studying animals that produce transgenic human CRP under an inflammatory 
stimulus we have come as close as we can in small animal models to the best 
available tests of causality. All o f the caveats and concerns outlined above apply 
equally to our work, but we have tried to tackle potential confounders and pitfalls 
where possible throughout our studies: the purity and integrity of the CRP can be 
vouched for and demonstrated, azide is removed where appropriate, the 
endotoxin concentration is insignificant, the antibodies used in detecting CRP are 
specific and the animals models chosen are established; our epidemiological 
study is the largest ever performed and our assays for measuring CRP precise, 
specific and reliable; finally we have in our sights a rationally designed inhibitor 
of CRP binding that inhibits CRP in vivo.
We found no protection from endotoxaemia in transgenic mice, despite the 
findings of others and we notably didn’t show enhanced atherogenesis in apoE 
knockout mice producing transgenic CRP. With respect to endotoxaemia one 
recent publication that claims protective effects of CRP against Vibrio vulnificus 
LPS, used commercially sourced CRP from the horseshoe crab, Limulus 
polyphemus [534]. This material was completely uncharacterised with regard to 
its purity and functional integrity and as already discussed Limulus CRP is 
heterogeneous in amino acid sequence, is only about 20% homologous with 
human CRP, is dodecameric rather than pentameric, is heavily and 
heterogeneously glycosylated, whilst human CRP is not a glycoprotein, and 
Limulus is an arachnid separated from primates by about 700 million years of 
evolution. In other studies no control proteins were used [431], whilst in the 
work with rabbit CRP transgenic mice, the control animals were not even of the
same strain [429]. Our present failure to find protection by exogenous human 
CRP suggests that this rather artificial phenomenon is unlikely to be of general 
significance. Our apoE study [491] didn’t tally with the first small study [436] 
but does fit with two other subsequent more robust analyses [492, 493]. One 
comment on our work dismissed it as "not terribly important or helpful...mouse 
models of atherosclerosis are interesting, but by no means definitive. I don't think 
you learn much from these studies where you create a disease in mice 
rapidly...and when you look at studies involving 10 000 patients where you find 
that CRP is a risk factor, a handful of mice is not important.” 
(http://www.medicinenet.com/script/main/art.asp?articlekey=47289)
This appears not to appreciate the literature [326, 366, 535]. Firstly whilst CRP 
is a risk marker in its own right, when confounders and traditional risk factors are 
accounted for, it adds very little further information. Secondly animal models 
are very instructive in modelling disease, so long as their limitations are 
acknowledged. We accept that the xenogeneic combination of human CRP, 
regulated by murine factors and functioning in a murine cellular and extracellular 
environment is artefactual but if CRP were playing a fundamental role in 
atherogenesis one would expect to see an effect. A pharmacological approach is 
therefore the most logical way forward in addressing the problem since the only 
definitive way to confirm or exclude a possible pathogenic role of human CRP in 
atherosclerosis and/or atherothrombotic events will be use of drugs that 
specifically target CRP in vivo and inhibit its presumed functions, specifically 
those that result from phosphocholine binding. The bisphosphocholine 
compound that we have rationally designed and studied is an attractive candidate
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for development as a cardioprotective and neuroprotective treatment in acute 
myocardial infarction and stroke respectively, and may well have wider 
applications in other acute and chronic disorders associated with increased CRP 
production. It also provides a starting point for development of specific CRP 
inhibitor drugs that could be used to establish whether or not CRP plays a causal 
role in atherosclerosis.
The studies presented and further studies now performed in rats undergoing 
myocardial infarction do show that RMM can specifically inhibit biological 
functions of human CRP by its bringing together of two pentamers. Further 
toxicological and pharmacokinetic/pharmacodynamic studies will be needed as 
will specific studies of what effects this drug has in its own right, aside from any 
specific binding to CRP. Is it binding to any other ligands in the serum, such as 
phosphocholine specific antibodies, including antibodies against OxLDL?
Importantly human studies will be needed early as the limitations expressed 
above about animal studies are such that only clinical studies in man can yield as 
definitive as possible answers. There could well be, however, concerns about 
such studies. The conservation of the pentraxin proteins over many millions of 
years evolution cannot be ignored, precisely because we don’t understand the 
protein fully. A strong protective role must be postulated to exist, and it must 
surely be the conservation of PC recognition and the abundance of such ligands 
in inflammatory and infectious situations, along with the similarities to antibody 
once CRP is ligand bound with respect to complement, that has made the protein 
so robust. The judicious use of complement once activated, and many contend
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that complement activation by CRP does not deplete the late complement 
components, may be important to how organisms handle foreign and self 
antigens.
An interesting study on targeted and restricted complement activation on 
acrosome-reacted spermatozoa was recently published in JCI, and perhaps is 
pertinent [536]. Upon exposure of human spermatozoa to autologous serum or 
follicular fluid, it was found unexpectedly that acrosome-reacted spermatozoa 
activated the complement cascade efficiently through C3 but not beyond. The 
study suggested that complement activation was initiated by CRP and was Clq, 
C2, and factor B dependent. This pattern is consistent with engagement of the 
classical pathway followed by amplification through the alternative pathway. 
C3b deposition was targeted to the inner acrosomal membrane, where it was 
cleaved to C3bi. Factor H, and not membrane cofactor protein (MCP; CD46), 
was the cofactor responsible for C3b cleavage. The authors of this study 
proposed that this localised deposition of complement fragments aided the fusion 
process between the spermatozoa and egg, in a role similar to that of complement 
in immune adherence. They hypothesised that C3bi, a ligand for integrin-related 
complement receptors, facilitates sperm-egg interactions.
More generally, and of significance to this discussion, they speculated that such a 
targeted and restricted form of complement activation on host cells was a 
common strategy to handle modified self. In conditions like apoptosis, 
ischaemia/reperfusion injury, and probably other types of alterations in host cell 
structure targeted and restricted activation of the complement system perhaps is a
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preferable means to activate the complement system. CRP may play an 
important role in this. In contrast to the desirable explosion of the cascade on 
microbes, complement activation on an apoptotic cell or during ischaemia- 
reperfusion is less robust, yet sufficient to facilitate the safe and relatively non­
inflammatory removal o f altered self, rapidly and safely in order to enhance 
wound healing and promote tissue sterility.
Extreme caution will be needed in designing appropriate human experiments. 
However any binding effects of the drug will be limited to an immediate effect 
on CRP in the circulation. CPHPC, the specific SAP ligand binding drug 
molecule which has been used in trials of treatment of amyloidosis, appears so 
far to be safe. This of course does not mean RMM would be but it is certainly 
encouraging that a plasma pentraxin protein can be removed from the circulation 
without immediate concerns.
In conjunction with a CRP inhibitor there are many further experiments that 
would be of interest. By already extending the studies in apoE mice to include 
18 month old mice, we hope to look at transgenic production of human CRP in a 
model including plaque rupture. Other experimental adjustments such as high fat 
diets, manipulation with statins or inducing specific vascular injuries may also 
prove interesting to study. Pigs may also be a possible species for studies 
looking at myocardial infarction or atherosclerosis One study has already 
reported that serum CRP values correlated with macrophage accumulation and 
coronary artery disease in hypercholesterolaemic pigs [537], and further work 
could be insightful, if  appropriately designed and executed; hence in the study
cited an antibody against human CRP was used to detect porcine CRP, which is 
sub-optimal. Our limited studies in a murine model of arthritis are also worth 
extending, particularly as discussed by backcrossing human CRP transgenic mice 
onto a susceptible strain. And although controversial, extra-hepatic expression of 
CRP has been described in the mouse model [435] and by some in man [538]. 
Local expression o f complement has been shown to be important in renal 
transplant rejection [539]; is there a similar role for CRP produced in the kidney 
or other tissues? Finally very recently a genome screen identified that a 
polymorphism in the Factor H gene was associated with development of age 
related macular degeneration (AMD) [540-543]. Indeed it was estimated that in 
individuals homozygous for the risk allele, the likelihood of AMD was increased 
by a factor of just over 7 fold. The polymorphism is in linkage disequilibrium 
with the risk allele and represents a tyrosine-histidine change at amino acid 402, 
in a region of the complement factor H protein that binds heparin and CRP. 
There is already some evidence that minor elevations in CRP are associated with 
age related macular degeneration [544, 545] and complement mediated damage 
has been speculated previously to be important in the pathophysiology of this 
very important eye disease [546, 547]. There is thus a clear link with CRP that 
experimentally needs addressing.
Clinically further studies of CRP in different settings are a priority. Areas of 
great interest include the metabolic syndrome, associated fatty disease of the 
liver, diabetes, statin use and risk stratification in acute coronary syndrome 
management. However it will prove more important to ensure that the studies 
are of sufficient size and duration with appropriately employed sensitive CRP
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assays to adequately answer questions. The creation of a CRP collaborative 
centre has been suggested by John Danesh, to allow deposition of the raw data on 
studies, and so facilitate pooling of results [168]. Genetic association studies will 
also continue to be important and are already underway.
14.2 Summary
In conclusion the studies presented in this thesis largely cast doubt for a very 
strong role clinically or pathologically for CRP in atherosclerosis but generate 
optimism that a pharmacological approach can be utilised to understand the in 
vivo properties of this protein in health and disease. This has the potential to 
generate a drug molecule that could be clinically very significant in myocardial 
infarction and stroke, where the evidence remains for a pathogenic role for CRP.
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